EP4322926A1 - Microbubble-assisted ultrasound-guided therapy - Google Patents
Microbubble-assisted ultrasound-guided therapyInfo
- Publication number
- EP4322926A1 EP4322926A1 EP22788800.5A EP22788800A EP4322926A1 EP 4322926 A1 EP4322926 A1 EP 4322926A1 EP 22788800 A EP22788800 A EP 22788800A EP 4322926 A1 EP4322926 A1 EP 4322926A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- microbubble
- microbubbles
- composition
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 196
- 238000002604 ultrasonography Methods 0.000 claims abstract description 79
- 201000011510 cancer Diseases 0.000 claims abstract description 54
- 239000000556 agonist Substances 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 203
- 239000000203 mixture Substances 0.000 claims description 197
- 238000000034 method Methods 0.000 claims description 124
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 claims description 92
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 claims description 89
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 claims description 73
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 44
- 210000002540 macrophage Anatomy 0.000 claims description 38
- 108020004999 messenger RNA Proteins 0.000 claims description 34
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims description 34
- 239000002101 nanobubble Substances 0.000 claims description 32
- 230000008685 targeting Effects 0.000 claims description 32
- 230000001965 increasing effect Effects 0.000 claims description 31
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 30
- 238000011068 loading method Methods 0.000 claims description 27
- 125000004122 cyclic group Chemical group 0.000 claims description 22
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 claims description 20
- 210000004443 dendritic cell Anatomy 0.000 claims description 20
- 238000012377 drug delivery Methods 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 19
- 238000001727 in vivo Methods 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 17
- 229940063675 spermine Drugs 0.000 claims description 17
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 16
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 16
- 229920006317 cationic polymer Polymers 0.000 claims description 16
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 15
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 14
- 229920002307 Dextran Polymers 0.000 claims description 12
- 239000012636 effector Substances 0.000 claims description 12
- 210000002865 immune cell Anatomy 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 9
- 206010027476 Metastases Diseases 0.000 claims description 8
- 210000000170 cell membrane Anatomy 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 7
- 230000005937 nuclear translocation Effects 0.000 claims description 7
- 229950003332 perflubutane Drugs 0.000 claims description 7
- 229920000768 polyamine Polymers 0.000 claims description 7
- 102000003945 NF-kappa B Human genes 0.000 claims description 6
- 108010057466 NF-kappa B Proteins 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 230000016396 cytokine production Effects 0.000 claims description 6
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 claims description 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000007115 recruitment Effects 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical class CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 230000030648 nucleus localization Effects 0.000 claims description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 230000008029 eradication Effects 0.000 claims description 2
- 238000005304 joining Methods 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 136
- 230000004913 activation Effects 0.000 abstract description 30
- 230000001225 therapeutic effect Effects 0.000 abstract description 17
- 206010061289 metastatic neoplasm Diseases 0.000 abstract description 16
- 230000037361 pathway Effects 0.000 abstract description 15
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 abstract description 6
- 238000009169 immunotherapy Methods 0.000 abstract description 6
- 230000005975 antitumor immune response Effects 0.000 abstract description 3
- 210000000805 cytoplasm Anatomy 0.000 abstract description 3
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 61
- 239000000427 antigen Substances 0.000 description 57
- 108091007433 antigens Proteins 0.000 description 57
- 102000036639 antigens Human genes 0.000 description 57
- 201000010099 disease Diseases 0.000 description 52
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 48
- 238000012384 transportation and delivery Methods 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 32
- 238000001994 activation Methods 0.000 description 29
- 238000000684 flow cytometry Methods 0.000 description 29
- 239000000243 solution Substances 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 22
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 19
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 208000026310 Breast neoplasm Diseases 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 230000028993 immune response Effects 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 17
- 206010006187 Breast cancer Diseases 0.000 description 15
- 229940044665 STING agonist Drugs 0.000 description 14
- 239000013543 active substance Substances 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000003834 intracellular effect Effects 0.000 description 13
- 230000001394 metastastic effect Effects 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 13
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- 230000009885 systemic effect Effects 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- 230000001086 cytosolic effect Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000015788 innate immune response Effects 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 230000021615 conjugation Effects 0.000 description 11
- 230000002519 immonomodulatory effect Effects 0.000 description 11
- 230000001976 improved effect Effects 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 230000004797 therapeutic response Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 9
- 230000001613 neoplastic effect Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000011284 combination treatment Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000012188 paraffin wax Substances 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 230000006023 anti-tumor response Effects 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 229940021747 therapeutic vaccine Drugs 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000000942 confocal micrograph Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
- -1 phospholipids) Chemical class 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 230000033289 adaptive immune response Effects 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000005809 anti-tumor immunity Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000005415 bioluminescence Methods 0.000 description 5
- 230000029918 bioluminescence Effects 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 5
- 230000003463 hyperproliferative effect Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000006054 immunological memory Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 230000035790 physiological processes and functions Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 241000239290 Araneae Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 229940117681 interleukin-12 Drugs 0.000 description 4
- 230000002601 intratumoral effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- 108010014726 Interferon Type I Proteins 0.000 description 3
- 102000002227 Interferon Type I Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 101150091206 Nfkbia gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 230000037453 T cell priming Effects 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000004721 adaptive immunity Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 101150116749 chuk gene Proteins 0.000 description 3
- 230000001268 conjugating effect Effects 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 238000012385 systemic delivery Methods 0.000 description 3
- 238000006177 thiolation reaction Methods 0.000 description 3
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 230000010472 type I IFN response Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XVWPFYDMUFBHBF-CLOONOSVSA-N (2S)-2-[[[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)phenyl]-oxomethyl]amino]-4-methylpentanoic acid methyl ester Chemical compound COC(=O)[C@H](CC(C)C)NC(=O)C1=CC=C(NC[C@@H](N)CS)C=C1C1=CC=CC2=CC=CC=C12 XVWPFYDMUFBHBF-CLOONOSVSA-N 0.000 description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- TZZNWMJZDWYJAZ-UHFFFAOYSA-N 2-(4-oxo-2-phenylchromen-8-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 TZZNWMJZDWYJAZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 108010017009 CD11b Antigen Proteins 0.000 description 2
- 102000004354 CD11b Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 108010030317 Macrophage-1 Antigen Proteins 0.000 description 2
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 2
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 2
- 101150060741 Sting1 gene Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000000339 bright-field microscopy Methods 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229960003685 imatinib mesylate Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000014567 type I interferon production Effects 0.000 description 2
- 238000012762 unpaired Student’s t-test Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- GECIDMICWWDIBO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2C(=O)ON1C(=O)CCC1=O GECIDMICWWDIBO-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 1
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- AUDYZXNUHIIGRB-UHFFFAOYSA-N 3-thiophen-2-ylpyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2SC=CC=2)=C1 AUDYZXNUHIIGRB-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000001783 Adamantinoma Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000017234 Bone cyst Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 208000001843 Carotid Body Tumor Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 1
- 108030002637 Cyclic GMP-AMP synthases Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 241001658031 Eris Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 102000013404 Geranyltranstransferase Human genes 0.000 description 1
- 108010026318 Geranyltranstransferase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 101150057269 IKBKB gene Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
- 102000002698 KIR Receptors Human genes 0.000 description 1
- 108010043610 KIR Receptors Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 206010068116 Metastatic uterine cancer Diseases 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108010082739 NADPH Oxidase 2 Proteins 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 238000004354 ROESY-TOCSY relay Methods 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 206010073334 Rhabdoid tumour Diseases 0.000 description 1
- 241001116459 Sequoia Species 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000006043 T cell recruitment Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 206010050283 Tumour ulceration Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 208000012080 benign lipomatous neoplasm Diseases 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005100 blood-tumour barrier Anatomy 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- PDXMFTWFFKBFIN-XPWFQUROSA-N cyclic di-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 PDXMFTWFFKBFIN-XPWFQUROSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 201000010073 fibrogenesis imperfecta ossium Diseases 0.000 description 1
- 201000010103 fibrous dysplasia Diseases 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229950009034 indoximod Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005252 lipomatous cancer Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GKFPROVOIQKYTO-UZLBHIALSA-N methyl (2s)-2-[[4-[[(2r)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoate Chemical compound CSCC[C@@H](C(=O)OC)NC(=O)C1=CC=C(NC[C@@H](N)CS)C=C1C1=CC=CC=C1 GKFPROVOIQKYTO-UZLBHIALSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 229960001133 nandrolone phenpropionate Drugs 0.000 description 1
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940127082 non-receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229960001218 pegademase Drugs 0.000 description 1
- 108010027841 pegademase bovine Proteins 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004647 pro-inflammatory pathway Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 201000011096 spinal cancer Diseases 0.000 description 1
- 208000014618 spinal cord cancer Diseases 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000025443 tumor of adipose tissue Diseases 0.000 description 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0039—Ultrasound therapy using microbubbles
Definitions
- CDNs Cyclic dinucleotides
- STING Stimulator of Interferon Genes
- a method of targeted in vitro or in vivo drug delivery using sonoporation entails administering to one or more target cells a composition comprising microbubbles loaded with a payload and then administering an ultrasound stimulus to the one or more target cells.
- the ultrasound stimulus is effective to sonoporate the one or more target cells.
- the payload may be an agonist for activating the Stimulator of Interferon Genes (STING) signaling pathway within the one or more target cells, such as a cyclic dinucleotide.
- the payload may be a cyclic dinucleotide for inducing or enhancing Type 1 Interferon production within one or more cells.
- the payload may be mRNA.
- the payload may be DNA, such as plasmid DNA (pDNA).
- the method may be an in vivo method which entails administering the microbubble composition and the ultrasound stimulus to a subject.
- the one or more target cells may be cancer cells.
- the one or more target cells may be immune cells.
- the immune cells may be professional antigen-presenting cells (APCs), such as macrophages and/or dendritic cells.
- the microbubbles may include targeting molecules on the external surfaces of the microbubbles that are effective to bind the one or more target cells.
- the targeting molecules may be antibodies.
- the targeting molecules may bind CD1 lb.
- the ultrasound stimulus may be administered at about 1-2 W/cm 2 , optionally with 50% duty cycle.
- the ultrasound stimulus may be administered for between about at least about 30-60 seconds.
- the one or more target cells may be exposed to the microbubbles for at least about 10 minutes prior to administering the ultrasound stimulus.
- the method may further entail using ultrasound to visualize the microbubbles prior to applying the ultrasound stimulus effective to sonoporate the cell membrane.
- the intensity of the ultrasound used to visualize the microbubbles can be less than the intensity of the ultrasound stimulus.
- the microbubbles may be decorated with spermine and the payload may be non-covalently bound to the spermine.
- the microbubbles may be decorated with spermine-dextran conjugates and the payload non-covalently bound to the spermine within the spermine-dextran conjugates.
- the microbubbles may have gas cores having a perfluorocarbon.
- the perfluorocarbon may be decafluorobutane.
- the microbubbles may have shells having phospholipids, optionally wherein the phospholipids include one or both of l,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC) and l,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) lipids.
- the microbubbles may have surfactant shells having PEGylated molecules.
- the average microbubble size of the microbubble composition may be between about 1 pm and about 10 pm.
- the average microbubble size of the microbubble composition may be between about 1 pm and about 5 pm.
- the average microbubble size of the microbubble composition may be about 3 pm.
- the microbubbles within the microbubble composition may be primarily nanobubbles or entirely nanobubbles.
- the average microbubble size of the microbubble composition may be between about 100 nm and 700 nm.
- the average microbubble size of the microbubble composition may be between about 200 nm and 600 nm.
- the average microbubble size of the microbubble composition may be between about 300 nm and 500 nm.
- the microbubble composition may include microbubbles with biodegradable linkers operably positioned between an exterior surface of a shell of the microbubble and the payload.
- the biodegradable linkers may be joining a spermine to a dextran or a spermine to another spermine.
- the payload may be cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).
- cGAMP cyclic guanosine monophosphate-adenosine monophosphate
- the method may be an in vitro method.
- the microbubble composition may be incubated with the one or more target cells at a concentration of at least about 5, 10, 15, 20, 25, or 30 microbubbles/cell.
- the step of administering the microbubble composition to the one or more target cells may entail mixing the composition with the one or more target cells in solution.
- the one or more target cells may be adhered to a surface and the step of administering the microbubble composition to the one or more target cells may entail exposing the surface to the composition in a manner such that the one or more cells are positioned over the microbubbles.
- a method of treating cancer in a subject in need thereof entails performing any of the aforementioned targeted drug delivery methods, in which administering the microbubble composition to the one or more target cells entails administering the microbubble composition and the ultrasound stimulus to the subject in need of treatment, and in which the payload is a cyclic dinucleotide.
- the subject may have been diagnosed with cancer.
- the subject may have a tumor.
- the subject may have one or more metastases.
- the microbubble composition may be administered intratumorally.
- the microbubble composition may be administered systemically.
- the microbubble composition may be administered intravenously.
- the microbubble composition may be a nanobubble composition.
- Administering the microbubble composition to the subject may entail administering multiple doses of the microbubble composition to the subject and administering the ultrasound stimulus to the subject may entail administering ultrasound stimulus effective to sonoporate the one or more target cells after each dose.
- the multiple doses may be administered at least one day apart.
- the administration may result in an increase in expression of IFN-a, IFN-b, and/or IFN-g within the one or more target cells.
- the administration may result in an increase in serum levels of IFN-a, IFN-b, and/or IFN-g.
- the administration may result in nuclear localization of nuclear translocation of phosphorylated IRF3 (pIRF3) and/or NF-KB p65 in the one or more target cells.
- pIRF3 nuclear localization of nuclear translocation of phosphorylated IRF3
- NF-KB p65 in the one or more target cells.
- the administration may result in increased recruitment of CD8+ and CD4+ T cells within the tumor.
- the administration may result in an increased number of effector memory T-cells and/or central memory T-cells that are specific to cancer cells within the subject.
- the administration may result in a decrease in tumor size.
- the administration may result in the eradication of the tumor.
- the administration may prevent or reduce the likelihood of future metastases.
- the administration may prevent or reduce the likelihood of recurrence of the cancer in the subject.
- the method may further entail treating the subject with immune checkpoint therapy.
- the immune checkpoint therapy may entail administering to the subject inhibitors that target CTLA4, PD-1, PD-L1, and/or CD47.
- a microbubble composition for therapeutic drug delivery.
- the microbubble composition includes a plurality of microbubbles and a plurality of cyclic dinucleotides.
- the microbubbles each have a gas core encapsulated by a surfactant shell.
- a plurality of cationic polymers is associated with the external surface of the surfactant shell of each microbubble.
- the cyclic dinucleotides are non-covalently bound to the cationic polymers on the external surface of the microbubbles.
- the cationic polymers may be polyamines.
- the polyamines may be spermines.
- the spermines may be conjugated to dextrans. Multiple spermines may be conjugated to each dextran.
- the plurality of cyclic dinucleotides may include cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).
- a method of the aforementioned microbubble compositions entails associating the cationic polymers with the microbubbles and loading the cyclic dinucleotides onto the microbubbles after the cationic polymers have been associated.
- the method entails binding the cyclic dinucleotides to the cationic polymers to form nanocomplexes and loading the nanocomplexes onto the microbubbles.
- microbubble composition formed by either of the aforementioned methods of making microbubble compositions.
- FIGs. 1A-1B depict size distributions of SpeDex-aCDl lb MBs (cMBs) measured by Coulter Counter (Fig. 1A) and SpeDex-cGAMP nanocomplexes measured using nanoparticle tracking analysis (Fig. IB).
- FIG. 2 depicts mean fluorescence intensity quantification of the DY547-c-diGMP uptake in BMDMs.
- FIG. 3 depicts quantification by flow cytometry of live and dead THP-1 and E0771 cells stained with Propidium Iodide (PI) after sonoporation with ncMBs at 1, 2, and 3 W/cm 2 .
- PI Propidium Iodide
- FIGs. 4A-4H depict qRT-PCR results showing fold changes in levels of: IFNa mRNA in THP-1 macrophages at various time points after treatment (Fig. 4A), IFNP mRNA in THP-1 macrophages at various time points after treatment (Fig. 4B), IFNa mRNA in BMDMs at various time points after treatment (Fig. 4C), IFNp mRNA in BMDMs at various time points after treatment (Fig. 4D), IFNa mRNA in wild type and STING/ BMDMs at 6 h post-treatment (Fig. 4E), IFNP mRNA in wild type and STING/ BMDMs at 6 h post-treatment (Fig. 4A), IFNP mRNA in THP-1 macrophages at various time points after treatment (Fig. 4B), IFNa mRNA in BMDMs at various time points after treatment (Fig. 4C), IFNp mRNA in BMDMs at various time points after treatment (Fig. 4D), IFNa
- FIGs. 5A-5H depict ELISA results showing protein levels in cell supernatants for: IFNa from THP-1 macrophages at various time points after treatment (Fig. 5 A), IFNp from THP-1 macrophages at various time points after treatment (Fig. 5B), IFNa from BMDMs at various time points after treatment (Fig. 5C), IFNP from BMDMs at various time points after treatment (Fig. 5D), IFNa from wild type and STING/ BMDMs at 6 h post-treatment (Fig. 5E), IFNP from wild type and STING/ BMDMs at 6 h post-treatment (Fig. 5F), IFNa from primary human peripheral blood monocyte derived macrophages at 6 h post-treatment (Fig. 5G), and IFNP from primary human peripheral blood monocyte derived macrophages at 6 h post-treatment (Fig. 5H).
- FIGs. 6A-6D depict western blot results showing STING, phosphorylated STING (pSTING SER366 or pSTING SER366 ), IRF3, phosphorylated IRF3 (pIRF3 SER366 or pIRF3 SER396 ), and b-actin (control) levels in: THP-1 macrophages at various time points after treatment (Fig. 6A), BMDMs at various time points after treatment (Fig. 6B), wild type and STING/ BMDMs at 6 h post-treatment (Fig. 6C), and primary human peripheral blood monocyte derived macrophages at 6 h post-treatment (Fig. 6D).
- FIGs. 7A-7C depict western blot results showing IKKa, IKKb, phosphorylated IKKa/b (Serl76/180), IkBa, phosphorylated IkBa (Ser32), NF-kB p65, phosphorylated NF-KB p65 (Ser536), and b-actin (control) levels in: THP-1 macrophages at various time points after treatment (Fig. 7A), BMDMs at various time points after treatment (Fig. 7B), and wild type and STING/ BMDMs at 6 h post-treatment (Fig. 7C).
- FIGs. 8A-8C illustrate the nuclear translocation of phosphorylated IRF3 (pIRF3) following various treatment.
- Fig. 8A depicts immunohistochemistry images of stained nuclei of wild type BMDMs, STING/ BMDMs, THP-1 macrophages, and peripheral blood monocyte derived macrophages at 6 h post-treatment with the additional staining of phospho-IRF3.
- Fig. 8B depicts the percentage of nuclear fluorescent positive BMDMs and Fig. 8C depicts the percentage of nuclear fluorescent positive THP-1 cells.
- FIGs. 9A-9C illustrate the nuclear translocation of NF-KB p65 following treatment.
- Fig. 9A depicts immunohistochemistry images of stained nuclei of wild type BMDMs, STING/ BMDMs, and THP-1 macrophages at 6 h post-treatment with the additional staining of NF-KB p65.
- Fig. 9B depicts the percentage of nuclear fluorescent positive BMDMs and
- Fig. 9C depicts the percentage of nuclear fluorescent positive THP-1 cells.
- FIG. 10 depicts the quantification by flow cytometry of the percentage of E0771 breast cancer cells that were phagocytized by BMDMs, which were treated 6 h before being co-cultured with the E0771 cells for 4 h.
- FIGs. 11 A-l IB depict normalized levels of proliferation, as measured by flow cytometry, of CD8 + (Fig. 11 A) and CD4 + T cells (Fig. 11B) from OT-I and OT-II transgenic mice, respectively, that recognize the cOVA-derived peptide antigens, after incubation for 72 h with STING and wild type BMDMs that had been treated and subsequently incubated with the OVA peptide antigens for 6 hours.
- FIGs. 12A-12C depict CD8 + T cell proliferation and cytokine levels for treated TAMs.
- Fig. 12A depicts normalized levels of proliferation, as measured by flow cytometry, of CD8 + T cells from OT-I transgenic mice after incubation for 72 h with TAMs that had been treated and subsequently incubated with the OVA peptide antigens for 6 hours.
- Figs. 12B-12C depict ELISA results showing protein levels in cell supernatants for IFNa (Fig. 12B) and IFNP (Fig. 12C) from wild type and STING/ BMDMs at 6 h post-treatment.
- FIGs. 13A-13D illustrate IRF3/NF-KB activation in BMDCs.
- Fig. 13 A depicts immunohistochemistry images of stained nuclei of wild type BMDCs and STING/ BMDCs at 6 h post-treatment with the additional staining of phospho-IRF3.
- Fig. 13B depicts the percentage of nuclear fluorescent positive BMDCs for phospho-IRF3.
- Fig. 13C depicts immunohistochemistry images of stained nuclei of wild type BMDCs and STING/ BMDCs at 6 h post-treatment with the additional staining of NF-KB p65.
- Fig. 13D depicts the percentage of nuclear fluorescent positive BMDCs for NF-KB p65.
- FIGs. 14A-14D illustrate increased type I IFN responses in BMDCs at 6 h post-treatment.
- FIGs. 14A-14B depict qRT-PCR results showing fold changes in levels of IFNa mRNA (Fig. 14A) and IFNp mRNA (Fig. 14B) in wild type and STING/ BMDCs.
- Figs. 14C-14D depict ELISA results showing protein levels in cell supernatants for IFNa (Fig. 14C) and IFNP (Fig. 14D) from wild type and STING/ BMDCs.
- FIGs. 15A-15B depict normalized levels of proliferation, as measured by flow cytometry, of CD8 + (Fig. 15 A) and CD4 + T cells (Fig. 15B) from OT-I and OT-II transgenic mice, respectively, after incubation for 72 h with STING and wild type BMDCs that had been treated and subsequently incubated with the OVA peptide antigens for 6 hours.
- FIGs. 16A-16B illustrate the specificity of in vivo delivery of DY547-c-diGMP via treatment with MUSIC to tumor-associated CD 1 lb+ cells in an orthotopic syngeneic murine breast cancer model relative to treatment with non-targeting microbubbles, as evaluated by flow cytometry performed on single cell suspensions.
- Fig. 16A depicts the percentage of CD1 lb + cells that are positive for DY547-c-diGMP.
- Fig. 16B depicts the percentage of CDl lb cells that are positive for DY547-c-diGMP.
- FIG. 17 shows contrast mode ultrasound (US) images of E0771 breast tumors (13 days) in C57BL/6J mice before injection of ncMBs (left, non-treatment), after injection of ncMBs (middle, pre-sonoporation), and after US sonoporation (right, post-sonoporation). Loss in signal represents bubbles being destroyed after exposure to US. Images are from the same mouse, representative of randomly treated wild-type (WT) mice.
- FIGs. 18A-18B depict the percentage of tumor area (day 18) that is CDl lb+ (Fig. 18A) and relative mean phosphorylated STING (pSTING) fluorescence intensity (Fig. 18B) as measured from confocal microscopy images of tumor paraffin section slides immunostained for recruited CD1 lb+ cells and pSTING+ cells.
- FIGs. 19A-19B depict the percentage of CDl lb+ cells (Fig. 19A) and TAMs (Fig. 19B) that are positive for pSTING as measured by flow cytometry performed on single cell suspensions of tumor tissue (day 18) from treated mice.
- FIGs. 20A-20D illustrate the increased recruitment of CD8+ and CD4+ T cells into tumors (day 18) after MUSIC treatment.
- Figs. 20A-15B depict the percentage of CD8+ T cells (Fig. 20A) and CD4+ T cells (Fig. 20B) detected in single cell suspensions of treated tumor tissue as measured by flow cytometry.
- Figs. 20C-20D depict the percentage of tumor area that is CD8+ (Fig. 20C) and CD4+ (Fig. 20D) as measured from confocal microscopy images of immunostained tumor paraffin section slides.
- FIGs. 21A-21I depict in vivo results of tumor treatment.
- Figs. 21A-21D depict results in wild type mice, including spider plots of tumor volume for individual mice within each treatment group (Fig. 21A), cumulative group results for tumor volume (Fig. 21B), survival curves (Fig. 21C), and representative photographs of mice at 24 days post tumor inoculation (Fig. 2 ID).
- Figs. 21E-21I depict results in STING/ mice, including average tumor volume (Figs. 21E, 21H), survival curves (Figs. 21F, 211), and spider plots of tumor volume for individual mice (Fig. 21G).
- FIG. 22 depicts tumor volumes for rechallenged MUSIC-treated mice that demonstrated complete tumor remission and non-treated naive mice (control).
- FIGs. 23A and 23B depict tumor volumes (Fig. 23 A) and survival curves (Fig. 23B) for STING mice treated with MUSIC or PBS (control).
- FIGs. 24A-24C depict the average percentages, as measured by flow cytometry, of CD8+ T cells isolated from treated tumor tissue samples (day 18) that were naive T cells (Fig. 24A; CD44 low CD62L high ), effector memory T cells (Fig. 24B; CD44 high CD62L low ), and central memory T cells (Fig. 24C; CD44 high CD62L high ).
- FIG. 25 depicts quantified IFN-g enzyme-linked immune absorbent spot (ELISpot) results for splenic T cells that were isolated from treated mice (day 18) and rechallenged by co-culturing with E0771 tumor cells at a ratio of 10:1 (T cells:E0771 cells) overnight.
- FIGs. 26A-26C depict in vivo results of tumor treatment in wild type mice and mice in which CD8 + cells were depleted using an anti-CD8 antibody prior to treatment, including spider plots of tumor volume for individual mice within each treatment group (Fig. 26A), mean tumor volumes (Fig. 26B), and survival rates (Fig. 26C).
- FIGs. 27A-27F depict ELISA results showing protein levels measured in treated mice (18 days) from tumor tissue (Figs. 27A-27C) and serum (Figs. 27D-27F) for: IFNa (Figs. 27A, 27D), IFNp (Figs. 27B, 27E), and IFN-g (Figs. 27C, 27F).
- FIGs. 28A-28B depict the percentage of treated tumor area (18 days) that is CD8 + (Fig. 28A) and PD-1 + (Fig. 20D) as measured from confocal microscopy images of immunostained tumor paraffin section slides from wild type and STINGY mice.
- FIGs. 29A-29B depict the relative mean fluorescence intensity for IFN-g (Fig. 29A) and PD-L1 (Fig. 29B) in randomly selected confocal microscopy images of immunostained tumor paraffin section slides from tread wild type and STING/ mice.
- FIGs. 30A-30C depict luminescence levels for bioluminescent tumor cells in mice treated with PBS only, MUSIC, cGAMP with US, cGAMP only, and MBs with US, including lung luminescence over time (Fig. 30A), final primary tumor and lung luminescence levels along with primary tumor volume and number of lung metastatic nodules (Fig. 30B), and heat mapping images of luminescence in extracted primary tumors, kidneys, livers, spleens, hearts, and lungs from representative mice (Fig. 30C).
- FIGs. 31A-31U depict the effects of combination therapy with MUSIC and systemic administration of an anti-PD-1 antibody (aPD-1) in spontaneously metastatic murine triple negative 4T1 breast tumor-bearing mice.
- Figs. 31 A-3 IB depict relative bioluminescence intensity in the lungs (Fig. 31 A) and primary tumor (Fig. 3 IB) of treated mice over time from representative in vivo images.
- Figs. 31C-31E depicts spider plots of tumor volume for individual mice within each treatment group (Fig. 31C), mean tumor volumes (Fig. 3 ID), and survival rates (Fig. 3 IE).
- Figs. 31F-31G depict the number of pulmonary metastatic modules (Fig. 3 IF) and relative bioluminescence intensity in the lungs of (Fig.
- FIGs. 31H-31L depict ELISA results showing protein levels measured in treated mice from tumor tissue (Figs. 31H-31I) and serum at 21 days post-inoculation (Figs. 31J-31L) for: IFNa (Figs. 31H, 31J), IFNP (Figs. 311, 3 IK), and IFN-g (Fig. 31L).
- Figs. 31M-31N depict the percentage of CD8+ T cells (Fig. 31M) and CD4+ T cells (Fig. 3 IN) detected in single cell suspensions of treated tumor tissue as measured by flow cytometry.
- Figs. 310-3 IP depict the percentage of tumor area that is CD8+ (Fig.
- Figs. 3 IQ-31R depict relative mean phosphorylated STING (pSTING) (Fig. 3 IQ) and IFN- g (Fig. 31R) fluorescence intensity levels as measured from confocal microscopy images of immunostained tumor paraffin section slides.
- Figs. 31S-31U depict the average percentages, as measured by flow cytometry, of CD8 + T cells isolated from treated tumor tissue samples that were naive T cells (Fig. 3 IS; CD44 low CD62L high ), effector memory T cells (Fig. 3 IT; CD44 high CD62L low ), and central memory T cells (Fig. 31U; CD44 high CD62L high ).
- FIG. 32 depicts the size distribution of nanobubbles (NBs) measured using nanoparticle tracking analysis.
- FIGs. 33A-33B illustrate the successful cytosolic delivery of Dy547-diGMP to THP-1 macrophages via sonoporation with ncNBs.
- Fig. 33A depicts fluorescent images of macrophages treated via incubation with Dy547-diGMP only (left) or sonoporation with Dy547-diGMP-loaded ncNBs (right).
- Fig. 33B depicts the detection of the secreted embryonic alkaline phosphatase (SEAP) reporter in the THP-1 macrophage supernatant following sonoporation.
- SEAP secreted embryonic alkaline phosphatase
- FIGs. 34A-34C illustrate the use of a clinical US scanner to detect the delivery of intravenously administered ncNBs to tumor tissue and sonoporate APCs within the tumor tissue.
- Figs. 34A-34C depict schematics of the treated mouse and US images of the tumor site before (Fig. 34A), during (Fig. 34B), and after (Fig. 34C) injection of the ncNBs.
- microbubble compositions may be used for targeted drug delivery (in vitro or in vivo ) of a payload to one or more target cells.
- the payload may be delivered to the cytosol of the one or more targeted cells by targeted sonoporation.
- the microbubbles may also be targeted to the one or more target cells by incorporation of targeting molecules, such as antibodies, that bind to the one or more target cells.
- the microbubbles may target professional antigen presenting cells (APCs) such as macrophages and dendritic cells (e.g., by the incorporation of an anti-CDl lb antibody).
- the payload may comprise any suitable agent that can be loaded onto the surface of the microbubbles.
- the payload may be mRNA or plasmid DNA (pDNA) for use in applications such as nucleotide-based vaccines or gene therapies.
- the payload may be an agonist of the cGAS- STING cytosolic DNA sensing pathway.
- the spatial and temporal targeting of STING activation afforded via sonoporation of drug-carrying microbubbles can allow for enhanced potency of STING agonists with decreased systemic inflammatory side effects and toxicity. Sonoporation is also particularly advantageous for delivering negatively charged payloads in general, such as nucleotides, across the negatively charged plasma membrane.
- such agonists may be used for the treatment of cancer, particularly solid tumor cancers (e.g., breast cancer, brain cancer, melanoma) or other cancers having solid masses (e.g., lymphomas).
- STING agonists may be used to activate downstream proinflammatory pathways in APCs that efficiently prime antigen-specific T cells, thus bridging innate and adaptive immune responses. Doing so can result in systemic antitumor immunity and/or antitumor memory responses.
- the microbubble composition may be used as a vaccine, such as therapeutic vaccine for the treatment of cancer, or a vaccine adjuvant.
- the human immune system may generally be divided into two arms, referred to as “innate immunity” and “adaptive immunity.”
- the innate arm of the immune system is predominantly responsible for an initial inflammatory response via a number of soluble factors, including the complement system and the chemokine/cytokine system; and a number of specialized cell types including mast cells, macrophages, dendritic cells (DCs), and natural killer cells.
- the adaptive immune arm involves a delayed and a longer lasting antibody response together with CD8 + and CD4 + T cell responses that play a critical role in immunological memory against an antigen.
- a third arm of the immune system may be identified as involving gd T cells and T cells with limited T cell receptor repertoires such as NKT cells and MAIT cells.
- antigen presenting cells For an effective immune response to an antigen, antigen presenting cells (APCs) must process and display the antigen in a proper MHC context to a T cell, which then will result in stimulation of cytotoxic T cells and helper T cells. Following antigen presentation, successful interaction of co- stimulatory molecules on both APCs and T cells must occur or activation will be aborted.
- GM-CSF and IL-12 serve as effective pro-inflammatory molecules in many tumor models.
- GM-CSF induces myeloid precursor cells to proliferate and differentiate into dendritic cells (DCs) although additional signals are necessary to activate their maturation to effective antigen-presenting cells necessary for activation of T cells.
- Barriers to effective immune therapies include tolerance to the targeted antigen that can limit induction of cytotoxic CD8 + T cells of appropriate magnitude and function, poor trafficking of the generated T cells to sites of malignant cells, and poor persistence of the induced T cell response.
- DCs that phagocytose tumor-cell debris process the material for major histocompatibility complex (MHC) presentation, upregulate expression of costimulatory molecules, and migrate to regional lymph nodes to stimulate tumor-specific lymphocytes.
- MHC major histocompatibility complex
- This pathway results in the proliferation and activation of CD4 + and CD8 + T cells that react to tumor-associated antigens.
- Such cells can be detected frequently in the blood, lymphoid tissues, and malignant lesions of cancer patients.
- Compounds which are capable of stimulating an innate immune response as well as simultaneously priming an adaptive immune response may be particularly useful as immunotherapies for treating cancer.
- compositions described herein are administered with an amount effective of an immunomodulatory payload to stimulate (e.g., induce, increase or enhance) an immune response.
- An “immune response” may generally refer to responses that induce, increase, or perpetuate the activation or efficiency of innate or adaptive immunity.
- the compositions may be used functionally as adjuvants.
- the compositions may or may not be administered together with other adjuvants.
- the immune response may be enhanced relative to delivery of the payload (e.g., an immunomodulatory compound) alone and/or using a delivery vehicle other than the microbubble compositions described herein.
- Specific stimulations of the immune response may comprise reducing inactivation and/or prolonging activation of T cells (e.g., increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation and effector functions of cells, and/or promoting T cell survival) or overcoming cell exhaustion and/or anergy.
- the composition may be effective to induce or increase the activation of STING.
- the compositions described herein may increase the number of immune cells producing proinflammatory cytokines, such as IFN-a, IFN- b, and/or IFN-g, and/or increase the production of proinflammatory cytokines in existing immune cells. The increases may be detectable in a subject’s serum.
- compositions described herein When used to stimulate an immune response, the compositions described herein may result in nuclear localization of pIRF3 and/or NFK-B in treated cells.
- the compositions described herein may recruit CD8 + and /or CD4 + T cells to a site of treatment, infection, and/or cancer (e.g., to a tumor).
- a stimulated immune response may result in an increase number of effector memory T-cells and/or central memory T-cells (e.g., within a site of treatment, infection, or cancer) that are specific to an antigen.
- the antigen may be administered with or as a part of the microbubble composition or be an antigen present within a treatment area (e.g., a tumor antigen).
- a stimulated immune response may comprise an improved B-memory cell response (e.g., an increased frequency of peripheral blood B lymphocytes capable of differentiation into antibody-secreting plasma cells upon antigen encounter as measured by stimulation of in vitro differentiation).
- an enhancement of an immune response may be quantified.
- the enhancement may be, for instance, at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, or 1,000% improved (e.g., increased) over a suitable baseline measurement.
- a suitable baseline measurement may be, for example, measured in a subject (e.g., prior to treatment) or a suitable reference population.
- the improvement may be statistically significant (e.g., p ⁇ 0.05).
- microbubble compositions which may be useful for drug delivery, according to the methods described elsewhere herein.
- Microbubbles are described herein.
- microbubble may refer to a gas-filled bubble formed by a surfactant shell encapsulating a gas core.
- the surfactant shell may comprise one or more types of molecules which lower the interfacial tension between the gas core and the exterior aqueous environment, such as a physiological environment.
- This exterior shell may comprise, for example, lipids (e.g., phospholipids), proteins (e.g., albumin), sugars, and/or polymers.
- the gas cores comprise a perfluorocarbon (e.g., decafluorobutane).
- the microbubble shells comprise l,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC) and/or l,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) lipids.
- DSPC l,2-Distearoyl-sn-Glycero-3-Phosphocholine
- DSPE l,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine
- one or more of the components of the microbubble shell may be PEGylated.
- PEG chains may extend outward from the external surface of the microbubble.
- Various microbubble formulations are well known in the art. Microbubbles may be produced, for example, without limitation by any of the methods disclosed in U.S. Patent Nos. 6,113,919 to Reiss et al.
- the bubble may be no greater than about 10 pm in diameter.
- the average microbubble size within a microbubble composition is at least about 1, 2, 3, 4, or 5 pm.
- the average microbubble size is approximately 1, 2, 3, 4, or 5 pm.
- the average microbubble size is between approximately 1-10, 1-5, 1-4, 1-3, 1-2, 2-5, 2-4, 2-3, 3-5, or 3-4 pm.
- microbubbles may comprise bubbles less than 1 pm (i.e. nanobubbles), such as bubbles between, for example, about 50 nm - 100 nm, about 50 nm - 200 nm, about 50 nm - 300 nm, about 100 nm - 200 nm, about 100 nm - 300 nm, about 100 nm - 400 nm, about 100 nm - 500 nm, about 100 nm -1 pm, about 200 nm - 1 pm, about 300 nm - 1 pm, or about 500 nm - 1 pm.
- bubbles less than 1 pm i.e. nanobubbles
- the average size of the microbubble composition is between about 100 nm - 700 nm, about 200 nm - 600 nm, or about 300 nm - 500 nm.
- the size of the microbubble composition (e.g., the average size or the maximum size) may be such that the microbubbles (or at least a majority of the microbubbles, e.g., at least 60%, 70%, 80%, 90%, 95%, 99% of the microbubbles) are able to extravasate the blood vessels of a subject, which may advantageously allow for systemic delivery of the microbubble composition in certain applications.
- the microbubble composition may be a nanobubble composition.
- a “nanobubble composition” may refer to a composition of microbubbles in which consists entirely of nanobubbles or is composed primarily of nanobubbles (e.g., at least about 60%, 70%, 80%, 90%, 95%, 99% of the microbubbles are nanobubbles).
- a nanobubble composition may be microbubble composition that is prepared in a manner to preferentially isolate nanobubbles or nanobubbles of a certain size.
- a nanobubble composition may be prepared, for example, by differential centrifugation, as described elsewhere herein.
- a nanobubble composition may have an average bubble size less than 1 pm.
- nanobubble compositions may be used for systemic delivery of microbubbles to a subject.
- various payloads may be loaded onto the microbubble compositions described herein.
- “loading” may refer to the binding of payload molecules to microbubbles.
- payloads may preferably be reversibly bound to microbubbles though non-covalent interactions (e.g., electrostatic interactions).
- payloads may preferably be bound to an external surface of the microbubbles (i.e. the microbubbles may be decorated with the payload).
- the microbubble compositions may incorporate one or more types of payload-binding molecules for loading the payload onto the microbubbles.
- the payload binding molecules may be polymers.
- the payload-binding molecules may be cationic (e.g., cationic polymers).
- the payload binding molecules may comprise polyamines.
- the polyamines may comprise spermines, as described in further detail elsewhere herein.
- loaded microbubble compositions may be prepared in various ways.
- the payload-binding molecules e.g., cationic polymers
- the microbubbles may be loaded with payload (e.g., by mixing or incubating with a payload solution).
- spermine decorated microbubbles e.g., SpeDex-decorated microbubbles
- CDNs e.g., cGAMP
- the payload-binding molecules may first be loaded with payload (e.g., via mixing) to form nanocomplexes, after which the resulting nanocomplexes may be conjugated to the microbubbles.
- a solution of CDNs e.g., cGAMP
- spermine or SpeDex e.g., spermine or SpeDex
- Loading active agents onto microbubbles may provide improved therapeutic efficacy relative to administering the active agent alone or in combination with the same microbubble composition but not bound to the microbubbles (e.g., with respect to the same microbubble compositions and the same amount of payload, loaded microbubble compositions may demonstrate increased intracellular delivery of the active agent after sonoporation relative to unbound combinations of the active agent and microbubble composition).
- the microbubbles are decorated with spermines, which are particularly effective in non-covalently binding negatively charged payloads.
- the spermines are interlinked by dextrans, which allow for effective loading of spermines and negatively charged payloads to the microbubble surface. See e.g., PCT/US2021/054820 to Lux et al., filed October 13, 2021, which is herein incorporated by reference in its entirety.
- Spermine-modified dextran (SpeDex) is a non toxic cationic branched biopolymer that allows high loading of negatively charged payloads.
- SpeDex-decorated microbubbles are loaded with CDNs, such as cGAMP, for delivery to target cells, preferably via sonoporation. Strong electrostatic interaction between negatively charged CDNs and the cationic SpeDex polymers allows for efficient and stable binding.
- the high loading capacity of such microbubble compositions for suitable payloads, such as CDNs, may allow for improved drug delivery (e.g., larger amounts of payload being delivered intracellularly to target cells in each administration).
- the payload may be any active agent which is able to be loaded onto a microbubble and preferably those that are suitable for intracellular delivery via sonoporation.
- the microbubble compositions described herein may be particularly useful for payloads which would benefit from targeted drug delivery.
- Payloads which stably bind spermine or SpeDex may, in particular, be suitable for drug delivery using the methods and/or compositions described herein, although other payload binding molecules (e.g., other cationic polymers such as polyamines) may be used to load microbubbles.
- the payload may bind to the microbubbles via electrostatic interactions between positive charges on the microbubble surface (e.g., positively charged primary and/or secondary amino groups) and negative charges exposed on the payload molecules, such as negatively charged phosphate groups on the sugar phosphate backbone of a nucleic acid or the phosphate group of a CDN.
- the microbubble compositions described herein may be loaded according to the ratio of the number of positively-chargeable amine groups (N) decorating the microbubbles of the microbubble composition to the number of negatively-charged phosphate groups (P) within the payload composition.
- the microbubble composition may be loaded at N:P ratios of approximately 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, or 1:20.
- the microbubble composition may be loaded at N:P ratios in which the number of phosphate groups (P) are at least about 5, 10, 15, or 20 times greater than the number of amine groups (N).
- the microbubble composition may be loaded atN:P ratios of approximately 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, or 20:1.
- the microbubble composition may be loaded at N:P ratios in which the number of amine groups (N) are at least about 5, 10, 15, or 20 times greater than the number of phosphate groups (P).
- the microbubble composition may be prepared at concentrations of approximately lxlO 7 - lxlO 10 , lxlO 7 - lxlO 9 , lxlO 7 - lxlO 8 , lxlO 8 - lxlO 10 , or lxlO 8 - lxlO 9 pg of payload (e.g., pDNA) per microbubble.
- payload e.g., pDNA
- the microbubble composition may, for example, be prepared at concentrations of at least about lxlO 8 , 2xl0 8 , 3xl0 8 , 4xl0 8 , 5xl0 8 , 6xl0 8 , 7xl0 8 , 8xl0 8 , 9xl0 8 pg/microbubble.
- the amount of payload that a microbubble composition is ultimately able to carry may depends in part on the amount of positive charges available (e.g., the surface density of the amino groups on the microbubble surface) as well as the ability of the positively charged polymer to stably bind the nucleic acid.
- the binding stability of a microbubble composition may generally be reduced at higher loading capacities.
- the microbubbles may be decorated with targeting molecules, which bind to specific cell types or other biological structures.
- the targeting molecule may be a protein or other biomolecule (e.g., a ligand for a cell surface receptor).
- the targeting molecule may be a biopolymer or component thereof, such as an extracellular matrix polymer (e.g., hyaluronic acid, collagen, elastin, fibronectin, laminin, or proteoglycans such as heparan sulfate, chondroitin sulfate, keratin sulfate).
- the targeting molecule is a monoclonal or polyclonal antibody, including antibody fragments or peptides derived from/modeled after antibodies with antigen-binding properties.
- the antibody may be a Fab fragment, an F(ab’)2 fragment, an Fab’ fragment, an Fv fragment, an scFv, a di-scFv, an sdAb, a recombinant IgG, a peptide comprising one or more complementary determining regions (CDRs), or any other antibody fragment or biomolecule with antigen binding properties well known in the art.
- the antibody may be specific for an antigen expressed on the cell surface of the targeted cell type (e.g., a cell surface receptor).
- the microbubbles may be configured to target cancerous / tumor cells.
- the microbubbles may be configured to target immune cells (e.g., T-cells, B, cells, neutrophils, eosinophils, basophils, mast cells, monocytes, macrophages, dendritic cells, natural killer cells, etc.).
- microbubble compositions may comprise targeting molecules which bind CDl lb (e.g., anti-CDl lb antibodies).
- CDl lb Cluster of differentiation molecule 11B
- IGAM integrin alpha M
- CR3A is one protein subunit that forms heterodimeric integrin alpha-M beta-2 (aMb2) molecule, also known as macrophage-1 antigen (Mac-1) or complement receptor 3 (CR3).
- aMb2 is expressed on the surface of many leukocytes involved in the innate immune system, including monocytes, granulocytes, macrophages, natural killer cells, and dendritic cells.
- APCs such as macrophages and dendritic cells, may be targeted for drug delivery by targeting CD1 lb.
- the targeting molecules may be covalently coupled to the external surface of the surfactant shell of the microbubble.
- Various conjugation strategies are well known in the art for conjugating targeting molecules to microbubbles. See, e.g., PCT/US2021/054820 to Lux et ak, filed October 13, 2021, which is herein incorporated by reference in its entirety.
- Microbubble compositions comprising targeting molecules may provide improved therapeutic efficacy relative to microbubble compositions not targeted to any cell type (e.g., with respect to the same microbubble compositions loaded with the same amount of payload, targeted microbubble compositions may demonstrate increased intracellular delivery of the payload after sonoporation even when using localized administration, such as after intratumoral injection). Payloads
- microbubble compositions described herein may be loaded with one or more “payloads” or “active agents.”
- payload or “active agent” or “drug,” as used herein, refer to any compound used for the treatment or diagnosis of a disease.
- Drug delivery may refer to the delivery of a payload or active agent to a cell or subject, preferably to a target organ, tissue, and/or cell type.
- a microbubble composition as used herein may facilitate drug delivery of the one or more active agents to a target organ, tissue, or cell.
- Exemplary active agents include, but are not limited to, compounds that rely on intracellular access and/or compounds that rely on access to cytosolic receptors/pathways, including STING agonists, such as cyclic dinucleotides (CDNs), as described in further detail herein.
- STING agonists such as cyclic dinucleotides (CDNs)
- CDNs cyclic dinucleotides
- Additional representative suitable active agents include, but are not limited to, STING antagonists, oligonucleotides, proteins, peptides, peptides, lipopeptides, polysaccharides, hydrophobic and amphiphilic small molecular drugs, antibodies, nanobodies, RNA, mRNA, miRNA, siRNA, aptamers, antibiotics, antigens (e.g., tumor antigens, tumor neoantigens), chemotherapeutics, imaging agents, quantum dots, any other suitable compound for disease treatment, or a combination thereof.
- the payload may comprise a nucleic acid.
- the nucleic acid may be, for example, a plasmid (e.g., pDNA), an siRNA, or a Dicer-substrate siRNA (DsiRNA).
- the nucleic acid may be DNA, RNA, or combinations thereof.
- the methods and/or compositions described herein may be used for targeted gene delivery (e.g., siRNA, mRNA, DNA, etc.), such as for gene therapy.
- the payload may comprise a protein.
- Protein therapeutics may comprise, for example, antibody -based drugs, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, Fc fusion proteins, growth factors, hormones, interferons, interleukins, thrombolytics, etc.
- Representative examples of therapeutic applications include, but are not limited to, delivery of immunostimulatory DNA to immune cells; cytosolic delivery of antigens to dendritic cells to increase antigen presentation on class I MHC, cytosolic delivery of vaccine antigen/adjuvant combinations and intracellular cytokine staining.
- Microbubble compositions may comprise mixtures of microbubbles having different payloads or payload profiles.
- a microbubble composition may comprise two or more of the active agents described herein, including the agents discussed with respect to combination therapies (e.g., a CDN and an anti-cancer agent).
- the microbubble compositions may have one or more types of targeting molecules and/or microbubble compositions may comprise mixtures of microbubbles having different targeting molecules or targeting molecule profiles.
- the methods and/or compositions of the present disclosure may be particularly useful for delivery of CDNs, particularly to immune cells, including both macrophages and dendritic cells.
- the methods and/or compositions of the present disclosure may be particularly useful for delivery of STING agonists, preferably intracellular delivery of STING agonists to target cells.
- An “agonist,” as it relates to a ligand and receptor, comprises a molecule, combination of molecules, a complex, or a combination of reagents, that stimulates the receptor.
- a STING agonist can encompass cGAMP, a mutein or derivative of cGAMP, a peptide mimetic of cGAMP, a small molecule that mimics the biological function of cGAMP, or an antibody that stimulates STING.
- preferred payloads may be cGAMP or other STING agonists.
- CDNs may be delivered to cancer cells.
- Stimulator of interferon genes is an adaptor protein in the cytoplasm of mammalian cells which activates the TANK binding kinase (TBK1) - interferon regulatory factor 3 (IRF3) signaling axis via a phosphorylation-dependent mechanism, resulting in the induction of IFN-b and other IRF-3 dependent gene products that strongly activate innate immunity.
- TKB1 is a serine/threonine protein kinase which regulates cell proliferation, apoptosis, autophage, and anti-tumor immunity. TKB1 phosphorylates and activates IRF3.
- IRF3 is an inteferon regulatory factor (transcription factor). Sting also activates the STAT6 transcription factor, which mediates signaling required for the development of T-helper type 2 (Th2) cells and Th2 immune response. STAT6 and IRF3 are responsible for antiviral response and innate immune response against intracellular pathogens. STING, thus, plays an important role in innate immunity. STING also activates NF-KB, a protein complex that controls transcription of DNA, cytokine production and cell survival, and which functions together with IRF3 to turn on the transcription of type I interferons (IFNs) and other cytokines.
- IFNs type I interferons
- STING induces type I interferon production when cells are infected with intracellular pathogens, such as viruses, mycobacteria and intracellular parasites.
- Type I interferons play important roles in both the adaptive and innate immune responses, prevent proliferation of pathogens, and have antiviral activities.
- Type I interferons, mediated by STING, protect nearby cells from local infection via paracrine signaling. STING is encoded in humans by the STING1 gene (Gene ID: 340061).
- STING is considered a pathogen recognition receptor (PRR) which functions as a direct cytosolic DNA sensor (CDS) and is a component of the host cytosolic surveillance pathway.
- PRR pathogen recognition receptor
- CDS direct cytosolic DNA sensor
- the pathway senses infection with intracellular pathogens and in response induces the production of IFN-b, leading to the development of an adaptive protective pathogen-specific immune response consisting of both antigen-specific CD4 + and CD8 + T cells as well as pathogen-specific antibodies.
- the STING signaling pathway in immune cells is a central mediator of innate immune response and when stimulated, induces expression of various interferons, cytokines and T cell recruitment factors that amplify and strengthen immune activity, including against infections and cancerous cells.
- the STING signaling pathway is described in further detail in Li et al., J Exp Med. 2018 May 7;215(5): 1287-1299 (doi: 10.1084/jem.20180139) and Zhu et al.
- Cyclic dinucleotides such as cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), are agonists of STING and have potential therapeutic applications, particularly in oncology and immunology.
- the cyclic dinucleotides recognized by STING are small-molecule second messengers used by all phyla of bacteria and are also produced as endogenous products of the cytosolic DNA sensor cyclic GMP-AMP synthase. Thus, such CDNs may be considered pathogen associated molecular patterns (PAMPs).
- the CDNs cyclic-di-AMP (produced by Listeria monocytogenes) and its analog cyclic-di-GMP (produced by Legionella pneumophila) are also agonists of STING.
- STING agonists A number of other STING agonists have been discovered, or developed, in attempt to either treat tumors alone, or to be used in combination with other cancer therapies to enhance their performance. See, e.g., La Nour et al. Oncoimmunology.
- STING agonists may be delivered directly into the cytoplasm of cells via the application of ultrasound to microbubble compositions loaded with the STING agonist.
- This delivery platform may be used as an immunotherapy for cancer, which in that context, is referred to as Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer (abbreviated as MUSIC herein).
- Microbubbles allow the targeted delivery of STING agonists, such as cGAMP, to target cells (e.g., cancer cells or immune cells) and ultrasound-induced sonoporation can be used to deliver the STING agonist payloads across cell membranes in an endocytosis-independent manner.
- compositions described herein are administered as immunogenic compositions or prophylactic vaccines which confer resistance in a subject to subsequent exposure to infectious agents, or as part of therapeutic vaccines, which can be used to initiate or enhance a subject's immune response to a pre-existing antigen, such as a viral antigen in a subject infected with a virus or with cancer.
- Immunogenic compositions may comprise immunomodulatory compounds which stimulate a desired immune response, as described elsewhere herein.
- the microbubbles may be loaded with immunomodulatory compounds, such as CDNs (e.g., cGAMP); antigens (e.g., protein or peptide antigens); or combinations thereof. Research has shown CDNs promote cellular and humoral immunity in vaccinated mice.
- CDN-based vaccine adjuvants may be used to improve vaccine efficacy.
- the use of the methods and/or compositions described herein to deliver immunomodulatory compounds, antigens, or combinations thereof may provide for increased antigen delivery and/or increased antigen presentation.
- a vaccine is formed by a combination of the immunomodulatory compound and antigen, wherein at least one or both the immunomodulatory compound and antigen are loaded onto a microbubble composition of the present disclosure.
- one of the vaccine components e.g., the antigen
- may be delivered via a different type of composition e.g., using a vehicle other than a microbubble composition or no vehicle at all.
- the immunomodulatory compound and antigen may be delivered together to act as a vaccine, whether they are part of a single pharmaceutical composition or not.
- Antigens can be, without limitation, peptides, proteins, polysaccharides, saccharides, lipids, nucleic acids, or combinations thereof.
- the antigen can be derived from a virus, bacterium, parasite, plant, protozoan, fungus, tissue or transformed cell such as a cancer or leukemic cell and can be a whole cell or immunogenic component thereof, e.g., cell wall components or molecular components thereof.
- Suitable antigens are known in the art and are available from commercial government and scientific sources.
- the antigens may be whole inactivated or attenuated organisms. These organisms may be infectious organisms, such as viruses, parasites and bacteria. These antigen may be a tumor cell.
- the antigens may be purified or partially purified polypeptides derived from tumors or viral or bacterial sources.
- the antigens can be recombinant polypeptides produced by expressing DNA encoding the polypeptide antigen in a heterologous expression system.
- the antigens can be DNA encoding all or part of an antigenic protein.
- the DNA may be in the form of vector DNA such as plasmid DNA.
- Antigens may be provided as single antigens or may be provided in combination.
- Antigens may be provided as complex mixtures of polypeptides or nucleic acids.
- Antigens may be allergens or environmental antigens.
- Antigens may be cancer antigens (an antigen that is typically expressed at higher levels in cancer cells than on non-cancer cells or is expressed solely by cancer cells).
- the microbubble compositions described herein may be used as part of a therapeutic vaccine.
- a “therapeutic vaccine” may refer to a vaccine which is administered after an infection or disease, such as cancer, has already affected a subject.
- a therapeutic vaccine may activate the immune system of a subject to fight an existing infection or disease.
- a therapeutic vaccine may help, for example, a subject’s immune system to recognize and respond to a cancerous cells.
- the microbubble composition may be delivered to a subject as a therapeutic vaccine which targets an existing cancer via targeted sonoporation of a cancer site (e.g., a tumor).
- the drug-loaded microbubble composition may be used to activate APCs, such as dendritic cells, ex vivo.
- APCs may be extracted from a subject via leukapheresis and activated ex vivo via sonoporation of drug- loaded microbubbles (e.g., loaded with a STING agonist, such as a CDN) as well as incubation with a cancer cell antigen or cancerous cells (e.g., isolated from a patient biopsy) before being reintroduced to the subject as a vaccine (e.g., a dendritic vaccine).
- Activation of the APCs may comprise treatment/incubation with other agents, such as granulocyte-macrophage colony stimulating factor (GM-CSF), for example.
- GM-CSF granulocyte-macrophage colony stimulating factor
- the methods of treatment described herein comprise administration of any of the drug- loaded microbubble compositions described elsewhere herein, preferably for intracellular delivery of the drug/payload to a target organ, tissue, or cell, including, for example, the intracellular delivery of immunomodulatory payloads (e.g., CDNs such as cGAMP), such as for the treatment of cancer and/or as part of vaccines, and genes for gene therapy.
- immunomodulatory payloads e.g., CDNs such as cGAMP
- a “disease,” “disorder,” “condition,” “illness,” “ailment,” or “indication” may be used interchangeably and may refer to any physiological state or pathology of a subject which may reasonably be treatable by the methods and/or compositions described herein.
- a disease may be caused by one or more contributing factors, including, for example, genetic factors (i.e. specific genotypes), epigenetic factors, behavioral/lifestyle factors (e.g., diet and exercise), age, and external factors (e.g., toxin exposures, infections, injuries, etc.), some of which may be interrelated.
- a disease may or may not have a definitive etiology.
- a disease may be associated with one or more symptoms.
- a disease may be a syndrome classified by one more symptoms.
- a disease may be clinically diagnosable by one or more well-known means in the art, including, for example, measurable clinical parameters (e.g., blood work, urinalysis, measurement of biomarkers); functional assessments; physical examinations; diagnostic imaging; histological analysis (e.g., biopsies); genotyping/genetic sequencing; evaluation of subject medical history; etc.
- Treatment of a disease or “treating” a disease may refer to an approach of applying the methods and/or compositions described herein for obtaining beneficial or desired results (a therapeutic response), including clinical results.
- “Therapy,” as used herein may be used interchangeably with “treatment.”
- Beneficial or desired results with respect to treating a subject for a disease may include, but are not limited to, one or more of preventing a disease, delaying the onset of a disease, curing or resolving a disease, lessening the severity of a disease, delaying progression of a disease, preventing the worsening of a disease, increasing the quality of life of one suffering from a disease, prolonging survival of a subject having a disease, and/or improving the therapeutic efficacy of other treatments for the disease (e.g., reducing the dose necessary to achieve a therapeutic response).
- beneficial or desired results may be achieved with respect to any aspect of a disease pathology or comorbidity associated therewith, including physiological states or processes that cause or contribute to a disease as well as effected physiological states or processes that manifest in symptoms or complications associated with the disease.
- lessening the severity of a disease may encompass alleviating (e.g., reducing the severity, frequency, or duration of or eliminating altogether) one or more symptoms associated with a disease or comorbidity thereof.
- assessments of beneficial or desired results may comprise assessments of any one or more factors that could be used, at least in part, to diagnose a disease or comorbidity thereof (e.g., assessing for discernible improvements in such a factor).
- the beneficial or desired results may be assessed relative to a population having the same risk factors, symptoms, and/or type and severity of disease (e.g. as assessed by clinical measurements) and not receiving treatment as described herein.
- treatment of a subject can imply that the subject is in need of treatment, e.g., in a situation where the subject has been diagnosed with or exhibits symptoms or complications associated with a disease reasonably expected to be treatable with a method and/or composition described herein.
- Treatment as used herein also encompasses prophylactic treatments.
- prevention when used in reference to a disease, includes a reduction in likelihood of developing a disease (e.g., reducing or improving on risk factors for a disease) and/or a reduction in severity of a disease upon onset.
- a subject may be in need of treatment (e.g., for preventing further development or progression of a disease) or determined to be at a relatively high risk of disease (e.g., such that prospective benefits of prophylactic treatment outweigh any risks, such as side effects, associated therewith).
- a “subject” is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), a non-primate (such as a cow, a pig, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, or a mouse), or a bird that can be treated with the methods and/or compositions of the present disclosure.
- Non human subjects may be livestock.
- the subject is a human, such as a human having cancer.
- the subject may be a female (e.g., a female human).
- the subject may be a male (e.g., a male human).
- the subject is an adult subject.
- the subject is a pediatric subject, such as a neonate, an infant, or a child.
- the subject may be an individual for which it is reasonably expected a therapeutic response could be achieved.
- Subjects may be individuals who are administered a composition of the present disclosure for experimental or research purposes (e.g., control subjects).
- a “patient,” as used herein, refers to a subject who exhibits symptoms and/or complications of a disease; has been diagnosed as having a disease; has been identified as being at a risk of developing a disease; and/or is under the treatment of a clinician (e.g., a physician), including for investigation of some pathology that could be associated with the disease, even if no defined disease has been diagnosed.
- a clinician e.g., a physician
- patient includes human and veterinary subjects. Any reference to subjects in the present disclosure, should be understood to include the possibility that the subject is a “patient” unless indicated otherwise, explicitly or by context.
- the microbubble compositions described herein may be incorporated into a pharmaceutical composition suitable for administration to a subject.
- Such pharmaceutical compositions may further comprise a “pharmaceutically acceptable carrier,” (interchangeable with “pharmaceutical carrier” or “carrier”) which may be any compound or composition useful in facilitating storage, stability, administration, cell targeting and/or delivery of the microbubbles to a target cell or cell population.
- a “pharmaceutically acceptable carrier,” as used herein, refers to a carrier or excipient that is suitable for use with the subjects or patients described elsewhere herein (e.g., humans and/or animals) without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
- the carrier can be a pharmaceutically acceptable solvent, dispersion media, suspending agent or other suitable vehicle, for delivering microbubble compositions as described herein to the subject, such as through, for example, intravenous injection.
- Pharmaceutically acceptable carriers may include any diluents, solvents (including water), fillers, extenders, preservatives, thickeners, antibacterial agents, antifungal agents, isotonic agents, pH modifiers, salts, colorants, flavorings, rheology modifiers, lubricants absorption delaying agents, antifoaming agents, surfactants, emulsifiers, adjuvants, suitable vehicles, coatings, erodible polymers, hydrogels, phospholipids, fatty acids, mono-di- and tri-glycerides and derivates thereof, waxes, oils, etc., which are compatible with pharmaceutical administration.
- compositions for pharmaceutically active substances are well known in the art. Except insofar as any conventional media or agent is incompatible with the microbubbles and/or components thereof (e.g., payloads, targeting molecules), use thereof in the compositions is contemplated. Supplementary active agents can also be incorporated into the pharmaceutical compositions.
- a pharmaceutical composition according to the disclosure may be formulated to be compatible with its intended route of administration, as described elsewhere herein.
- the pharmaceutical composition can be included in a kit, container, pack, or dispenser together with instructions for administration.
- Treatment of a subject, organ, tissue, cell, or body fluid with a composition described herein generally comprises administering the composition to a subject, organ, tissue, cell, or body fluid, respectively.
- Administration refers to inducement of contact between an exogenous compound, such as the microbubble compositions described herein and/or payloads loaded thereon, a placebo, or a control, to a subject, organ, tissue, cell, or body fluid.
- Treatment of a cell for example, encompasses contact of a compound to the cell, as well as contact of a compound to a fluid, where the fluid is in contact or placed into contact with the cell.
- Administration may be performed for therapeutic or experimental (e.g., basic research, clinical research, pharmacokinetic studies) purposes.
- the microbubbles may be administered locally, regionally or systemically as desired, for example and without limitation: intravenously, intramuscularly, subcutaneously, dermally, subdermally, intraperitoneally, transdermally, iontophoretically, orally, and transmucosally.
- devices useful in delivering the microbubbles to a subject include needle/syringes, catheters, trocars, stents or projectiles.
- the microbubbles are delivered directly to a cite in need of an immune response.
- the microbubbles may be delivered intratumorally, which includes delivery internal to a tumor and/or immediately adjacent to a tumor or a cancer cell such that the decoy diffuses to contact the tumor or cancer cell.
- the microbubbles are administered at a site adjacent to or leading to one or more lymph nodes which are close to the site in need of an immune response (e.g., a tumor).
- Treatments may comprise one or more rounds of administration (administration of one or more doses) of a composition described herein.
- a “treatment regimen” or simply “regimen,” as used herein may refer to a course of treatment comprising multiple administrations of a composition described herein.
- the composition may be the same for each round of administration (or for at least some of the rounds of administration) or may be different for at least some rounds of administration.
- the doses may be the same or different for different rounds of administering the same composition.
- a treatment regimen may be defined by a dosing schedule (e.g., a dosing frequency or temporal pattern of administrations), a total number of administrations/doses, and/or a total duration in time of treatment.
- each round of administration may comprise administering the same composition at the same dose via the same route of administration.
- a treatment regimen may comprise specific compositions (including combination therapies), doses, and/or routes of administration where any of these variables is not consistent at each round of administration.
- the administrations can be spaced apart by time intervals of approximately one 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, or 45 minutes; by intervals of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours; by 1, 2, 3, 4, 5, 6, or 7 days; by 1, 2, 3, 4, or 5 weeks; or by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more months, including intervening time ranges.
- the doses may be administered at substantially regular time intervals (a frequency of administration).
- the administrations are not limited to dosing intervals that are spaced equally in time, but may encompass doses at non-equal intervals as well.
- a dosing frequency may be determined based at least in part on pharmacokinetic and/or pharmacodynamics profiles for the composition being administered as is well understood in the art.
- the frequency of administration may be tailored to generally maintain an administered composition, a component thereof (e.g., a payload), a metabolite thereof, or a biological response thereto (e.g., a marker of therapeutic efficacy) above a threshold (e.g., effective for inducing a therapeutic response), below a threshold (e.g., for avoiding or minimizing adverse effects, including toxicity concerns and side effects), or within a prescribed range.
- a threshold e.g., effective for inducing a therapeutic response
- a threshold e.g., for avoiding or minimizing adverse effects, including toxicity concerns and side effects
- the administrations may be spaced apart over a duration of treatment.
- the duration of the treatment regimen may be, for example, approximately or at least about 1, 2, 3, 4, or 5 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months; or 1, 2, 3, 4, or 5 years.
- a treatment regimen may comprise, by example, a total of about 2, 3, 4, 5, 6, 7, 8, 9, 10,
- the treatment may be continued along some dosing schedule (e.g., at a dosing frequency) at least until a therapeutic response is achieved or until a therapeutic response is shown to be likely maintained for a sufficient period of time absent further administrations.
- some dosing schedule e.g., at a dosing frequency
- therapeutically effective in reference to amounts, frequencies, durations, and regimens refers to the amount of a composition, frequency of administration, duration of treatment, or design of treatment regimen, respectively, which would be reasonably expected to be sufficient in achieving a therapeutic response, such as those benefits and results described elsewhere herein with respect to treatments.
- therapeutically effective may refer to an amount, frequency, duration, or regimen that is sufficient to achieve some statistically significant (e.g., p ⁇ 0.05) measure of a therapeutic response.
- therapeutically effective may refer to an amount, frequency, duration, or regimen that is sufficient to achieve at least about a 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% change in a baseline value (e.g., measured in a subject prior to treatment or measured in a suitable reference population).
- Means for statistically evaluating therapeutic efficacy are well known in the art.
- therapeutic efficacy may be assessed by comparing outcomes in a population of subjects treated with a particular amount, frequency, duration, and/or regimen against outcomes to a population of similarly situated subjects not receiving treatment as described herein.
- Therapeutically effective amounts, frequencies, durations, and regimens of the administering the compositions described herein may vary according to factors such as the degree of susceptibility of the individual, the age, gender, and weight of the individual, and idiosyncratic responses of the individual. Unless dictated otherwise, explicitly or by context, a “therapeutically effective” amount, frequency, duration, and/or regimen is not limited to a minimal amount, frequency, and/or duration sufficient to achieve a therapeutic response or a regimen comprising such minimal amounts, frequencies, and/or durations.
- the therapeutic efficacy of the dosing amount, dosing frequency, and/or treatment duration may be interrelated, particularly depending on the therapeutic response used to evaluate efficacy. For instance, more sustained measures of therapeutic efficacy (e.g., curing a disease) are likely to require more rounds of administration than a more transient measure of therapeutic efficacy (e.g., alleviating a symptom of a disease).
- Therapeutically effective amounts of a pharmaceutical composition, a microbubble composition within a pharmaceutical composition, and/or a payload of the microbubble composition may be interrelated.
- the effective amount of a microbubble composition may be determinable, for instance, based on a loading efficiency of the particular combination of microbubble composition and payload, as may be readily measured experimentally, as described, for example, elsewhere herein.
- the dosage of microbubbles administered to a subject may depend on the route of administration. Data obtained from in vitro cell-based assays and/or animal studies can be used in formulating a range of dosages for use in subjects (e.g., humans). The dosage may lie within a range of circulating concentrations that includes the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed, the route of administration utilized, and the particular indication (e.g., cancer type) being treated. For instance, intratumoral injection may require smaller dosages than systemic administration routes. Intravenous, or intramuscular systemic delivery may require larger dosages.
- An effective amount of payload (e.g., a CDN such as cGAMP) to be administered (e.g., systemically) may generally be between about 0.1 pg/kg - 1,000 mg/kg, 1 pg/kg - 1,000 mg/kg, 10 pg/kg - 1,000 mg/kg, 100 pg/kg - 1,000 mg/kg, 1 mg/kg - 1,000 mg/kg, 0.1 pg/kg - 100 mg/kg, 1 pg/kg - 100 mg/kg, 10 pg/kg - 100 mg/kg, 100 pg/kg - 100 mg/kg, 1 mg/kg - 100 mg/kg, 0.1 pg/kg - 10 mg/kg, 1 pg/kg - 10 mg/kg, 10 pg/kg - 10 mg/kg, 100 pg/kg - 10 mg/kg, 1 mg/kg - 10 mg/kg, 1 mg/kg - 10 mg/kg, etc.
- a CDN such as
- the effective amount may depend upon a variety of factors including, for example, the activity of the specific payload employed, subject-specific factors (age, body weight, general health, sex and diet of the individual being treated), the time and route of administration, the rate of excretion, other treatments which have previously been administered, the precise condition being treated, the severity of the particular condition undergoing treatment, etc.
- the attending clinician may use appropriate discretion as is understood in the art on deciding upon an effective dose.
- Guidance for methods of treatment and diagnosis are well known in the art (see, e.g., Maynard, et al. (1996) A Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca Raton, Fla.; Dent (2001) Good Laboratory and Good Clinical Practice, Urch Publ., London, UK).
- the present disclosure provides methods of delivering payloads to one or more cells using the microbubbles described herein with sonoporation techniques.
- Methods for performing sonoporation are well known in the art. See, e.g., Chowdhury et al., Ultrasonography. 2017 Jul;36(3):171-184 (doi: 10.14366/usg.17021); Tzu-Yin et al., Curr Pharm Biotechnol. 2013;14(8):743-52 (doi: 10.2174/1389201014666131226114611); Xu et al., Adv. Therap., 4: 2100154. (doi.
- Sonoporation uses sound, typically at ultrasonic frequencies, for increasing the permeability of the cell plasma membrane in order to facilitate the delivery of a payload across the membrane and into the cell. Sonoporation may be particularly beneficial for delivering payloads across the blood-brain barrier or blood-tumor barrier. For in vivo applications, sonoporation may be an advantageous means of drug delivery as ultrasound can penetrate deep into the subject’s tissue in a non-invasive manner as well as provide spatially and temporally targeted delivery with minimal or no side effects to non-targeted tissue.
- Microbubbles can function as nuclei for acoustic cavitation in ultrasound-mediated drug delivery, effectively scattering ultrasound waves due to the high compressibility of the microbubbles. Sonoporation is believed to induce transient increases in cell permeability via the formation of transient pores in the cell plasma membrane. Without being bound by theory, collapsing microbubbles may produce local shock waves, water jets, and shear forces that are able to permeabilize nearby cell membranes. Sonoporation may allow the direct delivery (i.e. outside the endosomal transport pathway) of therapeutics, such as nucleic acids, into a cell’s cytosol.
- microbubble shells should be stiff enough to withstand small pressure perturbations but elastic enough to oscillate in response to the ultrasound waves. Lower degrees of polydispersity in microbubble size may be desirable so that larger proportions of a microbubble composition are sensitive to the same amplitudes of ultrasound.
- microbubbles subjected to low-intensity ultrasound may oscillate stably around a resonant diameter, termed stable cavitation. Stable cavitation generates local shear forces and acoustic microstreaming.
- microbubbles tend to undergo large size variations which cause them implode in an event termed inertial cavitation, the collapse resulting in water jetting, shock waves and other inertial phenomena. Both stable and transient microbubble cavitations may induce cell membrane permeabilization. Sonoporation is believed to provide a pathway to intracellular drug delivery independent of endocytosis.
- ultrasound triggering of sonoporation with microbubbles may be performed at frequencies between about 0.1 MHz and about 10 MHz, between about 0.5 MHz and about 5 MHz, or between about 1 MHz and about 3 MHz.
- ultrasound triggering may be performed at intensities between about 100 mW/cm 2 and about 1 kW/cm 2 , between about 100 mW/cm 2 and about 1 W/cm 2 , between about 300 mW/cm 2 and about 1 W/cm 2 , between about 500 mW/cm 2 and about 1 W/cm 2 , between about 700 mW/cm 2 and about 1 W/cm 2 , between about 1 W/cm 2 and about 500 W/cm 2 , between about 1 W/cm 2 and about 100 W/cm 2 , between about 1 W/cm 2 and about 100 W/cm 2 , between about 1 W/cm 2 and about 50 W/cm 2 , between about 1 W/
- the ultrasound triggering may be performed at a maximal intensity permitted by a regulatory agency (e.g., the FDA), such as, for example, approximately 720 mW/cm 2 (for diagnostic ultrasound).
- the ultrasound triggering may be performed at a duty cycle between about 10% and 100%, between about 20% and about 90%, between about 30% and about 80%, between about 40% and about 70%, or between about 50% and about 60%.
- the duty cycle is about 50%.
- the mechanical index (MI) of the ultrasound may be between about 0.05 and about 5, between about 0.1 and about 5, between about 0.5 and about 5, between about 1 and about 5, between about 2 and about 5, between about 3 and about 5, between about 4 and about 5.
- the ultrasound triggering may be performed at a maximal mechanical index permitted by a regulatory agency (e.g., the FDA), such as, for example, approximately 1.9 (for diagnostic ultrasound).
- the ultrasound triggering may be delivered for about 10 s - 3 min, 10 s - 2 min, 10 s - 1 min, 10 s - 50 s, 10 s - 40 s, 10 s - 30 s, 30 s - 3 min, 30 s - 2 min, 30 s - 1 min, 30 s - 50 s, 30 s - 40 s, 1 min- 3 min, or 1 min - 2 min, 2 min - 3min.
- ultrasound may be used to visualize the microbubbles prior to sonoporation (e.g., to confirm targeted localization of the microbubbles).
- Such an ultrasound stimulus may be administered at parameters (e.g., an intensity) that are configured not to induce sonoporation.
- compositions and/or methods described herein may be used to treat a disease associated with abnormal apoptosis or an abnormal differentiative process, including cellular proliferative disorders (e.g., hyperproliferative disorders) and/or cellular differentiative disorders, such as cancer.
- Cancers may be treated, for example, with an immunomodulatory composition (e.g., comprising a CDN such as cGAMP) or a vaccine, as described elsewhere herein.
- cancer or “cancerous”
- hyperproliferative or “cancerous”
- hyperproliferative or “cancerous”
- hyperproliferative or “neoplastic” refer to cells having the capacity for autonomous growth (i.e., an abnormal state or condition characterized by rapidly proliferating cell growth).
- a “tumor” or “neoplasm” may be used interchangeably to refer to an abnormal growth of cells.
- Hyperproliferative and neoplastic disease states may be categorized as pathologic/malignant (i.e., characterizing or constituting a disease state), or categorized as non-pathologic/benign (i.e., as a deviation from normal but not associated with a disease state).
- cancer cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness.
- “Pathologic hyperproliferative” cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair.
- cancer or “neoplasm” as used herein encompass malignancies of the various organ systems, including those affecting the lung, breast, thyroid, lymph glands and lymphoid tissue, gastrointestinal organs, and the genitourinary tract, as well as to adenocarcinomas.
- carcinoma refers specifically to cancerous malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas.
- Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary.
- carcinosarcomas which include malignant tumors composed of carcinomatous and sarcomatous tissues.
- An “adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.
- Adenocarcinomas are generally considered to include cancerous malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.
- Additional examples of proliferative disorders include hematopoietic neoplastic disorders, which include diseases involving hyperplastic/neoplastic cells of hematopoietic origin (e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof).
- neoplastic conditions in subjects which may include-benign or malignant tumors (e.g., adrenal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, thyroid, hepatic, cervical, endometrial, esophageal and uterine carcinomas; sarcomas; glioblastomas; and various head and neck tumors); leukemias and lymphoid malignancies; other disorders such as neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders.
- tumors e.g., adrenal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, thyroid, hepatic, cervical, endometrial, esophageal and uterine carcinomas; sarcomas; glioblastomas; and various head and neck tumors
- neoplastic conditions subject to treatment in accordance with the methods and/or compositions described herein may be selected from the group including, but not limited to, adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallblad
- Neoplastic conditions comprising solid tumors, in particular, may benefit from treatment according to the methods and/or compositions described herein, as localized masses of target cells may be efficiently targeted by sonoporation, although hematologic malignancies are also contemplated within the scope of the disclosure.
- Some lymphomas, in particular, may present as solid masses may be effectively targeted by the methods and/or compositions described herein.
- the proliferative disorder will comprise a solid tumor including, but not limited to, adrenal, liver, kidney, bladder, breast, gastric, ovarian, cervical, uterine, esophageal, colorectal, prostate, pancreatic, lung (both small cell and non-small cell), thyroid, carcinomas, sarcomas, glioblastomas and various head and neck tumors.
- a solid tumor including, but not limited to, adrenal, liver, kidney, bladder, breast, gastric, ovarian, cervical, uterine, esophageal, colorectal, prostate, pancreatic, lung (both small cell and non-small cell), thyroid, carcinomas, sarcomas, glioblastomas and various head and neck tumors.
- compositions and methods may be used to treat an existing tumor (e.g., primary tumor) in a subject by using sonoporation to target drug delivery to that tumor.
- Treatment may result in the improvement, reduction, or alleviation of one or more symptoms of cancer as is known in the art, including for example, tumor size, tumor volume, tumor growth, or metastasis.
- Such improvements may be quantified and may be, for instance, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, or 1,000% improved over baseline measurements as measured in a subject (e.g., prior to treatment) or a suitable reference population.
- the improvement may be statistically significant (e.g., p ⁇ 0.05).
- markers of an innate or adaptive immunity response may include, for example, measurement of markers of an innate or adaptive immunity response (e.g., proinflammatory markers, T-cells, etc.). Such markers may be measured, for example, in tissue biopsies or cell suspension prepared therefrom or in blood (e.g., serum) levels. Changes in marker levels from treatment may be at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, or 1,000% over baseline measurements as measured in a subject (e.g., prior to treatment) or a suitable reference population. Changes may be statistically significant (e.g., p ⁇ 0.05).
- the treatment may be, at least in part, prophylactic.
- the treatment may, for example, comprise treatment of subjects who present with benign or precancerous tumors and/or prevent or reduce the likelihood of worsening of a cancer (e.g., growth of a tumor or metastatic spread of a tumor) or the recurrence of a cancer.
- a metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver.
- the treatments described herein are also contemplated to encompass treatment of metastatic tumors.
- some specific therapeutic responses may include, but are not limited to, one or more of destroying neoplastic or cancerous cells, inducing apoptosis in neoplastic or cancerous cells, reducing the proliferation of neoplastic or cancerous cells, reducing metastasis of neoplastic cells found in cancers, tumor regression (i.e. shrinking the size (e.g., diameter or volume) of a tumor), enhanced immune memory against an existing cancer, and enhanced therapeutic efficacy of anti-cancer agents (e.g., immune checkpoint inhibitors), such as those described elsewhere herein (including those described with respect to combination therapies).
- Enhanced therapeutic efficacy of other treatments for cancer or comorbidities associated therewith may allow for decreased dosages of those treatments.
- Treatment of subjects with a microbubble composition as described herein may be combined with other treatments for the same disease that the payload is being administered to treat, such as cancer, and/or comorbidities associated therewith.
- Anti-cancer therapies such as treatment with an anticancer agent and radiation therapy are well known in the art. These therapies can be administered to a subject according to any effective protocol, though the treatments may be modified as needed to optimize the combination treatment along with the microbubble composition.
- radiation therapy is performed by administering to the subject a suitable radiation dose of a suitable time at any suitable interval according to well- established protocols.
- Anticancer agents are administered according to typical protocols for the given drug.
- Non-limiting classes of drugs that may be useful in combination with the microbubble compositions described herein include: tyrosine kinase inhibitors, such as gefitinib (IressaTM) and imatinib mesylate (GleevecTM); monoclonal antibodies, such as rituximab (RituxanTM) and cetuximab (ErbituxTM); angiogenesis inhibitors, such as endostatin; immune modulators, such as interleukin- 12 (IL-12) and interleukin-2 (IL-2); non-receptor tyrosine kinase inhibitors, such AG490 JAK2 inhibitor and PP2 src family kinase inhibitor or dasatinib; serine/threonine kinase inhibitors, such as U0126 for MEK1/2, wortmanin for PI3K; famesyl or geranyl transferase inhibitors, such as FTI-277 and GGTI-298; G
- Non-limiting examples of specific anticancer agents include: AG-490; aldesleukin; alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine; An-238; anastrozole; arsenic trioxide; asparaginase; BCG Live (Bacillus Calmette-Guerin); bevazizumab; bexarotene; bleomycin; busulfan; calusterone; capecitabine; capecitabine; carboplatin; carmustine; celecoxib; cetuximab; chlorambucil; cisplatin; cladribine; cyclophosphamide; cyclophosphamide; cytarabine; dactinomycin; darbepoetin alfa; dasatinib; daunorubicin; daunorubicin, daunomycin; denileukin diftitox; dexrazoxan
- Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage.
- Tumors co opt certain immune-checkpoint pathways as a maj or mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors.
- Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies were the first of this class of immunotherapeutics to receive FDA approval (ipilimumab).
- Inhibitors of additional immune-checkpoint proteins such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), have since been approved and demonstrated broad and diverse opportunities to enhance antitumor immunity with the potential to produce durable clinical responses.
- PD-1 programmed cell death protein 1
- P-L1 programmed death-ligand 1
- PD-1 functioning as an immune checkpoint, plays an important role in down-regulating the immune system by preventing the activation of T cells, which in turn reduces autoimmunity and promotes self-tolerance.
- the inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen-specific T cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells).
- Therapeutics that block PD-1 binding the PD-1 inhibitors (e.g., anti-PD-1 antibodies, anti-PD-Ll antibodies), activate the immune system to attack tumors and are therefore used to treat some types of cancer.
- Approved checkpoint inhibitors for PD-1 and PD-L1 include nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, and cemiplimab.
- Additional inhibitory checkpoint molecules which may be targeted to provide immune checkpoint therapy include, but are not necessarily limited to, CD47, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG3, NOX2, TIM-3, VISTA, and SIGLEC7.
- the methods and/or compositions described herein may be administered in combination with immune checkpoint therapy, such as an immune checkpoint inhibitor (e.g., antibody), including any of the inhibitors described herein or any suitable inhibitor that targets an immune checkpoint molecule described herein.
- immune checkpoint therapy such as an immune checkpoint inhibitor (e.g., antibody), including any of the inhibitors described herein or any suitable inhibitor that targets an immune checkpoint molecule described herein.
- the methods and/or compositions herein, such as those that activate STING e.g., delivery of CDNs such as cGAMP
- CDNs such as CDNs such as cGAMP
- Spe-Dex MBs were prepared as described in PCT/US2021/054820 to Lux et al., filed October 13, 2021 and herein incorporated by reference in its entirety. Briefly, Potassium periodate (6.25 mmol) was added to a solution of Dextran 40k (6.25 mmol of glucose monomers) in milliQ water (20 ml). The reaction was vigorously stirred in the dark for 7 h at room temperature and then spin filtered 2 x using spin filters (MWCO 10 kDa, AMICON ® ) at 4,000g ⁇ for 10 min at 4 °C with water washing.
- spin filters MWCO 10 kDa, AMICON ®
- the resulting retentate was dialyzed for 24 h against water using a regenerated cellulose semi permeable membrane (MWCO 3.5-5 kDa) and then added to a solution of spermine (2.96 mmol) in borate buffer (19 ml, 0.1 M, pH 11) over 5 h via syringe pump.
- the resulting solution was gently stirred for 24 h at room temperature followed by the addition of NaBHi (9.48 mmol) under ice bath and stirring for 48 h at room temperature. An additional portion of NaBHi (9.48 mmol) was then added and stirring continued for 24 h under the same conditions.
- Crude product was dialyzed against water (MWCO 3.5-5 kDa) for 48 h followed by lyophilization for 48 h to yield spermine-modified dextran (SpeDex).
- SpeDex conjugation onto MBs was verified using fluorescently labeled SpeDex.
- Fluorescent labeling of SpeDex polymers was done using amine reactive 5/6-carboxyfluorescein succinimidyl ester (MfS-fluorescein). Briefly, SpeDex polymer (5 mg) was dissolved in 1 ml of 1 x borate buffer (50 mmol/1, pH 8.5). MfS-fluorescein (5 mg, 10.562 pmol) was dissolved in DMF (0.5 ml) and added dropwise to SpeDex solution with vigorous stirring. The reaction was stirred for 1 h, dialyzed for 48 h (MWCO 3.5 kDa), and lyophilized for 48 h.
- MfS-fluorescein amine reactive 5/6-carboxyfluorescein succinimidyl ester
- Microbubbles were likewise formulated as previously reported. Briefly, lipid films containing a mixture of l,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-Distearoyl-sn- Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000] (DSPE-PEG2k), and l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[maleimide(polyethylene glycol)5000] (DSPE-PEG(5000)-mal) with a 90:5:5 molar ratio were prepared.
- DSPC 1,2-Distearoyl-sn-glycero-3-phosphocholine
- DSPE-PEG2k 1,2-Distearoyl-sn- Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000]
- PBS Perfluorobutane
- anti-CDl lb antibodies aCDl lb or isotype IgG (non-targeting control antibody) were thiolated and conjugated onto the surface of the MBs’ maleimide groups.
- Anti-CDl lb was first thiolated to allow for conjugation onto maleimide-bearing Spe-Dex MBs.
- Spe-Dex MBs were then added to the solution of anti- CDl lb at a ratio of 0.345 equivalents of antibody per maleimide and rotated end-over-end for 15 hours at 4 °C to allow for conjugation. Afterwards, the solution was washed 3x with PBS at 300g for 3 min.
- the number of aCDl lb on SpeDex MBs was measured by running known quantities of antibody on a SDS PAGE gel and measuring the intensities of their bands. Using this standard curve resulted in approximately 291,774 aCDl lb molecules per cMB (data not shown).
- both Spe-Dex MBs and cMBs were incubated with cGAMP at a nitrogen: phosphate (N:P) ratio of 1:34, fluorescently labeled with l,l’-dioctadecyl- 3, 3, 3’, 3’- tetramethylindodicarbocyanine (DiD), and then added to either 300,000 THP-1 macrophages (CDl lb+) or E0771 murine breast cancer cells (CDl lb-) plated on 12-well plates. The wells were washed three times, filled with Perfluorobutane (PFB)-saturated PBS, and imaged with brightfield and fluorescence microscopy.
- PFB Perfluorobutane
- Nanocomplex decorated microbubbles can also be formulated by first preparing cGAMP SpeDex nanocomplexes and conjugating them to the MB surface in a one pot reaction with aCDl lb. Briefly, a solution of SpeDex polymer was added to a solution of cGAMP at equal volumes and at a N:P ratio of 1 : 10. The mixture was vortexed and then incubated for 30 min. The size distribution of the resulting cGAMP-SpeDex nanocomplexes was evaluated using nanoparticle tracking analysis (NT A) (PARTICLE METRIXTM, ZETAVIEW®) and is shown in Figure IB. The average nanocomplex size was determined to be 168.8 ⁇ 9.4 nm.
- NT A nanoparticle tracking analysis
- Nanocomplexes were then conjugated onto maleimide-bearing MBs at a 1:20 maleimide: SpeDex molar ratio and rotated for 4 h followed by three washes with PBS to afford nanocomplex-conjugatd MBs (ncMBs).
- ncMBs were characterized using a Coulter Counter (BECKMAN COULTER ® MULTISIZERTM 4) (data not shown).
- Example 4 Sonoporation of Mouse Bone Marrow-Derived Macrophages and THP-1 Macrophages using diGMP Loaded Spe-Dex-CDllb MBs.
- ncMBs can efficiently deliver CDNs to the cytosol of APCs
- ncMBs loaded with a fluorescently labeled CDN DY547-c-diGMP
- macrophages were incubated with macrophages and then sonoporated.
- human THP-1 monocytes were spun down and resuspended in RPMI, 20% FBS, 1% penicillin/streptomycin (P/S).
- Phorbol 12-myristate 13-acetate was added to obtain a final concentration of 200 nM to differentiate the monocytes into macrophages. 1 mL per well of the cell solution was plated in a 12 well plate (400,000 cells/well) and left to differentiate for 3 days. Afterwards, cells were washed once with PBS then replenished with fresh RPMI.
- BMDMs Mouse bone marrow-derived macrophages
- M-CSF macrophage colony- stimulating factor
- MFI mean fluorescence intensity
- Mouse BMDMs and human THP-1 cells were cultured as described above.
- Primary human peripheral blood monocyte derived macrophages underwent induced differentiation using CD1 lb+ cells sorted from PBMC (STEMCELL TECHNOLOGIES ® ) by culturing cells with macrophage colony-stimulating factor (M-CSF, 50 ng/ml) for 7 days.
- M-CSF macrophage colony-stimulating factor
- pIRF3 phosphorylated IRF3
- NF-KB another major downstream component of the STING pathway, was also activated upon MUSIC treatment, as shown by the phosphorylation of IKKa/b, IkBa, and p65 in THP-1 cells and mouse BMDMs, but was not observed in BMDMs from STING/ mice, as shown in Figures 7A-7C.
- the activation of NF-KB signaling is supported by the increased translocation of p65 into the nucleus in both BMDMs and THP-1 cells after MUSIC treatment, as shown in Figure 9 A, where it acts as a transcription factor for proinflammatory cytokine genes.
- NF-kB the phosphorylation caused by cGAMP alone in THP-1 macrophages is comparable to that caused by MUSIC, probably because THP-1 macrophages have a cGAMP receptor that can cause NF-kB phosphorylation.
- BMDMs do not have this receptor, which is why cGAMP alone showed no phosphorylation of any of the proteins.
- IRF3 and NF-kB translocate to the nucleus, which was visualized using immunostaining. This translocation was not visible in cGAMP only samples. MB only samples showed no effect in any of the experiments when compared to negative controls. Furthermore, repeating the experiments using STING cells showed loss of efficacy.
- STING cells showed a complete reduction in mRNA expression, interferon expression, phosphorylation, and translocation, giving further proof that all these effects were due to STING pathway activation.
- Experiments in primary human peripheral blood monocyte derived macrophages produced similar results, thus confirming the specificity and efficacy of MUSIC in activating STING signaling in human primary APCs.
- Example 6 Phagocytosis of E0771 Breast Cancer Cells by MUSIC-treated Mouse Bone Marrow-Derived Macrophages (BMDMs).
- MUSIC was also able to enhance the phagocytosis ability of treated macrophage, which is consistent with previous findings that STING activation in macrophages can improve their phagocytosis functions.
- BMDMs were cultured for 6 h after treatment as described in Example 5. E0771 cells were pre-stained with Far Red for 2 h, and then co-cultured with the BMDMs at a ratio of 1 : 1. Phagocytosis was measured by flow cytometry after 4 h co-culture. Quantification of phagocytized E0771 cells by BMDMs from three biologically independent experiments is shown in Figure 10.
- Example 7 OT-I and II Cell Proliferation using BMDMs and tumor-associated macrophages (TAMs) Treated with MUSIC.
- TAMs tumor-associated macrophages
- Macrophages are professional APCs that can prime T cells. This process can be amplified through activation of STING, as macrophages that have had their STING pathway activated are better able to present antigens to prime T-cells, causing their proliferation and resulting in potent antitumor immunity. This was confirmed using T-cells engineered to recognize OVA antigen (OT cells).
- BMDMs were treated with MUSIC as described in Example 5 and then incubated with either an MHC-I or MHC-II binding OVA peptide (amino acids 257-264 or 323-339, respectively) for 6 hours.
- OT-I cells were washed then incubated for 72 hours with either OT-I cells if they received the MHC-I binding peptide or OT-II cells if they received the MHC-II binding peptide.
- the proliferation of OT cells was then quantified using flow cytometry. As shown in Figure 11A-11B, proliferation of both CD4 + and CD8 + T cells was increased when co-cultured with MUSIC-treated BMDMs relative to other treatment groups. This enhanced T-cell priming effect by MUSIC was absent in STING-/- BMDMs, suggesting that it is a STING-dependent response.
- OT-I cells (which are CD8 + ) had approximately a 2.5x increase in proliferation when the BMDMs were treated with MUSIC compared to negative controls.
- OT-II cells (which are CD4 + ) had approximately a 3.5x increase when compared to negative controls.
- TAMs tumor-associated macrophages
- Figure 12A tumor-associated macrophages
- Figure 12B-12C induced IFN protein expression
- Example 8 Treatment of Mouse Bone Marrow-Derived Dendritic Cells (BMDCs) using MUSIC.
- BMDCs Mouse Bone Marrow-Derived Dendritic Cells
- BMDCs bone marrow- derived dendritic cells
- GM-CSF granulocyte macrophage colony-stimulating factor
- An orthotopic syngeneic murine breast cancer model was used to test the effectiveness of the MUSIC platform in activating the STING pathway in vivo in syngeneic hosts. Briefly, 1 million E0771 breast cancer cells in 50 pL PBS were injected subcutaneously into the lower mammary fat pad of 6-week old female C57BL/6J mice. The delivery efficiency of CDNs in vivo was first assessed using DY547-c-diGMP loaded ncMBs conjugated with either IgG (non-targeting) or aCDl lb (targeting). The mice were injected intratumorally with 20 pL of solution infused at 1 pL/second using a syringe pump for a dose of 2.8 x 10 7 MBs.
- ncMBs IgG or MUSIC Two hours after ultrasound treatment
- the delivery of DY547-c-diGMP in tumor-associated CDl lb+ cells was more than 7-fold higher when using ncMBs as compared to non-targeted IgG-ncMBs.
- non-specific uptake of CDNs in CD1 lb- cells was negligible and 4-fold lower with ncMBs as compared to the IgG-ncMBs.
- Orthotopic mammary fat pad tumors were established as in Example 9. The tumors were grown for 13 days before mice were randomized into treatment group and controls groups based on tumor size: PBS only, cGAMP only, ncMBs only, cMBs+US only, IgG-ncMBs+US, and MUSIC . The mice had an average tumor volume of 100 mm 3 and any differences between the means were determined to not be statistically significant using ANOVA. The mice were injected intratumorally with 20 pL of solution infused at 1 pL/second using a syringe pump. A dose of 100 pg of cGAMP was used for all cGAMP groups and a dose of 2.7 x 10 7 MBs was used for all MB groups.
- mice were treated every other day for a total of three treatments (days 13, 15, and 17). US, where part of the treatment group, was applied by using acoustic coupling gel and a 1-MHz plane wave transducer operating at 4 W/cm 2 for 60 seconds and a 50% duty cycle given to opposite sides of the tumor for a total treatment time of 120 seconds. At 18 days post tumor inoculation treated mice were sacrificed.
- MUSIC enabled imaged-guided delivery of CDNs in vivo is shown in Figure 17.
- Immunohistochemical staining of tumor sections three days after treatment (not shown) confirmed that MUSIC prevented Ki67 expression, indicating inhibited tumor cell proliferation, but had no direct effects on other tissues.
- Immunostaining by confocal microscopy was used to visualize recruited CD1 lb+ cells and pSTING+ cells in tumor paraffin section slides. Fluorescence intensity was measured and compared by IMAGEJTM software from three randomly selected images, as shown in Figures 18A-18B. Single cell suspensions from tumor tissues were also collected for flow cytometry analysis, with CD1 lb, CD68, and IL-10 165 being used to gate TAMs.
- Evaluation of the tumor immune microenvironment revealed increased phosphorylation of STING in MUSIC-treated tumor tissues, most preferentially in CDl lb+ cells.
- the increased phosphorylation of STING in CDl lb+ cells correlated with increased recruitment of CD8+ and CD4+ T cells into the tumor after MUSIC treatment as quantified by flow cytometry, as shown in Figures 20A-20B.
- Activated CD8+ T cells and CD4+ T cells were also detected and quantified by immunostaining in tumor paraffin section slides, as shown in Figures 20C-20D.
- mice were treated with MUSIC, cGAMP, cMBs (+US), or non-targeted IgG-ncMBs (+US) and monitored over time. Tumor sizes were measured every two days using digital calipers, and tumor volume was calculated according to an ellipsoid formula as 0.5xlength> ⁇ width 2 . Mice were sacrificed if any tumor ulceration was observed or if tumors reached 2000 mm 3 in volume. The final tumor volume comparison between the MUSIC and control groups was done when the first mice from a control group was sacrificed. Tumor volumes and survival curves are shown in Figures 21 A-21D.
- mice from Example 10 were reimplanted with the same E0771 breast cancer cells on the contralateral fat pad of the original tumor for a tumor rechallenging experiment.
- Non- treated naive mice were also implanted with tumors as a control.
- MUSIC treated mice showed no tumor growth 19 days after tumor implantation, suggesting that these mice have immune memory against E0771 cells, whereas the naive mice showed obvious tumor growth (Figure 22).
- STING mice were treated as described above.
- T cells collected from spleens of MUSIC-treated tumor-bearing mice and rechallenged with the E0771 tumor cells in vitro demonstrated a robust IFN-g response, as seen in Figure 25, thus confirming that the local MUSIC treatment generated systemic immune memory in vivo.
- CD8+ T cells from tumor-bearing mice were depleted using an anti-CD8 antibody injected 24 h prior to MUSIC treatment and every 72 h until the end of the experiment. The elimination of CD8+ T cells in these animals abrogated the antitumor effect of MUSIC, resulting in half the mice dying at day 21 ( Figures 26A-26C).
- IFN and IFN-g levels were measured in tumors ( Figures 27A-27C) and serum ( Figures 27D-27F), and were found to be elevated in both upon MUSIC treatment. Since IFN-g is known to induce the expression of immune checkpoints such as PD-L1, the expression of PD-1 and PD-L1 was measured in T cells and tumor cells, respectively, by comparing the fluorescence intensity from three randomly selected immunostained images ( Figures 28A-28B).
- Example 12 Evaluation of systemic antitumor immune responses against metastatic breast cancer.
- metastatic 4T1 tumors were established through orthotopic implantations in the mammary fat pad of Balb/cJ mice using luciferase-expressing 4T1 cells. At 12 days post tumor implantation, mice were intraperitoneally injected with 1.5 mg D-luciferin (SYD LABSTM) per 10 g body weight. At 10 min after injection, the presence and metastases of the tumors were monitored by bioluminescence imaging (BLI) using an In Vivo Imaging System (PerkinElmer IVIS® Lumina III).
- MUSIC treatment showed dramatic inhibition of tumor growth, increased mice survival, and a greater percentage of tumor-free mice compared to cGAMP alone.
- MUSIC treatment also resulted in an 11-fold decrease in metastatic burden when compared to cGAMP alone.
- Example 13 Sensitizing Tumors to PD-1 Blockade with MUSIC.
- Example 14 Conjugating NBs with cationic polymers allowed similar cGAMP loading efficiency as MBs.
- nanobubbles may be used to allow systemic injection and ultrasound-guided therapy.
- phospholipids were emulsified with PFB, as described with MBs, but the centrifugation steps post formulation were modified. Specifically, the suspension of emulsified phospholipids was centrifuged at 50g- for 5 min, and the top layer containing large MBs was discarded while the infranatant containing liposomes and NBs was kept and characterized by nanoparticle tracking analysis (NT A) (PARTICLE METRIXTM, ZETAVIEW®).
- NT A nanoparticle tracking analysis
- SpeDex was conjugated onto NBs and the mixture was then rotated for 2 h, after which thiolated anti-CD 1 lb antibodies were added, as described elsewhere herein.
- the resulting suspension was centrifuged at 700g- for 5 min and the top layer containing SpeDex-aCDl lb NBs was kept while the infranatant was recycled to increase NB yield.
- the infranatant was re-amalgamated into NBs as described above followed by a final centrifugation at 700g- for 5 min to remove liposomes, antibodies, free lipids and polymers. Both NB suspensions were characterized by NTA and combined.
- This modified procedure yielded NBs having a mean size of 290 nm and a count of 2.6 x 10 11 NBs/mL.
- the size distribution is shown in Figure 32.
- Conjugation of SpeDex and aCDl lb onto NBs was confirmed using flow cytometry by gating the forward scatter (FSC) and side scatter (SSC) signals for the signature shape of bubbles (approximately 84.5% of particles) and by using fluorescent FITC-SpeDex and AF647-aCDl lb (data not shown).
- FSC forward scatter
- SSC side scatter
- Flow cytometry showed 100% of NBs conjugated with SpeDex and 91% of NBs conjugated with aCDl lb.
- ncNBs were obtained by loading cGAMP as described elsewhere herein. Both FITC-cGAMP and 2’-0-(6-[DY547]- aminohexylcarbamoyl)-cyclic diguanosine monophosphate (DY547-diGMP), a fluorescent analog of cGAMP, were used to confirm stability and loading efficiency of the dinucleotide by flow cytometry and fluorescence spectrophotometry (data not shown). cGAMP loading was highly efficient with 7.1 x 10 6 cGAMP molecules loaded per NB, corresponding to a 78% loading efficiency or 0.027 pg of cGAMP/pm 2 . The loading efficiency of cGAMP in ncNBs was very close to the loading value obtained with ncMBs (0.033 pg/pm 2 ).
- Example 15 Sonoporation of macrophages with targeted ncNBs allows the cytosolic delivery of cGAMP.
- ncNBs were incubated with human THP-1 macrophages at a ratio of 500 ncNBs/cell for 10 min, followed by a washing step to remove any unbound ncNBs. Sonoporation was performed using a plane wave single element transducer transmitting at 1 MHz (SONITRON ® GTS, 15 mm diameter) at a power of 1 W/cm 2 with 20% duty cycle for 60 seconds. Successful cytosolic delivery was confirmed by fluorescence microscopy when compared to incubation with Dy547-diGMP alone, as shown in Figure 33A).
- Example 16 Systemically administered ncNBs accumulate in the tumor and can be imaged by US.
- ncNBs are an acoustically responsive material that can reach the tumor micro-environment and activate STING in APCs under US guidance
- a clinical US scanner was used to image ncNBs following IV injection into the orthotopic syngeneic murine breast cancer model produced from implantation of E0771 breast cancer cells, described elsewhere herein.
- mice were anesthetized with isoflurane and a catheter tubing was placed in the lateral tail vein for injection of ncMBs.
- a 50 pL suspension containing 5 xlO 9 ncNBs was injected followed by a 50 pL flush of saline.
- Example 17 Loading of SpeDex MBs with mRNA.
- an element means one element or more than one element, e.g., a plurality of elements.
- “about” or “approximately” will be understood by persons of ordinary skill and will vary to some extent depending on the context in which it is used. When referring to a number or a numerical range, the terms generally mean that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and, thus, the number or numerical range may vary from, for example, between 1% and 20% of the stated number or numerical range. In some aspects, “about” indicates a value within 20% of the stated value. In more preferred aspects, “about” indicates a value within 10% of the stated value. In even more preferred aspects, “about” indicates a value within 1% of the stated value. The variation encompassed by about may be above or below the recited number or range, unless indicated otherwise, explicitly or by context.
- the term “at least” or “no less than” prior to a value or series of values is understood to include the value adjacent to the term “at least” or “no less than” and all subsequent logical values or integers that could logically be included, as understood from context.
- “at least” or “no less than” is present before a series of values or a range of values, it is understood that “at least” or “no less than” can modify each of the values in the series or range as just described.
- the term “down to” will be understood to mean the same as “at least” or “no less than” and will also include the value adjacent to the term “down to” unless indicated otherwise, explicitly or by context.
- no more than or “no greater than” are understood to include the value adjacent to the phrase (unless indicated otherwise explicitly or by context) and all lower values or integers that could logically be included, as understood from context (down to and including zero if negative values are not possible, down to but not including zero if the values must be positive, or down to and including 1 if the value must be a positive integer).
- no more than or “no greater” is present before a series of values or a range of values, it is understood that “no more than” or “no greater than” can modify each of the values in the series or range as just described.
- the term “up to” will be understood to mean the same as “no more than” or “no greater than” and will also include the value adjacent to the term “up to” unless indicated otherwise, explicitly or by context.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Surgical Instruments (AREA)
Abstract
The innate immune sensing STING pathway has emerged as a potential therapeutic target to boost antitumor immune responses. STING resides in the cytoplasm, and its agonists, such as cGAMP, are dinucleotides that are difficult to deliver intracellularly. Disclosed herein is a microbubble-based platform (Microbubble (MB)-assisted UltraSound (US)-guided Immunotherapy of Cancer (MUSIC)) that can be used for targeted activation of STING, such as for treatment of primary and metastatic tumors.
Description
MICROBUBBLE-ASSISTED ULTRASOUND-GUIDED THERAPY
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of priority to U.S. Provisional Application No. 63/173,956, filed on April 12, 2021 and U.S. Provisional Application No. 63/316,360, filed on March 3, 2022, the entire contents of which are hereby incorporated herein by reference.
BACKGROUND
Cyclic dinucleotides (CDNs) have been found to have interesting immune-stimulatory properties through their activation of Stimulator of Interferon Genes (STING). CDNs produced by bacteria elicit an innate immune response that is critical for effective host defense against infection. However, as small molecules, CDNs are rapidly flushed from the injection site, leading to systemic inflammatory side effects. Furthermore, poor CDN internalization and localization in the cytosolic compartments of cells presents a significant barrier to the potential of CDN-based therapeutics. Therefore, there remains a need for strategies effecting targeted and effective intracellular delivery of CDNs.
SUMMARY
According to one aspect of the disclosure, provided herein is a method of targeted in vitro or in vivo drug delivery using sonoporation. The method entails administering to one or more target cells a composition comprising microbubbles loaded with a payload and then administering an ultrasound stimulus to the one or more target cells. The ultrasound stimulus is effective to sonoporate the one or more target cells.
The payload may be an agonist for activating the Stimulator of Interferon Genes (STING) signaling pathway within the one or more target cells, such as a cyclic dinucleotide. The payload may be a cyclic dinucleotide for inducing or enhancing Type 1 Interferon production within one or more cells. The payload may be mRNA. The payload may be DNA, such as plasmid DNA (pDNA).
The method may be an in vivo method which entails administering the microbubble composition and the ultrasound stimulus to a subject. The one or more target cells may be cancer
cells. The one or more target cells may be immune cells. The immune cells may be professional antigen-presenting cells (APCs), such as macrophages and/or dendritic cells.
The microbubbles may include targeting molecules on the external surfaces of the microbubbles that are effective to bind the one or more target cells. The targeting molecules may be antibodies. The targeting molecules may bind CD1 lb.
The ultrasound stimulus may be administered at about 1-2 W/cm2, optionally with 50% duty cycle. The ultrasound stimulus may be administered for between about at least about 30-60 seconds. The one or more target cells may be exposed to the microbubbles for at least about 10 minutes prior to administering the ultrasound stimulus. The method may further entail using ultrasound to visualize the microbubbles prior to applying the ultrasound stimulus effective to sonoporate the cell membrane. The intensity of the ultrasound used to visualize the microbubbles can be less than the intensity of the ultrasound stimulus.
The microbubbles may be decorated with spermine and the payload may be non-covalently bound to the spermine. The microbubbles may be decorated with spermine-dextran conjugates and the payload non-covalently bound to the spermine within the spermine-dextran conjugates. The microbubbles may have gas cores having a perfluorocarbon. The perfluorocarbon may be decafluorobutane. The microbubbles may have shells having phospholipids, optionally wherein the phospholipids include one or both of l,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC) and l,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) lipids. The microbubbles may have surfactant shells having PEGylated molecules.
The average microbubble size of the microbubble composition may be between about 1 pm and about 10 pm. The average microbubble size of the microbubble composition may be between about 1 pm and about 5 pm. The average microbubble size of the microbubble composition may be about 3 pm.
The microbubbles within the microbubble composition may be primarily nanobubbles or entirely nanobubbles. The average microbubble size of the microbubble composition may be between about 100 nm and 700 nm. The average microbubble size of the microbubble composition may be between about 200 nm and 600 nm. The average microbubble size of the microbubble composition may be between about 300 nm and 500 nm.
The microbubble composition may include microbubbles with biodegradable linkers operably positioned between an exterior surface of a shell of the microbubble and the payload.
The biodegradable linkers may be joining a spermine to a dextran or a spermine to another spermine.
The payload may be cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).
The method may be an in vitro method. The microbubble composition may be incubated with the one or more target cells at a concentration of at least about 5, 10, 15, 20, 25, or 30 microbubbles/cell. The step of administering the microbubble composition to the one or more target cells may entail mixing the composition with the one or more target cells in solution. The one or more target cells may be adhered to a surface and the step of administering the microbubble composition to the one or more target cells may entail exposing the surface to the composition in a manner such that the one or more cells are positioned over the microbubbles.
According to another aspect of the disclosure, provided herein is a method of treating cancer in a subject in need thereof. The method entails performing any of the aforementioned targeted drug delivery methods, in which administering the microbubble composition to the one or more target cells entails administering the microbubble composition and the ultrasound stimulus to the subject in need of treatment, and in which the payload is a cyclic dinucleotide.
The subject may have been diagnosed with cancer. The subject may have a tumor. The subject may have one or more metastases. The microbubble composition may be administered intratumorally. The microbubble composition may be administered systemically. The microbubble composition may be administered intravenously. The microbubble composition may be a nanobubble composition.
Administering the microbubble composition to the subject may entail administering multiple doses of the microbubble composition to the subject and administering the ultrasound stimulus to the subject may entail administering ultrasound stimulus effective to sonoporate the one or more target cells after each dose. The multiple doses may be administered at least one day apart.
The administration may result in an increase in expression of IFN-a, IFN-b, and/or IFN-g within the one or more target cells. The administration may result in an increase in serum levels of IFN-a, IFN-b, and/or IFN-g. The administration may result in nuclear localization of nuclear translocation of phosphorylated IRF3 (pIRF3) and/or NF-KB p65 in the one or more target cells. The administration may result in increased recruitment of CD8+ and CD4+ T cells within the
tumor. The administration may result in an increased number of effector memory T-cells and/or central memory T-cells that are specific to cancer cells within the subject. An increased number of effector memory T-cells and/or central memory T-cells may be found, specifically, within the tumor. The administration may result in a decrease in tumor size. The administration may result in the eradication of the tumor. The administration may prevent or reduce the likelihood of future metastases. The administration may prevent or reduce the likelihood of recurrence of the cancer in the subject. The method may further entail treating the subject with immune checkpoint therapy. The immune checkpoint therapy may entail administering to the subject inhibitors that target CTLA4, PD-1, PD-L1, and/or CD47.
According to another aspect of the disclosure, provided herein is a microbubble composition for therapeutic drug delivery. The microbubble composition includes a plurality of microbubbles and a plurality of cyclic dinucleotides. The microbubbles each have a gas core encapsulated by a surfactant shell. A plurality of cationic polymers is associated with the external surface of the surfactant shell of each microbubble. The cyclic dinucleotides are non-covalently bound to the cationic polymers on the external surface of the microbubbles.
The cationic polymers may be polyamines. The polyamines may be spermines. The spermines may be conjugated to dextrans. Multiple spermines may be conjugated to each dextran. The plurality of cyclic dinucleotides may include cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).
According to another aspect of the disclosure, provided herein is a method of the aforementioned microbubble compositions. The method entails associating the cationic polymers with the microbubbles and loading the cyclic dinucleotides onto the microbubbles after the cationic polymers have been associated.
According to another aspect of the disclosure, provided herein is another method of making the aforementioned microbubble composition. The method entails binding the cyclic dinucleotides to the cationic polymers to form nanocomplexes and loading the nanocomplexes onto the microbubbles.
According to another aspect of the disclosure, provided herein is the microbubble composition formed by either of the aforementioned methods of making microbubble compositions.
According to another aspect of the disclosure, provided herein is the use of any one of the aforementioned microbubble compositions in any one of the aforementioned methods of drug delivery and/or treatment of cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGs. 1A-1B depict size distributions of SpeDex-aCDl lb MBs (cMBs) measured by Coulter Counter (Fig. 1A) and SpeDex-cGAMP nanocomplexes measured using nanoparticle tracking analysis (Fig. IB).
FIG. 2 depicts mean fluorescence intensity quantification of the DY547-c-diGMP uptake in BMDMs.
FIG. 3 depicts quantification by flow cytometry of live and dead THP-1 and E0771 cells stained with Propidium Iodide (PI) after sonoporation with ncMBs at 1, 2, and 3 W/cm2.
FIGs. 4A-4H depict qRT-PCR results showing fold changes in levels of: IFNa mRNA in THP-1 macrophages at various time points after treatment (Fig. 4A), IFNP mRNA in THP-1 macrophages at various time points after treatment (Fig. 4B), IFNa mRNA in BMDMs at various time points after treatment (Fig. 4C), IFNp mRNA in BMDMs at various time points after treatment (Fig. 4D), IFNa mRNA in wild type and STING/ BMDMs at 6 h post-treatment (Fig. 4E), IFNP mRNA in wild type and STING/ BMDMs at 6 h post-treatment (Fig. 4F), IFNa mRNA in primary human peripheral blood monocyte derived macrophages at 6 h post-treatment (Fig. 4G), and IFNP mRNA in primary human peripheral blood monocyte derived macrophages at 6 h post treatment (Fig. 4H).
FIGs. 5A-5H depict ELISA results showing protein levels in cell supernatants for: IFNa from THP-1 macrophages at various time points after treatment (Fig. 5 A), IFNp from THP-1 macrophages at various time points after treatment (Fig. 5B), IFNa from BMDMs at various time points after treatment (Fig. 5C), IFNP from BMDMs at various time points after treatment (Fig. 5D), IFNa from wild type and STING/ BMDMs at 6 h post-treatment (Fig. 5E), IFNP from wild type and STING/ BMDMs at 6 h post-treatment (Fig. 5F), IFNa from primary human peripheral blood monocyte derived macrophages at 6 h post-treatment (Fig. 5G), and IFNP from primary human peripheral blood monocyte derived macrophages at 6 h post-treatment (Fig. 5H).
FIGs. 6A-6D depict western blot results showing STING, phosphorylated STING (pSTINGSER366 or pSTINGSER366), IRF3, phosphorylated IRF3 (pIRF3SER366 or pIRF3SER396), and
b-actin (control) levels in: THP-1 macrophages at various time points after treatment (Fig. 6A), BMDMs at various time points after treatment (Fig. 6B), wild type and STING/ BMDMs at 6 h post-treatment (Fig. 6C), and primary human peripheral blood monocyte derived macrophages at 6 h post-treatment (Fig. 6D).
FIGs. 7A-7C depict western blot results showing IKKa, IKKb, phosphorylated IKKa/b (Serl76/180), IkBa, phosphorylated IkBa (Ser32), NF-kB p65, phosphorylated NF-KB p65 (Ser536), and b-actin (control) levels in: THP-1 macrophages at various time points after treatment (Fig. 7A), BMDMs at various time points after treatment (Fig. 7B), and wild type and STING/ BMDMs at 6 h post-treatment (Fig. 7C).
FIGs. 8A-8C illustrate the nuclear translocation of phosphorylated IRF3 (pIRF3) following various treatment. Fig. 8A depicts immunohistochemistry images of stained nuclei of wild type BMDMs, STING/ BMDMs, THP-1 macrophages, and peripheral blood monocyte derived macrophages at 6 h post-treatment with the additional staining of phospho-IRF3. Fig. 8B depicts the percentage of nuclear fluorescent positive BMDMs and Fig. 8C depicts the percentage of nuclear fluorescent positive THP-1 cells.
FIGs. 9A-9C illustrate the nuclear translocation of NF-KB p65 following treatment. Fig. 9A depicts immunohistochemistry images of stained nuclei of wild type BMDMs, STING/ BMDMs, and THP-1 macrophages at 6 h post-treatment with the additional staining of NF-KB p65. Fig. 9B depicts the percentage of nuclear fluorescent positive BMDMs and Fig. 9C depicts the percentage of nuclear fluorescent positive THP-1 cells.
FIG. 10 depicts the quantification by flow cytometry of the percentage of E0771 breast cancer cells that were phagocytized by BMDMs, which were treated 6 h before being co-cultured with the E0771 cells for 4 h.
FIGs. 11 A-l IB depict normalized levels of proliferation, as measured by flow cytometry, of CD8+ (Fig. 11 A) and CD4+ T cells (Fig. 11B) from OT-I and OT-II transgenic mice, respectively, that recognize the cOVA-derived peptide antigens, after incubation for 72 h with STING and wild type BMDMs that had been treated and subsequently incubated with the OVA peptide antigens for 6 hours.
FIGs. 12A-12C depict CD8+T cell proliferation and cytokine levels for treated TAMs. Fig. 12A depicts normalized levels of proliferation, as measured by flow cytometry, of CD8+ T cells from OT-I transgenic mice after incubation for 72 h with TAMs that had been treated and
subsequently incubated with the OVA peptide antigens for 6 hours. Figs. 12B-12C depict ELISA results showing protein levels in cell supernatants for IFNa (Fig. 12B) and IFNP (Fig. 12C) from wild type and STING/ BMDMs at 6 h post-treatment.
FIGs. 13A-13D illustrate IRF3/NF-KB activation in BMDCs. Fig. 13 A depicts immunohistochemistry images of stained nuclei of wild type BMDCs and STING/ BMDCs at 6 h post-treatment with the additional staining of phospho-IRF3. Fig. 13B depicts the percentage of nuclear fluorescent positive BMDCs for phospho-IRF3. Fig. 13C depicts immunohistochemistry images of stained nuclei of wild type BMDCs and STING/ BMDCs at 6 h post-treatment with the additional staining of NF-KB p65. Fig. 13D depicts the percentage of nuclear fluorescent positive BMDCs for NF-KB p65.
FIGs. 14A-14D illustrate increased type I IFN responses in BMDCs at 6 h post-treatment. FIGs. 14A-14B depict qRT-PCR results showing fold changes in levels of IFNa mRNA (Fig. 14A) and IFNp mRNA (Fig. 14B) in wild type and STING/ BMDCs. Figs. 14C-14D depict ELISA results showing protein levels in cell supernatants for IFNa (Fig. 14C) and IFNP (Fig. 14D) from wild type and STING/ BMDCs.
FIGs. 15A-15B depict normalized levels of proliferation, as measured by flow cytometry, of CD8+ (Fig. 15 A) and CD4+ T cells (Fig. 15B) from OT-I and OT-II transgenic mice, respectively, after incubation for 72 h with STING and wild type BMDCs that had been treated and subsequently incubated with the OVA peptide antigens for 6 hours.
FIGs. 16A-16B illustrate the specificity of in vivo delivery of DY547-c-diGMP via treatment with MUSIC to tumor-associated CD 1 lb+ cells in an orthotopic syngeneic murine breast cancer model relative to treatment with non-targeting microbubbles, as evaluated by flow cytometry performed on single cell suspensions. Fig. 16A depicts the percentage of CD1 lb+ cells that are positive for DY547-c-diGMP. Fig. 16B depicts the percentage of CDl lb cells that are positive for DY547-c-diGMP.
FIG. 17 shows contrast mode ultrasound (US) images of E0771 breast tumors (13 days) in C57BL/6J mice before injection of ncMBs (left, non-treatment), after injection of ncMBs (middle, pre-sonoporation), and after US sonoporation (right, post-sonoporation). Loss in signal represents bubbles being destroyed after exposure to US. Images are from the same mouse, representative of randomly treated wild-type (WT) mice.
FIGs. 18A-18B depict the percentage of tumor area (day 18) that is CDl lb+ (Fig. 18A) and relative mean phosphorylated STING (pSTING) fluorescence intensity (Fig. 18B) as measured from confocal microscopy images of tumor paraffin section slides immunostained for recruited CD1 lb+ cells and pSTING+ cells.
FIGs. 19A-19B depict the percentage of CDl lb+ cells (Fig. 19A) and TAMs (Fig. 19B) that are positive for pSTING as measured by flow cytometry performed on single cell suspensions of tumor tissue (day 18) from treated mice.
FIGs. 20A-20D illustrate the increased recruitment of CD8+ and CD4+ T cells into tumors (day 18) after MUSIC treatment. Figs. 20A-15B depict the percentage of CD8+ T cells (Fig. 20A) and CD4+ T cells (Fig. 20B) detected in single cell suspensions of treated tumor tissue as measured by flow cytometry. Figs. 20C-20D depict the percentage of tumor area that is CD8+ (Fig. 20C) and CD4+ (Fig. 20D) as measured from confocal microscopy images of immunostained tumor paraffin section slides.
FIGs. 21A-21I depict in vivo results of tumor treatment. Figs. 21A-21D depict results in wild type mice, including spider plots of tumor volume for individual mice within each treatment group (Fig. 21A), cumulative group results for tumor volume (Fig. 21B), survival curves (Fig. 21C), and representative photographs of mice at 24 days post tumor inoculation (Fig. 2 ID). Figs. 21E-21I depict results in STING/ mice, including average tumor volume (Figs. 21E, 21H), survival curves (Figs. 21F, 211), and spider plots of tumor volume for individual mice (Fig. 21G).
FIG. 22 depicts tumor volumes for rechallenged MUSIC-treated mice that demonstrated complete tumor remission and non-treated naive mice (control).
FIGs. 23A and 23B depict tumor volumes (Fig. 23 A) and survival curves (Fig. 23B) for STING mice treated with MUSIC or PBS (control).
FIGs. 24A-24C depict the average percentages, as measured by flow cytometry, of CD8+ T cells isolated from treated tumor tissue samples (day 18) that were naive T cells (Fig. 24A; CD44lowCD62Lhigh), effector memory T cells (Fig. 24B; CD44highCD62Llow), and central memory T cells (Fig. 24C; CD44highCD62Lhigh).
FIG. 25 depicts quantified IFN-g enzyme-linked immune absorbent spot (ELISpot) results for splenic T cells that were isolated from treated mice (day 18) and rechallenged by co-culturing with E0771 tumor cells at a ratio of 10:1 (T cells:E0771 cells) overnight.
FIGs. 26A-26C depict in vivo results of tumor treatment in wild type mice and mice in which CD8+ cells were depleted using an anti-CD8 antibody prior to treatment, including spider plots of tumor volume for individual mice within each treatment group (Fig. 26A), mean tumor volumes (Fig. 26B), and survival rates (Fig. 26C).
FIGs. 27A-27F depict ELISA results showing protein levels measured in treated mice (18 days) from tumor tissue (Figs. 27A-27C) and serum (Figs. 27D-27F) for: IFNa (Figs. 27A, 27D), IFNp (Figs. 27B, 27E), and IFN-g (Figs. 27C, 27F).
FIGs. 28A-28B depict the percentage of treated tumor area (18 days) that is CD8+ (Fig. 28A) and PD-1+ (Fig. 20D) as measured from confocal microscopy images of immunostained tumor paraffin section slides from wild type and STINGY mice.
FIGs. 29A-29B depict the relative mean fluorescence intensity for IFN-g (Fig. 29A) and PD-L1 (Fig. 29B) in randomly selected confocal microscopy images of immunostained tumor paraffin section slides from tread wild type and STING/ mice.
FIGs. 30A-30C depict luminescence levels for bioluminescent tumor cells in mice treated with PBS only, MUSIC, cGAMP with US, cGAMP only, and MBs with US, including lung luminescence over time (Fig. 30A), final primary tumor and lung luminescence levels along with primary tumor volume and number of lung metastatic nodules (Fig. 30B), and heat mapping images of luminescence in extracted primary tumors, kidneys, livers, spleens, hearts, and lungs from representative mice (Fig. 30C).
FIGs. 31A-31U depict the effects of combination therapy with MUSIC and systemic administration of an anti-PD-1 antibody (aPD-1) in spontaneously metastatic murine triple negative 4T1 breast tumor-bearing mice. Figs. 31 A-3 IB depict relative bioluminescence intensity in the lungs (Fig. 31 A) and primary tumor (Fig. 3 IB) of treated mice over time from representative in vivo images. Figs. 31C-31E depicts spider plots of tumor volume for individual mice within each treatment group (Fig. 31C), mean tumor volumes (Fig. 3 ID), and survival rates (Fig. 3 IE). Figs. 31F-31G depict the number of pulmonary metastatic modules (Fig. 3 IF) and relative bioluminescence intensity in the lungs of (Fig. 31G) treated mice (28 days) determined via ex vivo macroscopic organ imaging and examination. FIGs. 31H-31L depict ELISA results showing protein levels measured in treated mice from tumor tissue (Figs. 31H-31I) and serum at 21 days post-inoculation (Figs. 31J-31L) for: IFNa (Figs. 31H, 31J), IFNP (Figs. 311, 3 IK), and IFN-g (Fig. 31L). Figs. 31M-31N depict the percentage of CD8+ T cells (Fig. 31M) and CD4+ T cells
(Fig. 3 IN) detected in single cell suspensions of treated tumor tissue as measured by flow cytometry. Figs. 310-3 IP depict the percentage of tumor area that is CD8+ (Fig. 310) and CD4+ (Fig. 3 IP) as measured from confocal microscopy images of immunostained tumor paraffin section slides. Figs. 3 IQ-31R depict relative mean phosphorylated STING (pSTING) (Fig. 3 IQ) and IFN- g (Fig. 31R) fluorescence intensity levels as measured from confocal microscopy images of immunostained tumor paraffin section slides. Figs. 31S-31U depict the average percentages, as measured by flow cytometry, of CD8+ T cells isolated from treated tumor tissue samples that were naive T cells (Fig. 3 IS; CD44lowCD62Lhigh), effector memory T cells (Fig. 3 IT; CD44highCD62Llow), and central memory T cells (Fig. 31U; CD44highCD62Lhigh).
FIG. 32 depicts the size distribution of nanobubbles (NBs) measured using nanoparticle tracking analysis.
FIGs. 33A-33B illustrate the successful cytosolic delivery of Dy547-diGMP to THP-1 macrophages via sonoporation with ncNBs. Fig. 33A depicts fluorescent images of macrophages treated via incubation with Dy547-diGMP only (left) or sonoporation with Dy547-diGMP-loaded ncNBs (right). Fig. 33B depicts the detection of the secreted embryonic alkaline phosphatase (SEAP) reporter in the THP-1 macrophage supernatant following sonoporation.
FIGs. 34A-34C illustrate the use of a clinical US scanner to detect the delivery of intravenously administered ncNBs to tumor tissue and sonoporate APCs within the tumor tissue. Figs. 34A-34C depict schematics of the treated mouse and US images of the tumor site before (Fig. 34A), during (Fig. 34B), and after (Fig. 34C) injection of the ncNBs.
FIG. 35 depicts an agarose gel showing the complete binding of 200 ng of mRNA to 9 million SpeDex MBs (Lane 1 = 200 ng mRNA, Lane 2 = 100 ng mRNA, Lane 3 = 50 ng mRNA, Lane 4 = 25 ng mRNA, Lane 5 = 200 ng mRNA complexed to SpeDex MBs).
PI TA 11 FI) DESCRIPTION
Disclosed herein are microbubble compositions as well as methods of making and using such compositions. According to certain aspects of the disclosure, microbubble compositions may be used for targeted drug delivery (in vitro or in vivo ) of a payload to one or more target cells. The payload may be delivered to the cytosol of the one or more targeted cells by targeted sonoporation. The microbubbles may also be targeted to the one or more target cells by incorporation of targeting molecules, such as antibodies, that bind to the one or more target cells. For instance, the
microbubbles may target professional antigen presenting cells (APCs) such as macrophages and dendritic cells (e.g., by the incorporation of an anti-CDl lb antibody). The payload may comprise any suitable agent that can be loaded onto the surface of the microbubbles. For example, the payload may be mRNA or plasmid DNA (pDNA) for use in applications such as nucleotide-based vaccines or gene therapies.
According to certain aspects of the disclosure, the payload may be an agonist of the cGAS- STING cytosolic DNA sensing pathway. The spatial and temporal targeting of STING activation afforded via sonoporation of drug-carrying microbubbles can allow for enhanced potency of STING agonists with decreased systemic inflammatory side effects and toxicity. Sonoporation is also particularly advantageous for delivering negatively charged payloads in general, such as nucleotides, across the negatively charged plasma membrane.
According to some aspects of the disclosure, such agonists may be used for the treatment of cancer, particularly solid tumor cancers (e.g., breast cancer, brain cancer, melanoma) or other cancers having solid masses (e.g., lymphomas). STING agonists may be used to activate downstream proinflammatory pathways in APCs that efficiently prime antigen-specific T cells, thus bridging innate and adaptive immune responses. Doing so can result in systemic antitumor immunity and/or antitumor memory responses. According to some aspects, the microbubble composition may be used as a vaccine, such as therapeutic vaccine for the treatment of cancer, or a vaccine adjuvant.
Immune System
The human immune system may generally be divided into two arms, referred to as “innate immunity” and “adaptive immunity.” The innate arm of the immune system is predominantly responsible for an initial inflammatory response via a number of soluble factors, including the complement system and the chemokine/cytokine system; and a number of specialized cell types including mast cells, macrophages, dendritic cells (DCs), and natural killer cells. In contrast, the adaptive immune arm involves a delayed and a longer lasting antibody response together with CD8+ and CD4+ T cell responses that play a critical role in immunological memory against an antigen. A third arm of the immune system may be identified as involving gd T cells and T cells with limited T cell receptor repertoires such as NKT cells and MAIT cells.
For an effective immune response to an antigen, antigen presenting cells (APCs) must process and display the antigen in a proper MHC context to a T cell, which then will result in stimulation of cytotoxic T cells and helper T cells. Following antigen presentation, successful interaction of co- stimulatory molecules on both APCs and T cells must occur or activation will be aborted. GM-CSF and IL-12 serve as effective pro-inflammatory molecules in many tumor models. For example, GM-CSF induces myeloid precursor cells to proliferate and differentiate into dendritic cells (DCs) although additional signals are necessary to activate their maturation to effective antigen-presenting cells necessary for activation of T cells. Barriers to effective immune therapies include tolerance to the targeted antigen that can limit induction of cytotoxic CD8+ T cells of appropriate magnitude and function, poor trafficking of the generated T cells to sites of malignant cells, and poor persistence of the induced T cell response.
DCs that phagocytose tumor-cell debris process the material for major histocompatibility complex (MHC) presentation, upregulate expression of costimulatory molecules, and migrate to regional lymph nodes to stimulate tumor-specific lymphocytes. This pathway results in the proliferation and activation of CD4+ and CD8+ T cells that react to tumor-associated antigens. Such cells can be detected frequently in the blood, lymphoid tissues, and malignant lesions of cancer patients. Compounds which are capable of stimulating an innate immune response as well as simultaneously priming an adaptive immune response may be particularly useful as immunotherapies for treating cancer.
Immunotherapy
According to some aspects of the disclosure, the compositions described herein are administered with an amount effective of an immunomodulatory payload to stimulate (e.g., induce, increase or enhance) an immune response. An “immune response” may generally refer to responses that induce, increase, or perpetuate the activation or efficiency of innate or adaptive immunity. The compositions may be used functionally as adjuvants. The compositions may or may not be administered together with other adjuvants. Furthermore, the immune response may be enhanced relative to delivery of the payload (e.g., an immunomodulatory compound) alone and/or using a delivery vehicle other than the microbubble compositions described herein.
Specific stimulations of the immune response may comprise reducing inactivation and/or prolonging activation of T cells (e.g., increasing antigen-specific proliferation of T cells,
enhancing cytokine production by T cells, stimulating differentiation and effector functions of cells, and/or promoting T cell survival) or overcoming cell exhaustion and/or anergy. According to certain embodiments, the composition may be effective to induce or increase the activation of STING. When used to stimulate an immune response, the compositions described herein may increase the number of immune cells producing proinflammatory cytokines, such as IFN-a, IFN- b, and/or IFN-g, and/or increase the production of proinflammatory cytokines in existing immune cells. The increases may be detectable in a subject’s serum. When used to stimulate an immune response, the compositions described herein may result in nuclear localization of pIRF3 and/or NFK-B in treated cells. When used to stimulate an immune response, the compositions described herein may recruit CD8+ and /or CD4+ T cells to a site of treatment, infection, and/or cancer (e.g., to a tumor). A stimulated immune response may result in an increase number of effector memory T-cells and/or central memory T-cells (e.g., within a site of treatment, infection, or cancer) that are specific to an antigen. The antigen may be administered with or as a part of the microbubble composition or be an antigen present within a treatment area (e.g., a tumor antigen). A stimulated immune response may comprise an improved B-memory cell response (e.g., an increased frequency of peripheral blood B lymphocytes capable of differentiation into antibody-secreting plasma cells upon antigen encounter as measured by stimulation of in vitro differentiation).
An enhancement of an immune response may be quantified. According to certain aspects, the enhancement may be, for instance, at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, or 1,000% improved (e.g., increased) over a suitable baseline measurement. A suitable baseline measurement may be, for example, measured in a subject (e.g., prior to treatment) or a suitable reference population. The improvement may be statistically significant (e.g., p < 0.05).
Microbubble Compositions for Drug Delivery
According to various aspects of the disclosure, described herein are microbubble compositions which may be useful for drug delivery, according to the methods described elsewhere herein.
Microbubbles
As used herein, “microbubble” (“MB”) may refer to a gas-filled bubble formed by a surfactant shell encapsulating a gas core. The surfactant shell may comprise one or more types of molecules which lower the interfacial tension between the gas core and the exterior aqueous environment, such as a physiological environment. This exterior shell may comprise, for example, lipids (e.g., phospholipids), proteins (e.g., albumin), sugars, and/or polymers. According to certain aspects, the gas cores comprise a perfluorocarbon (e.g., decafluorobutane). According to certain aspects, the microbubble shells comprise l,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC) and/or l,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) lipids. According to certain aspects, one or more of the components of the microbubble shell (e.g., the phospholipids) may be PEGylated. For instance, PEG chains may extend outward from the external surface of the microbubble. Various microbubble formulations are well known in the art. Microbubbles may be produced, for example, without limitation by any of the methods disclosed in U.S. Patent Nos. 6,113,919 to Reiss et al. (issued Sept. 5, 200), 10,912,848 to Kim et al. (issued Feb. 9, 2021); or U.S. Patent Application Publication Nos. US 2002/0150539 to Unger (Oct. 17, 2002), US 2013/0336891 to Dayton et al. (published Dec. 19, 2013), or US 2018/0272012 to de Gracia Lux et al. (published Sept. 27, 2018); or Zhou, J Healthc Eng. 2013;4(2):223-54 (doi: 10.1260/2040- 2295.4.2.223), each of which is hereby incorporated by reference in its entirety.
In some embodiments, the bubble may be no greater than about 10 pm in diameter. In some embodiments, the average microbubble size within a microbubble composition is at least about 1, 2, 3, 4, or 5 pm. In some embodiments, the average microbubble size is approximately 1, 2, 3, 4, or 5 pm. In some embodiments, the average microbubble size is between approximately 1-10, 1-5, 1-4, 1-3, 1-2, 2-5, 2-4, 2-3, 3-5, or 3-4 pm.
Unless otherwise specified, microbubbles, as used herein, may comprise bubbles less than 1 pm (i.e. nanobubbles), such as bubbles between, for example, about 50 nm - 100 nm, about 50 nm - 200 nm, about 50 nm - 300 nm, about 100 nm - 200 nm, about 100 nm - 300 nm, about 100 nm - 400 nm, about 100 nm - 500 nm, about 100 nm -1 pm, about 200 nm - 1 pm, about 300 nm - 1 pm, or about 500 nm - 1 pm. In certain embodiments, the average size of the microbubble composition is between about 100 nm - 700 nm, about 200 nm - 600 nm, or about 300 nm - 500 nm. The size of the microbubble composition (e.g., the average size or the maximum size) may be such that the microbubbles (or at least a majority of the microbubbles, e.g., at least 60%, 70%,
80%, 90%, 95%, 99% of the microbubbles) are able to extravasate the blood vessels of a subject, which may advantageously allow for systemic delivery of the microbubble composition in certain applications.
According to certain aspects, the microbubble composition may be a nanobubble composition. As used herein, a “nanobubble composition” may refer to a composition of microbubbles in which consists entirely of nanobubbles or is composed primarily of nanobubbles (e.g., at least about 60%, 70%, 80%, 90%, 95%, 99% of the microbubbles are nanobubbles). A nanobubble composition may be microbubble composition that is prepared in a manner to preferentially isolate nanobubbles or nanobubbles of a certain size. A nanobubble composition may be prepared, for example, by differential centrifugation, as described elsewhere herein. A nanobubble composition may have an average bubble size less than 1 pm. According to certain aspects, nanobubble compositions may be used for systemic delivery of microbubbles to a subject.
According to certain aspects of the disclosure, various payloads, such as CDNs, may be loaded onto the microbubble compositions described herein. As used herein, “loading” may refer to the binding of payload molecules to microbubbles. According to some aspects of the disclosure, payloads may preferably be reversibly bound to microbubbles though non-covalent interactions (e.g., electrostatic interactions). According to some aspects of the disclosure, payloads may preferably be bound to an external surface of the microbubbles (i.e. the microbubbles may be decorated with the payload). The microbubble compositions may incorporate one or more types of payload-binding molecules for loading the payload onto the microbubbles. The payload binding molecules may be polymers. According to some preferred aspects of the disclosure, the payload-binding molecules may be cationic (e.g., cationic polymers). For example, the payload binding molecules may comprise polyamines. According to some preferred aspects of the disclosure, the polyamines may comprise spermines, as described in further detail elsewhere herein.
According to various aspects of the disclosure, loaded microbubble compositions (compositions of microbubbles loaded with/bound to payloads) may be prepared in various ways. In some instances, the payload-binding molecules (e.g., cationic polymers) may first be associated with (e.g., conjugated to the microbubble surface), after which the microbubbles may be loaded with payload (e.g., by mixing or incubating with a payload solution). For example, spermine decorated microbubbles (e.g., SpeDex-decorated microbubbles) may be mixed with a solution of
CDNs (e.g., cGAMP). In some instances, the payload-binding molecules may first be loaded with payload (e.g., via mixing) to form nanocomplexes, after which the resulting nanocomplexes may be conjugated to the microbubbles. For example, a solution of CDNs (e.g., cGAMP) may be mixed with a solution of spermine or SpeDex to form nanocomplexes, after which the nanocomplexes may be conjugated to microbubble surfaces (e.g., via free amine groups on the spermine). Loading active agents onto microbubbles may provide improved therapeutic efficacy relative to administering the active agent alone or in combination with the same microbubble composition but not bound to the microbubbles (e.g., with respect to the same microbubble compositions and the same amount of payload, loaded microbubble compositions may demonstrate increased intracellular delivery of the active agent after sonoporation relative to unbound combinations of the active agent and microbubble composition).
According to particular aspects of the disclosure, the microbubbles are decorated with spermines, which are particularly effective in non-covalently binding negatively charged payloads. According to more particular aspects of the present disclosure, the spermines are interlinked by dextrans, which allow for effective loading of spermines and negatively charged payloads to the microbubble surface. See e.g., PCT/US2021/054820 to Lux et al., filed October 13, 2021, which is herein incorporated by reference in its entirety. Spermine-modified dextran (SpeDex) is a non toxic cationic branched biopolymer that allows high loading of negatively charged payloads. According to specific aspects of the disclosure, SpeDex-decorated microbubbles are loaded with CDNs, such as cGAMP, for delivery to target cells, preferably via sonoporation. Strong electrostatic interaction between negatively charged CDNs and the cationic SpeDex polymers allows for efficient and stable binding. The high loading capacity of such microbubble compositions for suitable payloads, such as CDNs, may allow for improved drug delivery (e.g., larger amounts of payload being delivered intracellularly to target cells in each administration).
The payload may be any active agent which is able to be loaded onto a microbubble and preferably those that are suitable for intracellular delivery via sonoporation. The microbubble compositions described herein may be particularly useful for payloads which would benefit from targeted drug delivery. Payloads which stably bind spermine or SpeDex may, in particular, be suitable for drug delivery using the methods and/or compositions described herein, although other payload binding molecules (e.g., other cationic polymers such as polyamines) may be used to load microbubbles. According to certain aspects of the disclosure, the payload may bind to the
microbubbles via electrostatic interactions between positive charges on the microbubble surface (e.g., positively charged primary and/or secondary amino groups) and negative charges exposed on the payload molecules, such as negatively charged phosphate groups on the sugar phosphate backbone of a nucleic acid or the phosphate group of a CDN. Depending on the payload, the microbubble compositions described herein may be loaded according to the ratio of the number of positively-chargeable amine groups (N) decorating the microbubbles of the microbubble composition to the number of negatively-charged phosphate groups (P) within the payload composition. In some embodiments, the microbubble composition may be loaded at N:P ratios of approximately 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, or 1:20. In some embodiments, the microbubble composition may be loaded at N:P ratios in which the number of phosphate groups (P) are at least about 5, 10, 15, or 20 times greater than the number of amine groups (N). In some embodiments, the microbubble composition may be loaded atN:P ratios of approximately 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, or 20:1. In some embodiments, the microbubble composition may be loaded at N:P ratios in which the number of amine groups (N) are at least about 5, 10, 15, or 20 times greater than the number of phosphate groups (P). In some embodiments, the microbubble composition may be prepared at concentrations of approximately lxlO 7 - lxlO 10, lxlO 7 - lxlO 9, lxlO 7 - lxlO 8, lxlO 8 - lxlO 10, or lxlO 8 - lxlO 9 pg of payload (e.g., pDNA) per microbubble. The microbubble composition may, for example, be prepared at concentrations of at least about lxlO 8, 2xl08, 3xl08, 4xl08, 5xl08, 6xl08, 7xl08, 8xl08, 9xl08 pg/microbubble. The amount of payload that a microbubble composition is ultimately able to carry may depends in part on the amount of positive charges available (e.g., the surface density of the amino groups on the microbubble surface) as well as the ability of the positively charged polymer to stably bind the nucleic acid. The binding stability of a microbubble composition may generally be reduced at higher loading capacities.
Targeting Molecules
The microbubbles may be decorated with targeting molecules, which bind to specific cell types or other biological structures. In some embodiments, the targeting molecule may be a protein or other biomolecule (e.g., a ligand for a cell surface receptor). In some embodiments, the targeting molecule may be a biopolymer or component thereof, such as an extracellular matrix polymer
(e.g., hyaluronic acid, collagen, elastin, fibronectin, laminin, or proteoglycans such as heparan sulfate, chondroitin sulfate, keratin sulfate). In some embodiments, the targeting molecule is a monoclonal or polyclonal antibody, including antibody fragments or peptides derived from/modeled after antibodies with antigen-binding properties. For instance, the antibody may be a Fab fragment, an F(ab’)2 fragment, an Fab’ fragment, an Fv fragment, an scFv, a di-scFv, an sdAb, a recombinant IgG, a peptide comprising one or more complementary determining regions (CDRs), or any other antibody fragment or biomolecule with antigen binding properties well known in the art. The antibody may be specific for an antigen expressed on the cell surface of the targeted cell type (e.g., a cell surface receptor). In some embodiments, the microbubbles may be configured to target cancerous / tumor cells. In some embodiments, the microbubbles may be configured to target immune cells (e.g., T-cells, B, cells, neutrophils, eosinophils, basophils, mast cells, monocytes, macrophages, dendritic cells, natural killer cells, etc.). According to certain aspects of the disclosure, microbubble compositions may comprise targeting molecules which bind CDl lb (e.g., anti-CDl lb antibodies). Cluster of differentiation molecule 11B (CDl lb), also known as integrin alpha M (ITGAM) or CR3A, is one protein subunit that forms heterodimeric integrin alpha-M beta-2 (aMb2) molecule, also known as macrophage-1 antigen (Mac-1) or complement receptor 3 (CR3). aMb2 is expressed on the surface of many leukocytes involved in the innate immune system, including monocytes, granulocytes, macrophages, natural killer cells, and dendritic cells. According to some aspects of the disclosure, APCs, such as macrophages and dendritic cells, may be targeted for drug delivery by targeting CD1 lb.
The targeting molecules may be covalently coupled to the external surface of the surfactant shell of the microbubble. Various conjugation strategies are well known in the art for conjugating targeting molecules to microbubbles. See, e.g., PCT/US2021/054820 to Lux et ak, filed October 13, 2021, which is herein incorporated by reference in its entirety. Microbubble compositions comprising targeting molecules may provide improved therapeutic efficacy relative to microbubble compositions not targeted to any cell type (e.g., with respect to the same microbubble compositions loaded with the same amount of payload, targeted microbubble compositions may demonstrate increased intracellular delivery of the payload after sonoporation even when using localized administration, such as after intratumoral injection).
Payloads
The microbubble compositions described herein may be loaded with one or more “payloads” or “active agents.” The terms “payload” or “active agent” or “drug,” as used herein, refer to any compound used for the treatment or diagnosis of a disease. Drug delivery may refer to the delivery of a payload or active agent to a cell or subject, preferably to a target organ, tissue, and/or cell type. A microbubble composition as used herein may facilitate drug delivery of the one or more active agents to a target organ, tissue, or cell.
Exemplary active agents include, but are not limited to, compounds that rely on intracellular access and/or compounds that rely on access to cytosolic receptors/pathways, including STING agonists, such as cyclic dinucleotides (CDNs), as described in further detail herein. The present disclosure, however, contemplates additional or alternative payloads besides CDNs.
Additional representative suitable active agents include, but are not limited to, STING antagonists, oligonucleotides, proteins, peptides, peptides, lipopeptides, polysaccharides, hydrophobic and amphiphilic small molecular drugs, antibodies, nanobodies, RNA, mRNA, miRNA, siRNA, aptamers, antibiotics, antigens (e.g., tumor antigens, tumor neoantigens), chemotherapeutics, imaging agents, quantum dots, any other suitable compound for disease treatment, or a combination thereof. According to certain aspects of the disclosure, the payload may comprise a nucleic acid. The nucleic acid may be, for example, a plasmid (e.g., pDNA), an siRNA, or a Dicer-substrate siRNA (DsiRNA). The nucleic acid may be DNA, RNA, or combinations thereof. For example, the methods and/or compositions described herein may be used for targeted gene delivery (e.g., siRNA, mRNA, DNA, etc.), such as for gene therapy. According to certain aspects of the disclosure, the payload may comprise a protein. Protein therapeutics may comprise, for example, antibody -based drugs, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, Fc fusion proteins, growth factors, hormones, interferons, interleukins, thrombolytics, etc. Representative examples of therapeutic applications include, but are not limited to, delivery of immunostimulatory DNA to immune cells; cytosolic delivery of antigens to dendritic cells to increase antigen presentation on class I MHC, cytosolic delivery of vaccine antigen/adjuvant combinations and intracellular cytokine staining.
Different types of payloads may be loaded onto the same microbubble (e.g., immunomodulatory compounds and antigens). Microbubble compositions may comprise mixtures
of microbubbles having different payloads or payload profiles. According to some aspects of the disclosure, a microbubble composition may comprise two or more of the active agents described herein, including the agents discussed with respect to combination therapies (e.g., a CDN and an anti-cancer agent). The microbubble compositions may have one or more types of targeting molecules and/or microbubble compositions may comprise mixtures of microbubbles having different targeting molecules or targeting molecule profiles.
STING Signaling and STING Agonists
As described elsewhere herein, the methods and/or compositions of the present disclosure may be particularly useful for delivery of CDNs, particularly to immune cells, including both macrophages and dendritic cells. Specifically, the methods and/or compositions of the present disclosure may be particularly useful for delivery of STING agonists, preferably intracellular delivery of STING agonists to target cells. An “agonist,” as it relates to a ligand and receptor, comprises a molecule, combination of molecules, a complex, or a combination of reagents, that stimulates the receptor. For example, a STING agonist can encompass cGAMP, a mutein or derivative of cGAMP, a peptide mimetic of cGAMP, a small molecule that mimics the biological function of cGAMP, or an antibody that stimulates STING. Accordingly, preferred payloads may be cGAMP or other STING agonists. According to some aspects of the disclosure, CDNs may be delivered to cancer cells.
Stimulator of interferon genes (STING), also known as transmembrane protein 173 (TMEM173) and MPYS/MITA/ERIS, is an adaptor protein in the cytoplasm of mammalian cells which activates the TANK binding kinase (TBK1) - interferon regulatory factor 3 (IRF3) signaling axis via a phosphorylation-dependent mechanism, resulting in the induction of IFN-b and other IRF-3 dependent gene products that strongly activate innate immunity. TKB1 is a serine/threonine protein kinase which regulates cell proliferation, apoptosis, autophage, and anti-tumor immunity. TKB1 phosphorylates and activates IRF3. IRF3 is an inteferon regulatory factor (transcription factor). Sting also activates the STAT6 transcription factor, which mediates signaling required for the development of T-helper type 2 (Th2) cells and Th2 immune response. STAT6 and IRF3 are responsible for antiviral response and innate immune response against intracellular pathogens. STING, thus, plays an important role in innate immunity. STING also activates NF-KB, a protein complex that controls transcription of DNA, cytokine production and cell survival, and which
functions together with IRF3 to turn on the transcription of type I interferons (IFNs) and other cytokines. STING induces type I interferon production when cells are infected with intracellular pathogens, such as viruses, mycobacteria and intracellular parasites. Type I interferons play important roles in both the adaptive and innate immune responses, prevent proliferation of pathogens, and have antiviral activities. Type I interferons, mediated by STING, protect nearby cells from local infection via paracrine signaling. STING is encoded in humans by the STING1 gene (Gene ID: 340061).
STING is considered a pathogen recognition receptor (PRR) which functions as a direct cytosolic DNA sensor (CDS) and is a component of the host cytosolic surveillance pathway. The pathway senses infection with intracellular pathogens and in response induces the production of IFN-b, leading to the development of an adaptive protective pathogen-specific immune response consisting of both antigen-specific CD4+ and CD8+ T cells as well as pathogen-specific antibodies. As described herein, the STING signaling pathway in immune cells is a central mediator of innate immune response and when stimulated, induces expression of various interferons, cytokines and T cell recruitment factors that amplify and strengthen immune activity, including against infections and cancerous cells. The STING signaling pathway is described in further detail in Li et al., J Exp Med. 2018 May 7;215(5): 1287-1299 (doi: 10.1084/jem.20180139) and Zhu et al., Mol Cancer.
2019 Nov 4; 18(1): 152 (doi: 10.1186/sl2943-019-1087-y), each of which is hereby incorporated by reference in its entirety.
Cyclic dinucleotides (CDNs), such as cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), are agonists of STING and have potential therapeutic applications, particularly in oncology and immunology. The cyclic dinucleotides recognized by STING are small-molecule second messengers used by all phyla of bacteria and are also produced as endogenous products of the cytosolic DNA sensor cyclic GMP-AMP synthase. Thus, such CDNs may be considered pathogen associated molecular patterns (PAMPs). The CDNs cyclic-di-AMP (produced by Listeria monocytogenes) and its analog cyclic-di-GMP (produced by Legionella pneumophila) are also agonists of STING. A number of other STING agonists have been discovered, or developed, in attempt to either treat tumors alone, or to be used in combination with other cancer therapies to enhance their performance. See, e.g., La Nour et al. Oncoimmunology.
2020 Jun 16;9(1): 1777624, which is herein incorporated by reference in its entirety. These include flavone acetic acid (FAA) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Examples of
cyclic purine dinucleotides that may bind STING and/or which may be delivered via the compositions described herein are described in some detail in, e.g., U.S. Pat. Nos. 7,709,458 and 7,592,326; W02007/054279; and Yan et al., Bioorg. Med. Chem Lett. 18: 5631 (2008), each of which is hereby incorporated by reference in its entirety.
Cyclic dinucleotides are difficult to deliver intracellularly. As described herein, STING agonists may be delivered directly into the cytoplasm of cells via the application of ultrasound to microbubble compositions loaded with the STING agonist. This delivery platform may be used as an immunotherapy for cancer, which in that context, is referred to as Microbubble-assisted Ultrasound-guided Immunotherapy of Cancer (abbreviated as MUSIC herein). Microbubbles allow the targeted delivery of STING agonists, such as cGAMP, to target cells (e.g., cancer cells or immune cells) and ultrasound-induced sonoporation can be used to deliver the STING agonist payloads across cell membranes in an endocytosis-independent manner.
Vaccines
According to some aspects of the disclosure, the compositions described herein are administered as immunogenic compositions or prophylactic vaccines which confer resistance in a subject to subsequent exposure to infectious agents, or as part of therapeutic vaccines, which can be used to initiate or enhance a subject's immune response to a pre-existing antigen, such as a viral antigen in a subject infected with a virus or with cancer. Immunogenic compositions may comprise immunomodulatory compounds which stimulate a desired immune response, as described elsewhere herein. The microbubbles may be loaded with immunomodulatory compounds, such as CDNs (e.g., cGAMP); antigens (e.g., protein or peptide antigens); or combinations thereof. Research has shown CDNs promote cellular and humoral immunity in vaccinated mice. Accordingly, CDN-based vaccine adjuvants may be used to improve vaccine efficacy. The use of the methods and/or compositions described herein to deliver immunomodulatory compounds, antigens, or combinations thereof may provide for increased antigen delivery and/or increased antigen presentation. According to some aspects, a vaccine is formed by a combination of the immunomodulatory compound and antigen, wherein at least one or both the immunomodulatory compound and antigen are loaded onto a microbubble composition of the present disclosure. According to some aspects, one of the vaccine components (e.g., the antigen) may be delivered via a different type of composition (e.g., using a vehicle other than a microbubble composition or no
vehicle at all). The immunomodulatory compound and antigen may be delivered together to act as a vaccine, whether they are part of a single pharmaceutical composition or not.
Antigens can be, without limitation, peptides, proteins, polysaccharides, saccharides, lipids, nucleic acids, or combinations thereof. The antigen can be derived from a virus, bacterium, parasite, plant, protozoan, fungus, tissue or transformed cell such as a cancer or leukemic cell and can be a whole cell or immunogenic component thereof, e.g., cell wall components or molecular components thereof. Suitable antigens are known in the art and are available from commercial government and scientific sources. The antigens may be whole inactivated or attenuated organisms. These organisms may be infectious organisms, such as viruses, parasites and bacteria. These antigen may be a tumor cell. The antigens may be purified or partially purified polypeptides derived from tumors or viral or bacterial sources. The antigens can be recombinant polypeptides produced by expressing DNA encoding the polypeptide antigen in a heterologous expression system. The antigens can be DNA encoding all or part of an antigenic protein. The DNA may be in the form of vector DNA such as plasmid DNA. Antigens may be provided as single antigens or may be provided in combination. Antigens may be provided as complex mixtures of polypeptides or nucleic acids. Antigens may be allergens or environmental antigens. Antigens may be cancer antigens (an antigen that is typically expressed at higher levels in cancer cells than on non-cancer cells or is expressed solely by cancer cells).
According to some aspects of the disclosure, the microbubble compositions described herein may be used as part of a therapeutic vaccine. As used herein, a “therapeutic vaccine” may refer to a vaccine which is administered after an infection or disease, such as cancer, has already affected a subject. A therapeutic vaccine may activate the immune system of a subject to fight an existing infection or disease. A therapeutic vaccine may help, for example, a subject’s immune system to recognize and respond to a cancerous cells. The microbubble composition may be delivered to a subject as a therapeutic vaccine which targets an existing cancer via targeted sonoporation of a cancer site (e.g., a tumor). According to some aspects, the drug-loaded microbubble composition may be used to activate APCs, such as dendritic cells, ex vivo. APCs may be extracted from a subject via leukapheresis and activated ex vivo via sonoporation of drug- loaded microbubbles (e.g., loaded with a STING agonist, such as a CDN) as well as incubation with a cancer cell antigen or cancerous cells (e.g., isolated from a patient biopsy) before being reintroduced to the subject as a vaccine (e.g., a dendritic vaccine). Activation of the APCs may
comprise treatment/incubation with other agents, such as granulocyte-macrophage colony stimulating factor (GM-CSF), for example.
Methods of Treatment
The methods of treatment described herein comprise administration of any of the drug- loaded microbubble compositions described elsewhere herein, preferably for intracellular delivery of the drug/payload to a target organ, tissue, or cell, including, for example, the intracellular delivery of immunomodulatory payloads (e.g., CDNs such as cGAMP), such as for the treatment of cancer and/or as part of vaccines, and genes for gene therapy.
Administration of Drug Loaded Microbubble Compositions
The methods and/or compositions described herein may be used to treat one or more various diseases. As used herein, a “disease,” “disorder,” “condition,” “illness,” “ailment,” or “indication” may be used interchangeably and may refer to any physiological state or pathology of a subject which may reasonably be treatable by the methods and/or compositions described herein. A disease may be caused by one or more contributing factors, including, for example, genetic factors (i.e. specific genotypes), epigenetic factors, behavioral/lifestyle factors (e.g., diet and exercise), age, and external factors (e.g., toxin exposures, infections, injuries, etc.), some of which may be interrelated. A disease may or may not have a definitive etiology. A disease may be associated with one or more symptoms. A disease may be a syndrome classified by one more symptoms. A disease may be clinically diagnosable by one or more well-known means in the art, including, for example, measurable clinical parameters (e.g., blood work, urinalysis, measurement of biomarkers); functional assessments; physical examinations; diagnostic imaging; histological analysis (e.g., biopsies); genotyping/genetic sequencing; evaluation of subject medical history; etc.
“Treatment” of a disease or “treating” a disease, as used herein, may refer to an approach of applying the methods and/or compositions described herein for obtaining beneficial or desired results (a therapeutic response), including clinical results. “Therapy,” as used herein, may be used interchangeably with “treatment.” Beneficial or desired results with respect to treating a subject for a disease may include, but are not limited to, one or more of preventing a disease, delaying the onset of a disease, curing or resolving a disease, lessening the severity of a disease, delaying progression of a disease, preventing the worsening of a disease, increasing the quality of life of
one suffering from a disease, prolonging survival of a subject having a disease, and/or improving the therapeutic efficacy of other treatments for the disease (e.g., reducing the dose necessary to achieve a therapeutic response). Such beneficial or desired results may be achieved with respect to any aspect of a disease pathology or comorbidity associated therewith, including physiological states or processes that cause or contribute to a disease as well as effected physiological states or processes that manifest in symptoms or complications associated with the disease. Thus, for example, lessening the severity of a disease may encompass alleviating (e.g., reducing the severity, frequency, or duration of or eliminating altogether) one or more symptoms associated with a disease or comorbidity thereof. Assessments of beneficial or desired results may comprise assessments of any one or more factors that could be used, at least in part, to diagnose a disease or comorbidity thereof (e.g., assessing for discernible improvements in such a factor). According to some aspects of the disclosure, the beneficial or desired results may be assessed relative to a population having the same risk factors, symptoms, and/or type and severity of disease (e.g. as assessed by clinical measurements) and not receiving treatment as described herein. Depending on the context, “treatment” of a subject can imply that the subject is in need of treatment, e.g., in a situation where the subject has been diagnosed with or exhibits symptoms or complications associated with a disease reasonably expected to be treatable with a method and/or composition described herein. “Treatment,” as used herein also encompasses prophylactic treatments. As used herein, “prevention” or “preventing,” when used in reference to a disease, includes a reduction in likelihood of developing a disease (e.g., reducing or improving on risk factors for a disease) and/or a reduction in severity of a disease upon onset. In cases of prophylactic treatment, a subject may be in need of treatment (e.g., for preventing further development or progression of a disease) or determined to be at a relatively high risk of disease (e.g., such that prospective benefits of prophylactic treatment outweigh any risks, such as side effects, associated therewith).
As used herein, a “subject” is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), a non-primate (such as a cow, a pig, a horse, a goat, a rabbit, a sheep, a hamster, a guinea pig, a cat, a dog, a rat, or a mouse), or a bird that can be treated with the methods and/or compositions of the present disclosure. Non human subjects may be livestock. According to some specific aspects of the disclosure, the subject is a human, such as a human having cancer. The subject may be a female (e.g., a female human). The subject may be a male (e.g., a male human). In some aspects, the subject is an adult subject.
In other aspects, the subject is a pediatric subject, such as a neonate, an infant, or a child. The subject may be an individual for which it is reasonably expected a therapeutic response could be achieved. Subjects may be individuals who are administered a composition of the present disclosure for experimental or research purposes (e.g., control subjects). A “patient,” as used herein, refers to a subject who exhibits symptoms and/or complications of a disease; has been diagnosed as having a disease; has been identified as being at a risk of developing a disease; and/or is under the treatment of a clinician (e.g., a physician), including for investigation of some pathology that could be associated with the disease, even if no defined disease has been diagnosed. The term “patient” includes human and veterinary subjects. Any reference to subjects in the present disclosure, should be understood to include the possibility that the subject is a “patient” unless indicated otherwise, explicitly or by context.
According to certain aspects of the disclosure, the microbubble compositions described herein may be incorporated into a pharmaceutical composition suitable for administration to a subject. Such pharmaceutical compositions may further comprise a “pharmaceutically acceptable carrier,” (interchangeable with “pharmaceutical carrier” or “carrier”) which may be any compound or composition useful in facilitating storage, stability, administration, cell targeting and/or delivery of the microbubbles to a target cell or cell population. A “pharmaceutically acceptable carrier,” as used herein, refers to a carrier or excipient that is suitable for use with the subjects or patients described elsewhere herein (e.g., humans and/or animals) without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio. The carrier can be a pharmaceutically acceptable solvent, dispersion media, suspending agent or other suitable vehicle, for delivering microbubble compositions as described herein to the subject, such as through, for example, intravenous injection. Pharmaceutically acceptable carriers may include any diluents, solvents (including water), fillers, extenders, preservatives, thickeners, antibacterial agents, antifungal agents, isotonic agents, pH modifiers, salts, colorants, flavorings, rheology modifiers, lubricants absorption delaying agents, antifoaming agents, surfactants, emulsifiers, adjuvants, suitable vehicles, coatings, erodible polymers, hydrogels, phospholipids, fatty acids, mono-di- and tri-glycerides and derivates thereof, waxes, oils, etc., which are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the microbubbles and/or components thereof (e.g., payloads,
targeting molecules), use thereof in the compositions is contemplated. Supplementary active agents can also be incorporated into the pharmaceutical compositions. A pharmaceutical composition according to the disclosure may be formulated to be compatible with its intended route of administration, as described elsewhere herein. The pharmaceutical composition can be included in a kit, container, pack, or dispenser together with instructions for administration.
Treatment of a subject, organ, tissue, cell, or body fluid with a composition described herein, generally comprises administering the composition to a subject, organ, tissue, cell, or body fluid, respectively. “Administration,” as used herein, refers to inducement of contact between an exogenous compound, such as the microbubble compositions described herein and/or payloads loaded thereon, a placebo, or a control, to a subject, organ, tissue, cell, or body fluid. Treatment of a cell, for example, encompasses contact of a compound to the cell, as well as contact of a compound to a fluid, where the fluid is in contact or placed into contact with the cell. Administration may be performed for therapeutic or experimental (e.g., basic research, clinical research, pharmacokinetic studies) purposes. When multiple compounds are “administered together” they are not necessarily administered as a single composition, although they may be. Such compounds may be delivered to a single subject as separate administrations, which may be at the same or different time, and which may be by the same route or different routes of administration, unless dictated otherwise explicitly or by context.
The microbubbles may be administered locally, regionally or systemically as desired, for example and without limitation: intravenously, intramuscularly, subcutaneously, dermally, subdermally, intraperitoneally, transdermally, iontophoretically, orally, and transmucosally. Non limiting examples of devices useful in delivering the microbubbles to a subject include needle/syringes, catheters, trocars, stents or projectiles. According to certain aspects of the disclosure, the microbubbles are delivered directly to a cite in need of an immune response. For example, the microbubbles may be delivered intratumorally, which includes delivery internal to a tumor and/or immediately adjacent to a tumor or a cancer cell such that the decoy diffuses to contact the tumor or cancer cell. According to certain aspects of the disclosure, the microbubbles are administered at a site adjacent to or leading to one or more lymph nodes which are close to the site in need of an immune response (e.g., a tumor).
Treatments, as described herein, may comprise one or more rounds of administration (administration of one or more doses) of a composition described herein. A “treatment regimen”
or simply “regimen,” as used herein may refer to a course of treatment comprising multiple administrations of a composition described herein. The composition may be the same for each round of administration (or for at least some of the rounds of administration) or may be different for at least some rounds of administration. The doses may be the same or different for different rounds of administering the same composition. A treatment regimen may be defined by a dosing schedule (e.g., a dosing frequency or temporal pattern of administrations), a total number of administrations/doses, and/or a total duration in time of treatment. Some of these parameters may be determined independently, whereas some may be dependent on the other parameters or combinations thereof. Some parameters may be left indefinite for a particular regimen. Some parameters may be determined or adjusted as treatment progresses. For example, a clinician may adjust dosing amount and/or frequency based on observable responses to prior rounds of administration. According to some aspects of the disclosure, each round of administration may comprise administering the same composition at the same dose via the same route of administration. According to some aspects of the disclosure, a treatment regimen may comprise specific compositions (including combination therapies), doses, and/or routes of administration where any of these variables is not consistent at each round of administration.
Where there is more than one administration, the administrations can be spaced apart by time intervals of approximately one 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, or 45 minutes; by intervals of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours; by 1, 2, 3, 4, 5, 6, or 7 days; by 1, 2, 3, 4, or 5 weeks; or by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more months, including intervening time ranges. The doses may be administered at substantially regular time intervals (a frequency of administration). The administrations, however, are not limited to dosing intervals that are spaced equally in time, but may encompass doses at non-equal intervals as well. According to some aspects of the disclosure, a dosing frequency may be determined based at least in part on pharmacokinetic and/or pharmacodynamics profiles for the composition being administered as is well understood in the art. For instance, the frequency of administration may be tailored to generally maintain an administered composition, a component thereof (e.g., a payload), a metabolite thereof, or a biological response thereto (e.g., a marker of therapeutic efficacy) above a threshold (e.g., effective for inducing a therapeutic response), below a threshold (e.g., for avoiding or minimizing adverse effects, including toxicity concerns and side effects), or within a prescribed range.
Where there is more than one administration, the administrations may be spaced apart over a duration of treatment. The duration of the treatment regimen may be, for example, approximately or at least about 1, 2, 3, 4, or 5 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months; or 1, 2, 3, 4, or 5 years. A treatment regimen may comprise, by example, a total of about 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,
85, 90, 95, 100 or more administrations. According to some aspects of the disclosure, the treatment may be continued along some dosing schedule (e.g., at a dosing frequency) at least until a therapeutic response is achieved or until a therapeutic response is shown to be likely maintained for a sufficient period of time absent further administrations.
“Therapeutically effective” or “effective,” as used herein, in reference to amounts, frequencies, durations, and regimens refers to the amount of a composition, frequency of administration, duration of treatment, or design of treatment regimen, respectively, which would be reasonably expected to be sufficient in achieving a therapeutic response, such as those benefits and results described elsewhere herein with respect to treatments. According to certain aspects of the disclosure, therapeutically effective may refer to an amount, frequency, duration, or regimen that is sufficient to achieve some statistically significant (e.g., p < 0.05) measure of a therapeutic response. According to certain aspects of the disclosure, therapeutically effective may refer to an amount, frequency, duration, or regimen that is sufficient to achieve at least about a 5%, 10%, 15%, 20%, 25%, 30%, 40%, or 50% change in a baseline value (e.g., measured in a subject prior to treatment or measured in a suitable reference population). Means for statistically evaluating therapeutic efficacy are well known in the art. According to some aspects of the disclosure, therapeutic efficacy may be assessed by comparing outcomes in a population of subjects treated with a particular amount, frequency, duration, and/or regimen against outcomes to a population of similarly situated subjects not receiving treatment as described herein. Therapeutically effective amounts, frequencies, durations, and regimens of the administering the compositions described herein may vary according to factors such as the degree of susceptibility of the individual, the age, gender, and weight of the individual, and idiosyncratic responses of the individual. Unless dictated otherwise, explicitly or by context, a “therapeutically effective” amount, frequency, duration, and/or regimen is not limited to a minimal amount, frequency, and/or duration sufficient to achieve a therapeutic response or a regimen comprising such minimal amounts, frequencies, and/or durations. The therapeutic efficacy of the dosing amount, dosing frequency, and/or treatment
duration may be interrelated, particularly depending on the therapeutic response used to evaluate efficacy. For instance, more sustained measures of therapeutic efficacy (e.g., curing a disease) are likely to require more rounds of administration than a more transient measure of therapeutic efficacy (e.g., alleviating a symptom of a disease).
Therapeutically effective amounts of a pharmaceutical composition, a microbubble composition within a pharmaceutical composition, and/or a payload of the microbubble composition may be interrelated. The effective amount of a microbubble composition may be determinable, for instance, based on a loading efficiency of the particular combination of microbubble composition and payload, as may be readily measured experimentally, as described, for example, elsewhere herein.
The dosage of microbubbles administered to a subject may depend on the route of administration. Data obtained from in vitro cell-based assays and/or animal studies can be used in formulating a range of dosages for use in subjects (e.g., humans). The dosage may lie within a range of circulating concentrations that includes the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed, the route of administration utilized, and the particular indication (e.g., cancer type) being treated. For instance, intratumoral injection may require smaller dosages than systemic administration routes. Intravenous, or intramuscular systemic delivery may require larger dosages.
An effective amount of payload (e.g., a CDN such as cGAMP) to be administered (e.g., systemically) may generally be between about 0.1 pg/kg - 1,000 mg/kg, 1 pg/kg - 1,000 mg/kg, 10 pg/kg - 1,000 mg/kg, 100 pg/kg - 1,000 mg/kg, 1 mg/kg - 1,000 mg/kg, 0.1 pg/kg - 100 mg/kg, 1 pg/kg - 100 mg/kg, 10 pg/kg - 100 mg/kg, 100 pg/kg - 100 mg/kg, 1 mg/kg - 100 mg/kg, 0.1 pg/kg - 10 mg/kg, 1 pg/kg - 10 mg/kg, 10 pg/kg - 10 mg/kg, 100 pg/kg - 10 mg/kg, 1 mg/kg - 10 mg/kg, etc. The effective amount may depend upon a variety of factors including, for example, the activity of the specific payload employed, subject-specific factors (age, body weight, general health, sex and diet of the individual being treated), the time and route of administration, the rate of excretion, other treatments which have previously been administered, the precise condition being treated, the severity of the particular condition undergoing treatment, etc. The attending clinician may use appropriate discretion as is understood in the art on deciding upon an effective dose. Guidance for methods of treatment and diagnosis are well known in the art (see, e.g.,
Maynard, et al. (1996) A Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca Raton, Fla.; Dent (2001) Good Laboratory and Good Clinical Practice, Urch Publ., London, UK).
Sonoyoration
The present disclosure provides methods of delivering payloads to one or more cells using the microbubbles described herein with sonoporation techniques. Methods for performing sonoporation are well known in the art. See, e.g., Chowdhury et al., Ultrasonography. 2017 Jul;36(3):171-184 (doi: 10.14366/usg.17021); Tzu-Yin et al., Curr Pharm Biotechnol. 2013;14(8):743-52 (doi: 10.2174/1389201014666131226114611); Xu et al., Adv. Therap., 4: 2100154. (doi. org/10.1002/adtp.202100154), each of which is hereby incorporated by reference in its entirety. Sonoporation uses sound, typically at ultrasonic frequencies, for increasing the permeability of the cell plasma membrane in order to facilitate the delivery of a payload across the membrane and into the cell. Sonoporation may be particularly beneficial for delivering payloads across the blood-brain barrier or blood-tumor barrier. For in vivo applications, sonoporation may be an advantageous means of drug delivery as ultrasound can penetrate deep into the subject’s tissue in a non-invasive manner as well as provide spatially and temporally targeted delivery with minimal or no side effects to non-targeted tissue. Microbubbles can function as nuclei for acoustic cavitation in ultrasound-mediated drug delivery, effectively scattering ultrasound waves due to the high compressibility of the microbubbles. Sonoporation is believed to induce transient increases in cell permeability via the formation of transient pores in the cell plasma membrane. Without being bound by theory, collapsing microbubbles may produce local shock waves, water jets, and shear forces that are able to permeabilize nearby cell membranes. Sonoporation may allow the direct delivery (i.e. outside the endosomal transport pathway) of therapeutics, such as nucleic acids, into a cell’s cytosol.
The intensity of the ultrasound waves and the composition of the microbubble shell may influence the effectiveness of the sonoporation. Microbubble shells should be stiff enough to withstand small pressure perturbations but elastic enough to oscillate in response to the ultrasound waves. Lower degrees of polydispersity in microbubble size may be desirable so that larger proportions of a microbubble composition are sensitive to the same amplitudes of ultrasound. Without being limited by theory, microbubbles subjected to low-intensity ultrasound may oscillate stably around a resonant diameter, termed stable cavitation. Stable cavitation generates local shear
forces and acoustic microstreaming. At higher pressure amplitudes, microbubbles tend to undergo large size variations which cause them implode in an event termed inertial cavitation, the collapse resulting in water jetting, shock waves and other inertial phenomena. Both stable and transient microbubble cavitations may induce cell membrane permeabilization. Sonoporation is believed to provide a pathway to intracellular drug delivery independent of endocytosis.
According to certain aspects of the disclosure, ultrasound triggering of sonoporation with microbubbles may be performed at frequencies between about 0.1 MHz and about 10 MHz, between about 0.5 MHz and about 5 MHz, or between about 1 MHz and about 3 MHz. In some embodiments, ultrasound triggering may be performed at intensities between about 100 mW/cm2 and about 1 kW/cm2, between about 100 mW/cm2 and about 1 W/cm2, between about 300 mW/cm2 and about 1 W/cm2, between about 500 mW/cm2 and about 1 W/cm2, between about 700 mW/cm2 and about 1 W/cm2, between about 1 W/cm2 and about 500 W/cm2, between about 1 W/cm2 and about 100 W/cm2, between about 1 W/cm2 and about 100 W/cm2, between about 1 W/cm2 and about 50 W/cm2, between about 1 W/cm2 and about 20 W/cm2, between about 1 W/cm2 and about 10 W/cm2, between about 1 W/cm2 and about 5 W/cm2, between about 1 W/cm2 and about 2 W/cm2, and between 0.1 W/cm2 and 1 W/cm2. In some applications, the ultrasound triggering may be performed at a maximal intensity permitted by a regulatory agency (e.g., the FDA), such as, for example, approximately 720 mW/cm2 (for diagnostic ultrasound). In some applications, the ultrasound triggering may be performed at a duty cycle between about 10% and 100%, between about 20% and about 90%, between about 30% and about 80%, between about 40% and about 70%, or between about 50% and about 60%. In some applications, the duty cycle is about 50%. In some applications, the mechanical index (MI) of the ultrasound may be between about 0.05 and about 5, between about 0.1 and about 5, between about 0.5 and about 5, between about 1 and about 5, between about 2 and about 5, between about 3 and about 5, between about 4 and about 5. In some applications, the ultrasound triggering may be performed at a maximal mechanical index permitted by a regulatory agency (e.g., the FDA), such as, for example, approximately 1.9 (for diagnostic ultrasound). In some applications, the ultrasound triggering may be delivered for about 10 s - 3 min, 10 s - 2 min, 10 s - 1 min, 10 s - 50 s, 10 s - 40 s, 10 s - 30 s, 30 s - 3 min, 30 s - 2 min, 30 s - 1 min, 30 s - 50 s, 30 s - 40 s, 1 min- 3 min, or 1 min - 2 min, 2 min - 3min. According to certain aspects of the disclosure, ultrasound may be used to visualize the microbubbles prior to sonoporation (e.g., to confirm targeted localization of the microbubbles). Such an ultrasound
stimulus may be administered at parameters (e.g., an intensity) that are configured not to induce sonoporation.
Treatment of Cancer
According to some aspects of the disclosure, the compositions and/or methods described herein may be used to treat a disease associated with abnormal apoptosis or an abnormal differentiative process, including cellular proliferative disorders (e.g., hyperproliferative disorders) and/or cellular differentiative disorders, such as cancer. Cancers may be treated, for example, with an immunomodulatory composition (e.g., comprising a CDN such as cGAMP) or a vaccine, as described elsewhere herein.
As used herein, the terms “cancer” (or “cancerous”), “hyperproliferative,” and “neoplastic” refer to cells having the capacity for autonomous growth (i.e., an abnormal state or condition characterized by rapidly proliferating cell growth). A “tumor” or “neoplasm” may be used interchangeably to refer to an abnormal growth of cells. Hyperproliferative and neoplastic disease states may be categorized as pathologic/malignant (i.e., characterizing or constituting a disease state), or categorized as non-pathologic/benign (i.e., as a deviation from normal but not associated with a disease state). These terms are meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. “Pathologic hyperproliferative” cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair. The terms “cancer” or “neoplasm” as used herein encompass malignancies of the various organ systems, including those affecting the lung, breast, thyroid, lymph glands and lymphoid tissue, gastrointestinal organs, and the genitourinary tract, as well as to adenocarcinomas. The term “carcinoma” refers specifically to cancerous malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas. Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary. The term also includes carcinosarcomas, which include malignant tumors composed of carcinomatous and sarcomatous tissues. An “adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the
tumor cells form recognizable glandular structures. Adenocarcinomas are generally considered to include cancerous malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus. Additional examples of proliferative disorders include hematopoietic neoplastic disorders, which include diseases involving hyperplastic/neoplastic cells of hematopoietic origin (e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof).
The methods and/or combinations described herein may be particularly useful for generally treating neoplastic conditions in subjects which may include-benign or malignant tumors (e.g., adrenal, liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, thyroid, hepatic, cervical, endometrial, esophageal and uterine carcinomas; sarcomas; glioblastomas; and various head and neck tumors); leukemias and lymphoid malignancies; other disorders such as neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders. More specifically, neoplastic conditions subject to treatment in accordance with the methods and/or compositions described herein may be selected from the group including, but not limited to, adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's Sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipoma/benign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancers (small cell carcinoma, adenocarcinoma, squamous cell carcinoma, large cell carcinoma etc.), medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple, myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors,
phaeochromocytoma, pituitary tumors, prostate cancer, posterious unveal melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).
Neoplastic conditions comprising solid tumors, in particular, may benefit from treatment according to the methods and/or compositions described herein, as localized masses of target cells may be efficiently targeted by sonoporation, although hematologic malignancies are also contemplated within the scope of the disclosure. Some lymphomas, in particular, may present as solid masses may be effectively targeted by the methods and/or compositions described herein. According to certain aspects of the disclosure, the proliferative disorder will comprise a solid tumor including, but not limited to, adrenal, liver, kidney, bladder, breast, gastric, ovarian, cervical, uterine, esophageal, colorectal, prostate, pancreatic, lung (both small cell and non-small cell), thyroid, carcinomas, sarcomas, glioblastomas and various head and neck tumors.
The compositions and methods may be used to treat an existing tumor (e.g., primary tumor) in a subject by using sonoporation to target drug delivery to that tumor. Treatment may result in the improvement, reduction, or alleviation of one or more symptoms of cancer as is known in the art, including for example, tumor size, tumor volume, tumor growth, or metastasis. Such improvements may be quantified and may be, for instance, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, or 1,000% improved over baseline measurements as measured in a subject (e.g., prior to treatment) or a suitable reference population. The improvement may be statistically significant (e.g., p < 0.05). Other suitable measures of treatment may include, for example, measurement of markers of an innate or adaptive immunity response (e.g., proinflammatory markers, T-cells, etc.). Such markers may be measured, for example, in tissue biopsies or cell suspension prepared therefrom or in blood (e.g., serum) levels. Changes in marker levels from treatment may be at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, or 1,000% over baseline measurements as measured in a subject (e.g., prior to treatment) or a suitable reference population. Changes may be statistically significant (e.g., p < 0.05). According to some aspects of the disclosure, the treatment may be, at least in part, prophylactic. The treatment may, for example, comprise treatment of subjects who present with benign or precancerous tumors and/or prevent or
reduce the likelihood of worsening of a cancer (e.g., growth of a tumor or metastatic spread of a tumor) or the recurrence of a cancer. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver. The treatments described herein are also contemplated to encompass treatment of metastatic tumors.
By way of example, where the compositions and/or methods described herein are used for treatment of cancer, some specific therapeutic responses may include, but are not limited to, one or more of destroying neoplastic or cancerous cells, inducing apoptosis in neoplastic or cancerous cells, reducing the proliferation of neoplastic or cancerous cells, reducing metastasis of neoplastic cells found in cancers, tumor regression (i.e. shrinking the size (e.g., diameter or volume) of a tumor), enhanced immune memory against an existing cancer, and enhanced therapeutic efficacy of anti-cancer agents (e.g., immune checkpoint inhibitors), such as those described elsewhere herein (including those described with respect to combination therapies). Enhanced therapeutic efficacy of other treatments for cancer or comorbidities associated therewith may allow for decreased dosages of those treatments.
Combination Therapies
Treatment of subjects with a microbubble composition as described herein may be combined with other treatments for the same disease that the payload is being administered to treat, such as cancer, and/or comorbidities associated therewith. Anti-cancer therapies, such as treatment with an anticancer agent and radiation therapy are well known in the art. These therapies can be administered to a subject according to any effective protocol, though the treatments may be modified as needed to optimize the combination treatment along with the microbubble composition. For example, and without limitation, radiation therapy is performed by administering to the subject a suitable radiation dose of a suitable time at any suitable interval according to well- established protocols. Anticancer agents are administered according to typical protocols for the given drug. Non-limiting classes of drugs that may be useful in combination with the microbubble compositions described herein include: tyrosine kinase inhibitors, such as gefitinib (Iressa™) and imatinib mesylate (Gleevec™); monoclonal antibodies, such as rituximab (Rituxan™) and cetuximab (Erbitux™); angiogenesis inhibitors, such as endostatin; immune modulators, such as interleukin- 12 (IL-12) and interleukin-2 (IL-2); non-receptor tyrosine kinase inhibitors, such AG490 JAK2 inhibitor and PP2 src family kinase inhibitor or dasatinib; serine/threonine kinase
inhibitors, such as U0126 for MEK1/2, wortmanin for PI3K; famesyl or geranyl transferase inhibitors, such as FTI-277 and GGTI-298; G-protein-coupled receptor inhibitors, such as RC3095 for bombesin and An-238 for somatostatin; and indoleamine 2,3 -di oxygenase (IDO) inhibitors, such as indoximod and epacadostat.
Non-limiting examples of specific anticancer agents include: AG-490; aldesleukin; alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine; An-238; anastrozole; arsenic trioxide; asparaginase; BCG Live (Bacillus Calmette-Guerin); bevazizumab; bexarotene; bleomycin; busulfan; calusterone; capecitabine; capecitabine; carboplatin; carmustine; celecoxib; cetuximab; chlorambucil; cisplatin; cladribine; cyclophosphamide; cyclophosphamide; cytarabine; dactinomycin; darbepoetin alfa; dasatinib; daunorubicin; daunorubicin, daunomycin; denileukin diftitox; dexrazoxane; docetaxel; doxorubicin; dromostanolone propionate; Elliott's B Solution; endostatin; epirubicin; epoetin alfa; estramustine; etoposide phosphate; etoposide, VP- 16; exemestane; filgrastim; floxuridine; fludarabine; fluorouracil; FTI-2777; fulvestrant; gefitinib; gemcitabine; gemcitabine; gemtuzumab ozogamicin; GGTI-298; goserelin acetate; gossypol; hydroxyurea; ibritumomab; idarubicin; idarubicin; ifosfamide; imatinib mesylate; interferon alfa- 2a; interferon alfa-2b; IL-2; IL-12; irinotecan; letrozole; leucovorin; levamisole; lomustine; meclorethamine; nitrogen mustard; megestrol acetate; melphalan, L-PAM; mercaptopurine, 6-MP; mesna; methotrexate; methoxsalen; mitomycin C; mitotane; mitoxantrone; nandrolone phenpropionate; nofetumomab; oprelvekin; oxaliplatin; paclitaxel; pamidronate; pegademase; pegaspargase; pegfilgrastim; pentostatin; pentostatin; pipobroman; plicamycin; mithramycin; porfimer sodium; PP2; procarbazine; quinacrine; rasburicase; RC3095; rituximab; sargramostim; streptozocin; talc; tamoxifen; temozolomide; teniposide, VM-26; testolactone; thioguanine, 6-TG; thiotepa; topotecan; toremifene; tositumomab; trastuzumab; tretinoin, ATRA; U0126; uracil mustard; valrubicin; vinblastine; vincristine; vinorelbine; wortmanin; and zoledronate.
Useful approaches to activating the adaptive immune response system (e.g., activating therapeutic antitumor immunity) include the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. Tumors co opt certain immune-checkpoint pathways as a maj or mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. Because many of the immune checkpoints are
initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies were the first of this class of immunotherapeutics to receive FDA approval (ipilimumab). Inhibitors of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), have since been approved and demonstrated broad and diverse opportunities to enhance antitumor immunity with the potential to produce durable clinical responses.
PD-1, functioning as an immune checkpoint, plays an important role in down-regulating the immune system by preventing the activation of T cells, which in turn reduces autoimmunity and promotes self-tolerance. The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen-specific T cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells). Therapeutics that block PD-1 binding, the PD-1 inhibitors (e.g., anti-PD-1 antibodies, anti-PD-Ll antibodies), activate the immune system to attack tumors and are therefore used to treat some types of cancer. Approved checkpoint inhibitors for PD-1 and PD-L1 include nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, and cemiplimab. Additional inhibitory checkpoint molecules which may be targeted to provide immune checkpoint therapy (checkpoint blockade) include, but are not necessarily limited to, CD47, A2AR, B7-H3, B7-H4, BTLA, IDO, KIR, LAG3, NOX2, TIM-3, VISTA, and SIGLEC7.
According to certain aspects of the disclosure, the methods and/or compositions described herein may be administered in combination with immune checkpoint therapy, such as an immune checkpoint inhibitor (e.g., antibody), including any of the inhibitors described herein or any suitable inhibitor that targets an immune checkpoint molecule described herein. The methods and/or compositions herein, such as those that activate STING (e.g., delivery of CDNs such as cGAMP) may increase therapeutic efficacy of immune checkpoint therapy, as demonstrated in the examples.
EXAMPLES
Example 1. Spe-Dex MB Fabrication.
Spe-Dex MBs were prepared as described in PCT/US2021/054820 to Lux et al., filed October 13, 2021 and herein incorporated by reference in its entirety. Briefly, Potassium periodate
(6.25 mmol) was added to a solution of Dextran 40k (6.25 mmol of glucose monomers) in milliQ water (20 ml). The reaction was vigorously stirred in the dark for 7 h at room temperature and then spin filtered 2 x using spin filters (MWCO 10 kDa, AMICON®) at 4,000g· for 10 min at 4 °C with water washing. The resulting retentate was dialyzed for 24 h against water using a regenerated cellulose semi permeable membrane (MWCO 3.5-5 kDa) and then added to a solution of spermine (2.96 mmol) in borate buffer (19 ml, 0.1 M, pH 11) over 5 h via syringe pump. The resulting solution was gently stirred for 24 h at room temperature followed by the addition of NaBHi (9.48 mmol) under ice bath and stirring for 48 h at room temperature. An additional portion of NaBHi (9.48 mmol) was then added and stirring continued for 24 h under the same conditions. Crude product was dialyzed against water (MWCO 3.5-5 kDa) for 48 h followed by lyophilization for 48 h to yield spermine-modified dextran (SpeDex).
For thiolation, SpeDex (3.55 pmol ML·) was dissolved with phosphate-buffered saline (PBS) 1 x, 5 mmol/1 ethylenediaminetetraacetic acid (EDTA, 0.5 ml). To this a 1 mg/ml aqueous solution of 2-iminothiolane HC1 (35.45 pmol) was added dropwise with vigorous stirring. The resulting mixture was stirred for 1 h, dialyzed for 48 h (MWCO 3.5 kDa), and lyophilized for 48 h.
SpeDex conjugation onto MBs was verified using fluorescently labeled SpeDex. Fluorescent labeling of SpeDex polymers was done using amine reactive 5/6-carboxyfluorescein succinimidyl ester (MfS-fluorescein). Briefly, SpeDex polymer (5 mg) was dissolved in 1 ml of 1 x borate buffer (50 mmol/1, pH 8.5). MfS-fluorescein (5 mg, 10.562 pmol) was dissolved in DMF (0.5 ml) and added dropwise to SpeDex solution with vigorous stirring. The reaction was stirred for 1 h, dialyzed for 48 h (MWCO 3.5 kDa), and lyophilized for 48 h.
Microbubbles (MBs) were likewise formulated as previously reported. Briefly, lipid films containing a mixture of l,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-Distearoyl-sn- Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000] (DSPE-PEG2k), and l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[maleimide(polyethylene glycol)5000] (DSPE-PEG(5000)-mal) with a 90:5:5 molar ratio were prepared. These films were prepared by dissolving DSPC, DSPE-PEG(2000), and DSPE-PEG(5000)-mal in 100 pi of chloroform and slowly evaporating the mixture with a rotary evaporator (BUCHI ROTO VAPOR® R-100) until mostly dry. The resulting films were then dried overnight under vacuum and stored at -20 °C for later use. The lipid films were solvated in a mixture of PBS 1 /propylene glycol/glycerol
(80: 10: 10 v/v/v, 2 ml total) and sonicated at 70 °C until clear or for 15 min. Perfluorobutane (PFB) vapor was then introduced in the solution, and the resulting mixture was tip sonicated at 70% amplitude for 5 seconds before being cooled down in an ice bath. The resulting MB formulation was washed with PBS 1 x pH 6.5 plus 1 mmol 1-1 EDTA using centrifugation (300g·, 3 min) to yield PEGylated MBs with terminal maleimide functions (mal-MBs).
Thiolated SpeDex was then dissolved in the same PBS solution at 10 mg/ml and added to mal-MBs at a 1:20 maleimide: SpeDex molar ratio. The solution was rotated end-over-end for 4 h then washed (300g·, 3 min) and characterized using a Coulter Counter (BECKMAN COULTER® MULTISIZER™ 4) (data not shown). SpeDex conjugation onto MBs was confirmed via fluorescence microscopy and conjugation efficiency was quantitatively determined via flow cytometry to be approximately 100% of MBs being conjugated to SpeDex (data not shown).
Example 2. Anti-CDllb Thiolation and Conjugation onto Spe-Dex MBs.
To allow MBs to target APCs such as macrophages and dendritic cells (DCs), anti-CDl lb antibodies (aCDl lb) or isotype IgG (non-targeting control antibody) were thiolated and conjugated onto the surface of the MBs’ maleimide groups. Anti-CDl lb was first thiolated to allow for conjugation onto maleimide-bearing Spe-Dex MBs. Briefly, a 2 mg/mL solution of Traut's reagent (2-Iminothiolane) in PBS pH 8.0 with 5 mM EDTA was added at a 600:1 molar ratio to a solution of anti-CDl lb in PBS with 50 mM EDTA. The resulting solution was rotated for 2 hours before having its buffer exchanged with PBS pH 6.5 with 1 mM EDTA using a ZEBA™ Spin desalting column (MWCO 7 kDA) (THERMO SCIENTIFIC™). The extent of thiolation was determined using the Measure-IT™ assay (THERMO SCIENTIFIC™) and was reported to be 1.67 thiols per antibody. Spe-Dex MBs were then added to the solution of anti- CDl lb at a ratio of 0.345 equivalents of antibody per maleimide and rotated end-over-end for 15 hours at 4 °C to allow for conjugation. Afterwards, the solution was washed 3x with PBS at 300g for 3 min.
Flow cytometry and fluorescence microscopy were used to confirm conjugation of APC- conjugated aCDl lb onto SpeDex MBs. The thiol-maleimide coupling reactions were highly efficient, with flow cytometry showing more than 99% of MBs conjugated with both SpeDex and aCDl lb on their surface (data not shown). The conjugation resulted in SpeDex- and aCD l ib- conjugated MBs (cMBs) having a size distribution of 1-10 pm with a mean size of 2.6 pm, as
measured by Coulter Counter (Figure 1 A). The number of aCDl lb on SpeDex MBs was measured by running known quantities of antibody on a SDS PAGE gel and measuring the intensities of their bands. Using this standard curve resulted in approximately 291,774 aCDl lb molecules per cMB (data not shown).
To validate targeting specificity, both Spe-Dex MBs and cMBs were incubated with cGAMP at a nitrogen: phosphate (N:P) ratio of 1:34, fluorescently labeled with l,l’-dioctadecyl- 3, 3, 3’, 3’- tetramethylindodicarbocyanine (DiD), and then added to either 300,000 THP-1 macrophages (CDl lb+) or E0771 murine breast cancer cells (CDl lb-) plated on 12-well plates. The wells were washed three times, filled with Perfluorobutane (PFB)-saturated PBS, and imaged with brightfield and fluorescence microscopy. The Spe-Dex MBs exhibited no targeting to the cells. Both bright field and fluorescence microscopy revealed an abundance of cell-ncMB complexes after incubation of ncMBs with THP-1 macrophages but not with E0771 cells (data not shown). These results show that ncMBs have specific targeting to APCs.
Example 3. Formation of SpeDex-cGAMP nanocomplexes and loading of MBs.
Two strategies were used to load cGAMP and form ncMBs. The first involved adding cGAMP to cMBs, as described in Example 2. This approach was used throughout the remaining examples, unless specified otherwise. A fluorescent analog of cGAMP (FITC FITC-cGAMP) was used to verify loading onto SpeDex SpeDex-aCDl lb MBs via fluorescent microscopy, flow cytometry, and spectrophotometry. Flow cytometry indicated that this approach resulted in highly efficient binding with more than 98% of cMBs carrying cGAMP. As shown in Table 1 below, analyzing the infranatant of the loaded cMBs with a spectrophotometer after washing indicated an average load of 1.25 c 108 cGAMP molecules per ncMB. MBs without SpeDex did not have any measurable loading of cGAMP, suggesting that SpeDex is a necessary component for cGAMP loading. These results show that ncMBs have high conjugation efficiency and high cGAMP loading.
Table 1: Loading of cGAMP onto cMBs
Nanocomplex decorated microbubbles (ncMBs) can also be formulated by first preparing cGAMP SpeDex nanocomplexes and conjugating them to the MB surface in a one pot reaction with aCDl lb. Briefly, a solution of SpeDex polymer was added to a solution of cGAMP at equal volumes and at a N:P ratio of 1 : 10. The mixture was vortexed and then incubated for 30 min. The size distribution of the resulting cGAMP-SpeDex nanocomplexes was evaluated using nanoparticle tracking analysis (NT A) (PARTICLE METRIX™, ZETAVIEW®) and is shown in Figure IB. The average nanocomplex size was determined to be 168.8 ± 9.4 nm. Nanocomplexes were then conjugated onto maleimide-bearing MBs at a 1:20 maleimide: SpeDex molar ratio and rotated for 4 h followed by three washes with PBS to afford nanocomplex-conjugatd MBs (ncMBs). ncMBs were characterized using a Coulter Counter (BECKMAN COULTER® MULTISIZER™ 4) (data not shown). Flow cytometry data of MBs conjugated with FITC labeled SpeDex and DY547-c-diGMP nanocomplexes showed that approximately 98% of MBs were conjugated with SpeDex polymer and approximately 80% of MBs carried the DY547-c-diGMP payload (data not shown).
Example 4. Sonoporation of Mouse Bone Marrow-Derived Macrophages and THP-1 Macrophages using diGMP Loaded Spe-Dex-CDllb MBs. To show that ncMBs can efficiently deliver CDNs to the cytosol of APCs, ncMBs loaded with a fluorescently labeled CDN (DY547-c-diGMP) were incubated with macrophages and then sonoporated.
Six days before treatment, human THP-1 monocytes were spun down and resuspended in RPMI, 20% FBS, 1% penicillin/streptomycin (P/S). Phorbol 12-myristate 13-acetate (PMA) was added to obtain a final concentration of 200 nM to differentiate the monocytes into macrophages. 1 mL per well of the cell solution was plated in a 12 well plate (400,000 cells/well) and left to differentiate for 3 days. Afterwards, cells were washed once with PBS then replenished with fresh RPMI.
Mouse bone marrow-derived macrophages (BMDMs) were isolated from the hind leg femur bone marrow of C57BL/6J mice and were cultured or activated with macrophage colony- stimulating factor (M-CSF, 50 ng ml-1) according to standardized procedures. The purity of the induced cells was assessed by flow cytometry for CD45+CD1 lb+ cells.
One day before treatment, cells were plated at 400,000 cells/well in a 12 well plate. On the day of treatment, Spe-Dex-CDl lb MBs (5 MBs/cell) were rotated with 10 nmol cGAMP for 15 min to allow for binding to MBs, yielding ncMBs. Cells were washed once, media was aspirated off, and the entire suspension of cGAMP -loaded MBs was added to the wells. Plates were flipped upside down and left to incubate for 10 min at 37 °C. Cells were diluted to 2.5 mL with PFB- saturated RPMI, placed on top of a water bath set to 37 °C, then sonoporated at 1 MHz, with 1 W/cm2 power density, 20% duty cycle (DC) for 60 seconds (SONITRON® GTS, 15 mm diameter). Fluorescence microscopy images were taken at different time points (0, 3, 6, 12, 24, and 48 h).
Sonoporation of BMDMs using DY547-diGMP loaded Spe-Dex MBs showed high uptake of diGMP in virtually all of the cells, whereas the diGMP only sample showed weak uptake and high background signal. Mean fluorescence intensity (MFI) of the BMDMs revealed that MUSIC treatment increased the uptake of CDNs by more than two folds relative to uptake of free CDN, as shown in Figure 2. THP-1 macrophages showed no STING activation, possibly because the fluorescent diGMP is too large to fit into the active pocket of STING.
To assess sonoporation toxicity, cell viabilities of E0771 and THP-1 cells were measured 48 h after MUSIC treatment at 1 W/cm2. Briefly, Propidium Iodide READY FLOW™ Reagent (THERMOFISHER®) was added to MUSIC -treated cells after 48 hours of incubation. Flow cytometry assays were performed for distinguishing dead cells from live cells. Fluorescence associated with cell viability was measured, which showed no loss of viability in E0771 cells and approximately a 25% viability decrease in THP-1 cells, as shown in Figure 3. These results show that ncMBs have improved cytosolic delivery of CDNs into macrophages and acceptable toxicity.
Example 5. Treatment of Macrophages using cGAMP Loaded Spe-Dex-CDllb MBs (MUSIC).
Mouse BMDMs and human THP-1 cells were cultured as described above. Primary human peripheral blood monocyte derived macrophages underwent induced differentiation using CD1 lb+ cells sorted from PBMC (STEMCELL TECHNOLOGIES®) by culturing cells with macrophage colony-stimulating factor (M-CSF, 50 ng/ml) for 7 days.
All macrophages were plated and treated as described in Example 4. cGAMP only (diluted in sterile PBS), cMBs + ultrasound (US) only, PBS, STING knockout cells (BMDM), and IgG- ncMBs+US (peripheral blood monocyte derived macrophages) were used as controls. Cells were then collected at various time points post-treatment for qRT-PCR (Figures 4A-4H), ELISA (Figures 5 A-5H), western blot (Figures 6A-6D; Figures 7A-7D), and immunostaining experiments (Figures 8A-8C; Figures 9A-9C).
Although no STING or IRF-3 phosphorylation was observed in BMDMs treated with cGAMP alone, a small degree of activation of the immune sensors was noted in THP-1 cells (Figure 6A), likely due to limited uptake of cGAMP by previously identified transporters on the plasma membrane of human cells. To confirm that IRF3 activation and downstream inflammatory responses are mediated by STING, BMDM from STING-/- mice were treated with MUSIC. As shown in Figure 6C, no type I IFN responses were observed in STING-/- mice, therefore confirming that the immune response generated by MUSIC and the activation of downstream effectors are STING-dependent.
To demonstrate that the activation of STING leads to the mobilization of downstream signal cascade and transcriptional activities, the nuclear translocation of phosphorylated IRF3 (pIRF3), which acts as a transcription factor for proinflammatory genes, was examined at 6 h after treatment, as shown in Figure 8A. Quantification of nuclear fluorescent positive cells was done by randomly measuring 500 cells in each 60 group (n=3), as shown in Figure 8B for BMDMs and Figure 8C for THP-1 cells. While some nuclear translocation of pIRF3 was observed only in in THP-1 cells treated with cGAMP alone, significantly higher nuclear translocation was observed in MUSIC -treated THP-1 cells compared to all controls.
NF-KB, another major downstream component of the STING pathway, was also activated upon MUSIC treatment, as shown by the phosphorylation of IKKa/b, IkBa, and p65 in THP-1
cells and mouse BMDMs, but was not observed in BMDMs from STING/ mice, as shown in Figures 7A-7C. The activation of NF-KB signaling is supported by the increased translocation of p65 into the nucleus in both BMDMs and THP-1 cells after MUSIC treatment, as shown in Figure 9 A, where it acts as a transcription factor for proinflammatory cytokine genes. Quantification of nuclear fluorescent positive cells was done by randomly measuring 500 cells in each 60 group (n=3), as shown in Figure 9B for BMDMs and Figure 9C for THP-1 cells. Indeed, the expression of IFN genes was higher in MUSIC-treated THP-1 cells and mouse BMDMs compared to cells treated with cGAMP alone (Figures 4A-4D), which correlated with a greater production of the proteins (Figures 5A-5D). In contrast, APCs from STING-/- mice showed no IFN mRNA expression (Figures 4E-4F) or protein expression (Figures 5E-5F), supporting that the effects of MUSIC treatment rely on STING signaling.
Treatment using MUSIC significantly increased the relative interferon mRNA expression in both THP-1 and BMDMs when compared to cGAMP alone at all time points, as shown by qRT- PCR results. The increased interferon mRNA expression correlated with a higher concentration of interferon proteins in the supernatant of the cells when compared to cGAMP alone as shown by ELISA. Western blot showed phosphorylation of STING and the downstream effectors IRF3 and NF-kB in MUSIC-treated samples, suggesting that the interferon production shown from qRT- PCR and ELISA is a direct result of STING activation. cGAMP alone caused slight phosphorylation of STING and IRF3 but not as much as with MUSIC. For NF-kB, the phosphorylation caused by cGAMP alone in THP-1 macrophages is comparable to that caused by MUSIC, probably because THP-1 macrophages have a cGAMP receptor that can cause NF-kB phosphorylation. BMDMs do not have this receptor, which is why cGAMP alone showed no phosphorylation of any of the proteins. After phosphorylation, IRF3 and NF-kB translocate to the nucleus, which was visualized using immunostaining. This translocation was not visible in cGAMP only samples. MB only samples showed no effect in any of the experiments when compared to negative controls. Furthermore, repeating the experiments using STING cells showed loss of efficacy. STING cells showed a complete reduction in mRNA expression, interferon expression, phosphorylation, and translocation, giving further proof that all these effects were due to STING pathway activation. Experiments in primary human peripheral blood monocyte derived macrophages produced similar results, thus confirming the specificity and efficacy of MUSIC in activating STING signaling in human primary APCs.
Example 6. Phagocytosis of E0771 Breast Cancer Cells by MUSIC-treated Mouse Bone Marrow-Derived Macrophages (BMDMs).
In addition to increased cytokine production, MUSIC was also able to enhance the phagocytosis ability of treated macrophage, which is consistent with previous findings that STING activation in macrophages can improve their phagocytosis functions. Briefly, BMDMs were cultured for 6 h after treatment as described in Example 5. E0771 cells were pre-stained with Far Red for 2 h, and then co-cultured with the BMDMs at a ratio of 1 : 1. Phagocytosis was measured by flow cytometry after 4 h co-culture. Quantification of phagocytized E0771 cells by BMDMs from three biologically independent experiments is shown in Figure 10.
Example 7. OT-I and II Cell Proliferation using BMDMs and tumor-associated macrophages (TAMs) Treated with MUSIC.
Macrophages are professional APCs that can prime T cells. This process can be amplified through activation of STING, as macrophages that have had their STING pathway activated are better able to present antigens to prime T-cells, causing their proliferation and resulting in potent antitumor immunity. This was confirmed using T-cells engineered to recognize OVA antigen (OT cells). BMDMs were treated with MUSIC as described in Example 5 and then incubated with either an MHC-I or MHC-II binding OVA peptide (amino acids 257-264 or 323-339, respectively) for 6 hours. Afterwards, macrophages were washed then incubated for 72 hours with either OT-I cells if they received the MHC-I binding peptide or OT-II cells if they received the MHC-II binding peptide. The proliferation of OT cells was then quantified using flow cytometry. As shown in Figure 11A-11B, proliferation of both CD4+ and CD8+ T cells was increased when co-cultured with MUSIC-treated BMDMs relative to other treatment groups. This enhanced T-cell priming effect by MUSIC was absent in STING-/- BMDMs, suggesting that it is a STING-dependent response. OT-I cells (which are CD8+) had approximately a 2.5x increase in proliferation when the BMDMs were treated with MUSIC compared to negative controls. OT-II cells (which are CD4+) had approximately a 3.5x increase when compared to negative controls.
In addition to BMDMs, MUSIC treatment of tumor-associated macrophages (TAMs) from E0771 tumors implanted in wild-type mice also potentiated T-cell priming (Figure 12A) and
induced IFN protein expression (Figure 12B-12C) but had no effect on TAMs from STING-/- mice, thus supporting the potential of MUSIC to induce anti -tumor responses in vivo.
Example 8. Treatment of Mouse Bone Marrow-Derived Dendritic Cells (BMDCs) using MUSIC.
Since dendritic cells (DCs) are another major type of professional APC, bone marrow- derived dendritic cells (BMDCs) were also treated with MUSIC. Mouse BMDCs were isolated from the hind leg femur bone marrow of C57BL/6J mice and were cultured or activated with granulocyte macrophage colony-stimulating factor (GM-CSF, 20 ng/ml), according to standardized procedures. The purity of the induced cells was assessed by flow cytometry for CD45+CDl lc+ cells. Similar robust STING and down-stream IRF3/NF-KB activation (Figures 13A-13D), increased type I IFN responses (Figures 14A-14D), and enhanced priming of antigen- specific T cells (Figures 15A-15B) were observed. Together, these findings demonstrated that MUSIC can effectively enhance STING activation in APCs, leading to improved priming of T cell responses.
Example 9. In Vivo CDN Delivery.
An orthotopic syngeneic murine breast cancer model was used to test the effectiveness of the MUSIC platform in activating the STING pathway in vivo in syngeneic hosts. Briefly, 1 million E0771 breast cancer cells in 50 pL PBS were injected subcutaneously into the lower mammary fat pad of 6-week old female C57BL/6J mice. The delivery efficiency of CDNs in vivo was first assessed using DY547-c-diGMP loaded ncMBs conjugated with either IgG (non-targeting) or aCDl lb (targeting). The mice were injected intratumorally with 20 pL of solution infused at 1 pL/second using a syringe pump for a dose of 2.8 x 107 MBs.
Two hours after ultrasound treatment (hereinafter ncMBs IgG or MUSIC) single cell suspensions from tumor tissues were isolated for flow cytometry analysis. CDl lb+/ cells with DY547-c-diGMP positive signals were measured and compared. Quantification of the cells as gated in each group (n=3) is shown in Figures 16A-16B, evaluated using an unpaired Student t- test. The delivery of DY547-c-diGMP in tumor-associated CDl lb+ cells was more than 7-fold higher when using ncMBs as compared to non-targeted IgG-ncMBs. Importantly, non-specific
uptake of CDNs in CD1 lb- cells was negligible and 4-fold lower with ncMBs as compared to the IgG-ncMBs.
Example 10. In Vivo STING Activation.
Orthotopic mammary fat pad tumors were established as in Example 9. The tumors were grown for 13 days before mice were randomized into treatment group and controls groups based on tumor size: PBS only, cGAMP only, ncMBs only, cMBs+US only, IgG-ncMBs+US, and MUSIC . The mice had an average tumor volume of 100 mm3 and any differences between the means were determined to not be statistically significant using ANOVA. The mice were injected intratumorally with 20 pL of solution infused at 1 pL/second using a syringe pump. A dose of 100 pg of cGAMP was used for all cGAMP groups and a dose of 2.7 x 107 MBs was used for all MB groups. The mice were treated every other day for a total of three treatments (days 13, 15, and 17). US, where part of the treatment group, was applied by using acoustic coupling gel and a 1-MHz plane wave transducer operating at 4 W/cm2 for 60 seconds and a 50% duty cycle given to opposite sides of the tumor for a total treatment time of 120 seconds. At 18 days post tumor inoculation treated mice were sacrificed.
MUSIC enabled imaged-guided delivery of CDNs in vivo is shown in Figure 17. Immunohistochemical staining of tumor sections three days after treatment (not shown) confirmed that MUSIC prevented Ki67 expression, indicating inhibited tumor cell proliferation, but had no direct effects on other tissues. Immunostaining by confocal microscopy was used to visualize recruited CD1 lb+ cells and pSTING+ cells in tumor paraffin section slides. Fluorescence intensity was measured and compared by IMAGEJ™ software from three randomly selected images, as shown in Figures 18A-18B. Single cell suspensions from tumor tissues were also collected for flow cytometry analysis, with CD1 lb, CD68, and IL-10 165 being used to gate TAMs. CD1 lb+ cells and TAMs with pSTING positive signals were measured and compared for each group (n=3), as shown in Figures 19A-19B. Evaluation of the tumor immune microenvironment revealed increased phosphorylation of STING in MUSIC-treated tumor tissues, most preferentially in CDl lb+ cells. The increased phosphorylation of STING in CDl lb+ cells correlated with increased recruitment of CD8+ and CD4+ T cells into the tumor after MUSIC treatment as quantified by flow cytometry, as shown in Figures 20A-20B. Activated CD8+ T cells and CD4+
T cells were also detected and quantified by immunostaining in tumor paraffin section slides, as shown in Figures 20C-20D.
To assess the effect of MUSIC-mediated STING activation on tumor growth, mice were treated with MUSIC, cGAMP, cMBs (+US), or non-targeted IgG-ncMBs (+US) and monitored over time. Tumor sizes were measured every two days using digital calipers, and tumor volume was calculated according to an ellipsoid formula as 0.5xlength><width2. Mice were sacrificed if any tumor ulceration was observed or if tumors reached 2000 mm3 in volume. The final tumor volume comparison between the MUSIC and control groups was done when the first mice from a control group was sacrificed. Tumor volumes and survival curves are shown in Figures 21 A-21D. MUSIC given every other day for three treatments led to the most significant tumor growth inhibition and survival benefit. Statistical analysis was done using an unpaired t-test for tumor sizes and Log-rank test for survival curves. A statistical difference was observed in both final tumor volumes and survival between MUSIC treated mice and control mice. Furthermore, 6 out of 10 MUSIC treated mice had complete tumor remission whereas only 2 out of 10 cGAMP treated mice showed a complete response. As expected, no antitumor effect were observed in STING-/- tumor-bearing mice treated with MUSIC, as seen in Figures 21E-21F. Furthermore, the effects of ultrasound (US) and CDl lb targeting was confirmed by comparing MUSIC with IgG-ncMBs (+US) and ncMBs groups, which showed lower antitumor effects, as seen in Figures 21G-21I.
Example 11. Assessment of antitumor immune memory.
Tumor-free mice from Example 10 were reimplanted with the same E0771 breast cancer cells on the contralateral fat pad of the original tumor for a tumor rechallenging experiment. Non- treated naive mice were also implanted with tumors as a control. MUSIC treated mice showed no tumor growth 19 days after tumor implantation, suggesting that these mice have immune memory against E0771 cells, whereas the naive mice showed obvious tumor growth (Figure 22). To assess the role of host cell STING activation in mediating MUSIC antitumor responses, STING mice were treated as described above. No statistically significant differences were observed between the MUSIC group and control group for either tumor size (Figure 23 A) or mouse survival (Figure 23B), suggesting that the observed antitumor efficacy is dependent upon the host cells’ STING pathway.
To further characterize MUSIC-mediated antitumor memory, treated tumor tissue samples were analyzed by flow cytometry, as shown in Figures 24A-24C, in which a moderate increase in the populations of CD44highCD62Llow effector memory and CD44highCD62Lhigh central memory cells was observed upon MUSIC treatment. In addition, T cells collected from spleens of MUSIC-treated tumor-bearing mice and rechallenged with the E0771 tumor cells in vitro , demonstrated a robust IFN-g response, as seen in Figure 25, thus confirming that the local MUSIC treatment generated systemic immune memory in vivo. To further establish the T cell’s role in mediating antitumor response of MUSIC, CD8+ T cells from tumor-bearing mice were depleted using an anti-CD8 antibody injected 24 h prior to MUSIC treatment and every 72 h until the end of the experiment. The elimination of CD8+ T cells in these animals abrogated the antitumor effect of MUSIC, resulting in half the mice dying at day 21 (Figures 26A-26C). Given that activation of STING in APCs leads to type I IFN production, and CD8+ T cells secrete IFN-g to produce antitumor effects, type I IFN and IFN-g levels were measured in tumors (Figures 27A-27C) and serum (Figures 27D-27F), and were found to be elevated in both upon MUSIC treatment. Since IFN-g is known to induce the expression of immune checkpoints such as PD-L1, the expression of PD-1 and PD-L1 was measured in T cells and tumor cells, respectively, by comparing the fluorescence intensity from three randomly selected immunostained images (Figures 28A-28B). Over 95% of intratumoral CD8+ T cells in the MUSIC-treated group exhibited elevated expression of PD-1, a marker of cytotoxic T-cell maturation and exhaustion. Tumor tissue PD-L1 expression also correlated positively with IFN-g level (Figure 29A-29B). Together, these results demonstrate that MUSIC treatment activates both innate and adaptive immune responses via STING-mediated T cell priming by APCs and provide a rationale for the use of MUSIC in combination with immune checkpoint blockade to generate improved antitumor responses.
Example 12. Evaluation of systemic antitumor immune responses against metastatic breast cancer.
To test whether MUSIC treatment can generate antitumor responses against metastatic breast cancer, metastatic 4T1 tumors were established through orthotopic implantations in the mammary fat pad of Balb/cJ mice using luciferase-expressing 4T1 cells. At 12 days post tumor implantation, mice were intraperitoneally injected with 1.5 mg D-luciferin (SYD LABS™) per 10 g body weight. At 10 min after injection, the presence and metastases of the tumors were
monitored by bioluminescence imaging (BLI) using an In Vivo Imaging System (PerkinElmer IVIS® Lumina III). Primary tumors were treated with PBS, cGAMP only, cGAMP + US, cMBs + US, or MUSIC (cMBs + cGAMP + US). The same cGAMP and MB dose was given intratumorally as described in Example 10 and the same US parameters were used. Treatments were given every other day for a total of 3 doses on days 12, 14, and 16. Primary tumor growth and systemic metastatic burden were monitored using digital calipers and bioluminescence imaging respectively. Animals were monitored for 30 days after tumor inoculation, at which point they were sacrificed and their organs collected. Bioluminescence showed that locally treating primary lesion of metastatic 4T1 breast cancer with MUSIC significantly decreased the systemic disease burden including metastases in the lungs when compared to cGAMP alone (Figures 30A- 30C).
In both syngeneic breast cancer models, MUSIC treatment showed dramatic inhibition of tumor growth, increased mice survival, and a greater percentage of tumor-free mice compared to cGAMP alone. MUSIC treatment also resulted in an 11-fold decrease in metastatic burden when compared to cGAMP alone. These results suggest that MUSIC treatment effectively activates STING in vivo , creating a systemic anti-tumor immune response.
Example 13. Sensitizing Tumors to PD-1 Blockade with MUSIC.
To test whether MUSIC could further sensitize poorly immunogenic tumors to PD-1 blockade, particularly those that are highly aggressive and widely metastatic, spontaneously metastatic murine triple negative 4T1 breast tumor-bearing mice were treated with MUSIC, as in Example 12, in combination with an anti-PD-1 antibody (aPD-1). aPD-1 was administered at a dose of 200 pg/mouse on days 12, 14, 16, 18, 20, and 22. Local MUSIC treatment in combination with systemic aPD-1 administration not only exhibited enhanced primary tumor control, but also significantly decreased systemic disease progression, as compared to either therapy alone, as seen in Figure 31A-31D. This improved antitumor response in the combination treatment arm directly translated into a superior survival benefit with a 76% increase in median survival as compared to free cGAMP or aPD-1 alone (Figure 3 IE). Macroscopic organ imaging and examination revealed significantly reduced lung disease burden and approximately 60% decrease in pulmonary metastatic nodules (Figures 31F-31G). To assess the effect of the combination treatment on local and systemic immunity, type I IFN levels were measured in both tumor (Figures 31H-31I) and
serum (Figures 31 J-31L) and found to be higher in the combination treatment group compared to the control groups. Both CD4+ and CD8+ T cell infiltrations also increased in the combination treatment group, as seen in Figures 31M-31P. Furthermore, the combination treatment showed enhanced phosphorylation of STING (Figure 31Q) and production of IFN-g (Figure 31R) with a low level of Ki67 expression (data not shown). To investigate the effect of the combination treatment on memory T cell responses, tumor infiltrating lymphocytes were collected from different treatment groups. The combination treatment was found to have increased the proportion of CD44highCD62Llow effector memory and CD44highCD62Lhigh central memory cells (Figures 31 S-31U). Together, these results demonstrate that MUSIC sensitized poorly immunogenic tumors to PD-1 blockade, and their combination enhanced local and systemic immune activations to produce improved antitumor responses.
Example 14. Conjugating NBs with cationic polymers allowed similar cGAMP loading efficiency as MBs.
In order to bypass the need for intratumoral injection when using 1-3 pm MBs, nanobubbles (NBs) may be used to allow systemic injection and ultrasound-guided therapy. To isolate smaller bubbles and remove any non gas-filled nanoparticles (e.g., liposomes), phospholipids were emulsified with PFB, as described with MBs, but the centrifugation steps post formulation were modified. Specifically, the suspension of emulsified phospholipids was centrifuged at 50g- for 5 min, and the top layer containing large MBs was discarded while the infranatant containing liposomes and NBs was kept and characterized by nanoparticle tracking analysis (NT A) (PARTICLE METRIX™, ZETAVIEW®). SpeDex was conjugated onto NBs and the mixture was then rotated for 2 h, after which thiolated anti-CD 1 lb antibodies were added, as described elsewhere herein. The resulting suspension was centrifuged at 700g- for 5 min and the top layer containing SpeDex-aCDl lb NBs was kept while the infranatant was recycled to increase NB yield. The infranatant was re-amalgamated into NBs as described above followed by a final centrifugation at 700g- for 5 min to remove liposomes, antibodies, free lipids and polymers. Both NB suspensions were characterized by NTA and combined.
This modified procedure yielded NBs having a mean size of 290 nm and a count of 2.6 x 1011 NBs/mL. The size distribution is shown in Figure 32. Conjugation of SpeDex and aCDl lb onto NBs was confirmed using flow cytometry by gating the forward scatter (FSC) and side scatter
(SSC) signals for the signature shape of bubbles (approximately 84.5% of particles) and by using fluorescent FITC-SpeDex and AF647-aCDl lb (data not shown). Flow cytometry showed 100% of NBs conjugated with SpeDex and 91% of NBs conjugated with aCDl lb. ncNBs were obtained by loading cGAMP as described elsewhere herein. Both FITC-cGAMP and 2’-0-(6-[DY547]- aminohexylcarbamoyl)-cyclic diguanosine monophosphate (DY547-diGMP), a fluorescent analog of cGAMP, were used to confirm stability and loading efficiency of the dinucleotide by flow cytometry and fluorescence spectrophotometry (data not shown). cGAMP loading was highly efficient with 7.1 x 106 cGAMP molecules loaded per NB, corresponding to a 78% loading efficiency or 0.027 pg of cGAMP/pm2. The loading efficiency of cGAMP in ncNBs was very close to the loading value obtained with ncMBs (0.033 pg/pm2).
Example 15. Sonoporation of macrophages with targeted ncNBs allows the cytosolic delivery of cGAMP.
To confirm cytosolic delivery in APCs, ncNBs were incubated with human THP-1 macrophages at a ratio of 500 ncNBs/cell for 10 min, followed by a washing step to remove any unbound ncNBs. Sonoporation was performed using a plane wave single element transducer transmitting at 1 MHz (SONITRON® GTS, 15 mm diameter) at a power of 1 W/cm2 with 20% duty cycle for 60 seconds. Successful cytosolic delivery was confirmed by fluorescence microscopy when compared to incubation with Dy547-diGMP alone, as shown in Figure 33A). STING activation was confirmed using THP1-BLUE™ NF-KB cells (INVIVOGEN®) that have been modified with a NF-KB-inducible secreted embryonic alkaline phosphatase (SEAP) reporter that is measured with a QUANTI-BLUE™ assay following sonoporation. No difference was observed between STING activation by ncNBs or ncMBs relative to a control of non-treated cells, as shown in Figure 33B.
Example 16. Systemically administered ncNBs accumulate in the tumor and can be imaged by US.
To confirm that the ncNBs are an acoustically responsive material that can reach the tumor micro-environment and activate STING in APCs under US guidance, a clinical US scanner was used to image ncNBs following IV injection into the orthotopic syngeneic murine breast cancer model produced from implantation of E0771 breast cancer cells, described elsewhere herein. At
7 days after inoculation, mice were anesthetized with isoflurane and a catheter tubing was placed in the lateral tail vein for injection of ncMBs. A 50 pL suspension containing 5 xlO9 ncNBs was injected followed by a 50 pL flush of saline. Mice breast tumors were imaged before, during and after ncNBs IV injection using a clinical US scanner (SIEMENS® ACUSON® Sequoia with a 18H6 transducer), as shown in Figures 34A-34C. Signal in the tumor increased dramatically as early as 90 s after injection, as seen in Figure 34B, confirming accumulation of ncNBs in the tumor). Upon increase of the mechanical index from 0.04 to 0.68, all signal in the tumor disappeared, as seen in Figure 34C, which demonstrates that a clinical scanner could be used to sonoporate APCs targeted with ncNBs.
Example 17. Loading of SpeDex MBs with mRNA.
To confirm that SpeDex microbubbles (MBs) can be loaded with nucleic acids in addition to CDNs, 9 million MBs were added to a solution of mRNA in PBS and mixed for 15 min. Afterwards, the solution was diluted with TRITRACK™ 6x loading buffer (90% glycerol) to obtain a 15% glycerol concentration. The entire volume was loaded onto a 1% agarose gel and ran at 80 V for 40 minutes. The gel is shown in Figure 35 (Lane 1 = 200 ng mRNA, Lane 2 = 100 ng mRNA, Lane 3 = 50 ng mRNA, Lane 4 = 25 ng mRNA, Lane 5 = 200 ng mRNA complexed to SpeDex MBs). As evident by the missing band, the 9 million SpeDex MBs were able to completely bind 200 ng mRNA. This equates to a loading of at least 1.57 x 103 pg/pm2 of mRNA of SpeDex
MB.
All data presented in the disclosed examples are shown as mean ± standard deviation (s.d.) or mean ±standard error of mean (s.e.m.) from at least triplicate conditions unless otherwise indicated. Each experiment was repeated independently at least three times unless otherwise indicated. Statistical analyses included unpaired Student t-test and one-way ANOVA with Tukey's or Dunnett’s multiple comparisons test, as appropriate. Survival was determined for mice in every group by the Kaplan-Meier method and compared by the log-rank (Mantel-Cox) test. The P values of less than 0.05 were considered to indicate statistical significance. No animals were excluded from the analyses.
All documents cited herein, including patents, patent applications, and publications, are herein incorporated by reference in their entirety just as if each specific mention of the document had explicitly stated the document to be incorporated by reference in its entirety. The relevance of the material incorporated by reference to the present disclosure is to be understood from context, including the specific context in which the incorporated document was mentioned.
It is understood that the disclosure herein contemplates any possible combination of the various aspects described herein even if not explicitly exemplified, unless indicated otherwise, explicitly or by context (e.g., where various aspects would be understood to be physically incompatible). The disclosure also contemplates combinations of the various aspects described herein with relevant features that are well known, routine, or conventional to those of ordinary skill in the art.
The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element, e.g., a plurality of elements.
The term “including” is used herein to mean, and is used interchangeably with, the phrase “including but not limited to.” The term “including” does not necessarily imply that additional elements beyond those recited must be present.
As used herein, “about” or “approximately” will be understood by persons of ordinary skill and will vary to some extent depending on the context in which it is used. When referring to a number or a numerical range, the terms generally mean that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and, thus, the number or numerical range may vary from, for example, between 1% and 20% of the stated number or numerical range. In some aspects, “about” indicates a value within 20% of the stated value. In more preferred aspects, “about” indicates a value within 10% of the stated value. In even more preferred aspects, “about” indicates a value within 1% of the stated value. The variation encompassed by about may be above or below the recited number or range, unless indicated otherwise, explicitly or by context.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth as used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless otherwise indicated, the numerical properties set forth in the following specification and claims
are approximations that may vary depending on the desired properties sought to be obtained in aspects of the present invention. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical values; however, inherently contain certain errors necessarily resulting from error found in their respective measurements.
It should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this disclosure.
As used herein, the term “at least” or “no less than” prior to a value or series of values is understood to include the value adjacent to the term “at least” or “no less than” and all subsequent logical values or integers that could logically be included, as understood from context. When “at least” or “no less than” is present before a series of values or a range of values, it is understood that “at least” or “no less than” can modify each of the values in the series or range as just described. The term “down to” will be understood to mean the same as “at least” or “no less than” and will also include the value adjacent to the term “down to” unless indicated otherwise, explicitly or by context.
As used herein, “no more than” or “no greater than” are understood to include the value adjacent to the phrase (unless indicated otherwise explicitly or by context) and all lower values or integers that could logically be included, as understood from context (down to and including zero if negative values are not possible, down to but not including zero if the values must be positive, or down to and including 1 if the value must be a positive integer). When “no more than” or “no greater” is present before a series of values or a range of values, it is understood that “no more than” or “no greater than” can modify each of the values in the series or range as just described. The term “up to” will be understood to mean the same as “no more than” or “no greater than” and will also include the value adjacent to the term “up to” unless indicated otherwise, explicitly or by context.
Where a range of values is provided, it is understood that all intervening values are encompassed by the disclosure as well as the upper and lower limits of the range. For example, recitation of a range would be inferred to disclose each intervening value (e.g., to the tenth of the unit of the lower limit unless the context clearly dictates otherwise) between the upper and lower
limit of that range and any other stated or intervening value in that stated range. Ranges excluding either or both of the upper and lower limits are also contemplated by the disclosure of a range.
Claims
1. A method of targeted in vitro or in vivo drug delivery using sonoporation, the method comprising (i) administering to one or more target cells a composition comprising microbubbles loaded with a payload and (ii) administering an ultrasound stimulus to the one or more target cells, wherein the ultrasound stimulus is effective to sonoporate the one or more target cells.
2. The method of claim 1, wherein the payload comprises an agonist for activating the Stimulator of Interferon Genes (STING) signaling pathway within the one or more target cells, optionally wherein the agonist is a cyclic dinucleotide.
3. The method of claim 1, wherein the payload comprises a cyclic dinucleotide for inducing or enhancing Type 1 Interferon production within one or more cells.
4. The method of any one of claims 1-3, wherein the method is an in vivo method comprising administering the microbubble composition and the ultrasound stimulus to a subject.
5. The method of any one of the preceding claims, wherein the one or more target cells comprise cancer cells.
6. The method of any one of the preceding claims, wherein the one or more target cells comprise immune cells.
7. The method of claim 6, wherein the immune cells comprise professional antigen-presenting cells (APCs).
8. The method of claim 7, wherein the APCs comprise macrophages
9. The method of claim 7 or 8, wherein the APCs comprise dendritic cells.
10. The method of any one of the preceding claims, wherein the microbubbles comprise targeting molecules on the external surfaces of the microbubbles, the targeting molecules being effective to bind the one or more target cells.
11. The method of claim 10, wherein the targeting molecules comprise antibodies.
12. The method of claim 10 or 11, wherein the targeting molecules bind CD1 lb.
13. The method of any one of the preceding claims, wherein the ultrasound stimulus is administered at about 1-2 W/cm2, optionally with 50% duty cycle.
14. The method of any one of the preceding claims, wherein the ultrasound stimulus is administered for between about at least about 30-60 seconds.
15. The method of any one of the preceding claims, wherein the one or more target cells are exposed to the microbubbles for at least about 10 minutes prior to administering the ultrasound stimulus.
16. The method of any one of the preceding claims, further comprising using ultrasound to visualize the microbubbles prior to applying the ultrasound stimulus effective to sonoporate the cell membrane, wherein the intensity of the ultrasound used to visualize the microbubbles is less than the intensity of the ultrasound stimulus.
17. The method of any one of the preceding claims, wherein the microbubbles are decorated with spermine, the payload being non-covalently bound to the spermine.
18. The method of any one of the preceding claims, wherein the microbubbles are decorated with spermine-dextran conjugates, the payload being non-covalently bound to the spermine within the spermine-dextran conjugates.
19. The method of any one of the preceding claims, wherein the microbubbles comprise gas cores comprising a perfluorocarbon, optionally wherein the perfluorocarbon is decafluorobutane.
20. The method of any one of the preceding claims, wherein the microbubbles comprise shells comprising phospholipids, optionally wherein the phospholipids comprise one or both of 1,2- Distearoyl-sn-Glycero-3-Phosphocholine (DSPC) and l,2-Distearoyl-sn-Glycero-3- Phosphoethanolamine (DSPE) lipids.
21. The method of any one of the preceding claims, wherein the microbubbles comprise surfactant shells comprising PEGylated molecules.
22. The method of any one of the preceding claims, wherein the average microbubble size of the microbubble composition is between about 1 pm and about 10 pm.
23. The method of claim 22, wherein the average microbubble size of the microbubble composition is between about 1 pm and about 5 pm
24. The method of claim 23, wherein the average microbubble size of the microbubble composition is about 3 pm.
25. The method of any one of claims 1-22, wherein the microbubbles are primarily nanobubbles.
26. The method of claim 25, wherein the microbubbles are entirely nanobubbles.
27. The method of claim 25 or 26, wherein the average microbubble size of the microbubble composition is between about 100 nm and 700 nm.
28. The method of claim 27, wherein the average microbubble size of the microbubble composition is between about 200 nm and 600 nm.
29. The method of claim 28, wherein the average microbubble size of the microbubble composition is between about 300 nm and 500 nm.
30. The method of any one of the preceding claims, wherein the microbubble composition comprises microbubbles with biodegradable linkers operably positioned between an exterior surface of a shell of the microbubble and the payload, optionally wherein the biodegradable linker is joining a spermine to a dextran or a spermine to another spermine.
31. The method of any one of the preceding claims, wherein the payload comprises cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).
32. The method of any one of claims 1, 2, or 4-31, wherein the method is an in vitro method.
33. The method of claim 32, wherein the composition comprising microbubbles is incubated with the one or more target cells at a concentration of at least about 5, 10, 15, 20, 25, or 30 microbubbles/cell.
34. The method of claim 32 or 33, wherein the step of administering to the one or more target cells a composition comprising microbubbles comprising mixing the composition with the one or more target cells in solution.
35. The method of claim 32 or 33, wherein the one or more target cells are adhered to a surface and wherein the step of administering to the one or more target cells a composition comprising microbubbles comprises exposing the surface to the composition comprising microbubbles such that the one or more cells are positioned over the microbubbles.
36. A method of treating cancer in a subject in need thereof, the method comprising performing the targeted drug delivery method of any one of claims 4-31, wherein administering the microbubble composition to the one or more target cells comprises administering the microbubble composition and the ultrasound stimulus to the subject, and wherein the payload comprises a cyclic dinucleotide.
37. The method of claim 36, wherein the subject has been diagnosed with cancer.
38. The method of claim 36 or 37, wherein the subject has a tumor.
39. The method of claim 38, wherein the subject has one or more metastases.
40. The method of claim 38, wherein the microbubble composition is administered intratumorally.
41. The method of any one of claims 36-39, wherein the microbubble composition is administered systemically.
42. The method of claim 41, wherein the microbubble composition is administered intravenously.
43. The method of claim 41 or 42, wherein the microbubble composition is a nanobubble composition.
44. The method of any one of claims 36-43, wherein administering the microbubble composition to the subject comprises administering multiple doses of the microbubble composition to the subject and administering the ultrasound stimulus to the subject comprises administering ultrasound stimulus effective to sonoporate the one or more target cells after each dose.
45. The method of claim 44, wherein the multiple doses are administered at least one day apart.
46. The method of any one of claims 36-45, wherein the administration results in an increase in expression of IFN-a, IFN-b, and/or IFN-g within the one or more target cells.
47. The method of any one of claims 36-46, wherein the administration results in an increase in serum levels of IFN-a, IFN-b, and/or IFN-g.
48. The method of any one of claims 36-47, wherein the administration results in nuclear localization of nuclear translocation of phosphorylated IRF3 (pIRF3) and/or NF-kB p65 in the one or more target cells.
49. The method of any one of claims 38-48, wherein the administration results in increased recruitment of CD8+ and CD4+ T cells within the tumor.
50. The method of any one of claims 37-49, wherein the administration results in an increased number of effector memory T-cells and/or central memory T-cells that are specific to cancer cells within the subject, optionally wherein an increased number of effector memory T-cells and/or central memory T-cells are found within the tumor.
51. The method of any one of claims 38-50, wherein the administration results in a decrease in tumor size.
52. The method of claim 51, wherein the administration results in the eradication of the tumor.
53. The method of any one of claims 36-52, wherein the administration prevents or reduces the likelihood of future metastases.
54. The method of any one of claims 37-53, wherein the administration prevents or reduces the likelihood of recurrence of the cancer in the subject.
55. The method of any one of claims 36-54, wherein the method further comprises treating the subject with immune checkpoint therapy.
56. The method of claim 55, wherein the immune checkpoint therapy comprises administering to the subject inhibitors that target CTLA4, PD-1, PD-L1, and/or CD47.
57. A microbubble composition for therapeutic drug delivery, the microbubble composition comprising: a plurality of microbubbles, wherein the microbubbles each comprise a gas core encapsulated by a surfactant shell, and wherein a plurality of cationic polymers are associated with the external surface of the surfactant shell of each microbubble; and a plurality of cyclic dinucleotides, wherein the cyclic dinucleotides are non-covalently bound to the cationic polymers on the external surface of the microbubbles.
58. The microbubble composition of claim 30, wherein the cationic polymers comprise polyamines.
59. The microbubble composition of claim 31, wherein the polyamines comprise spermines.
60. The microbubble composition of claim 32, wherein the spermines are conjugated to dextrans, optionally wherein multiple spermines are conjugated to each dextran.
61. The microbubble composition of any one of claims 30-33, wherein the plurality of cyclic dinucleotides comprises cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).
62. A method of making the microbubble composition of anyone of claims 57-61, the method comprising: associating the cationic polymers with the microbubbles; and loading the cyclic dinucleotides onto the microbubbles after the cationic polymers have been associated.
63. A method of making the microbubble composition of anyone of claims 57-61, the method comprising: binding the cyclic dinucleotides to the cationic polymers to form nanocomplexes; and loading the Nanocomplexes onto the microbubbles.
64. The microbubble composition formed by claim 62 or 63.
65. Use of the microbubble composition of any one of claims 57-61 or 64 in any one of the methods of claim 1-56.
66. The method of claim 1, wherein the payload comprises mRNA.
67. The method of claim 1, wherein the payload comprises DNA, optionally plasmid DNA (pDNA).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163173956P | 2021-04-12 | 2021-04-12 | |
US202263316360P | 2022-03-03 | 2022-03-03 | |
PCT/US2022/024485 WO2022221324A1 (en) | 2021-04-12 | 2022-04-12 | Microbubble-assisted ultrasound-guided therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4322926A1 true EP4322926A1 (en) | 2024-02-21 |
Family
ID=83641003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP22788800.5A Pending EP4322926A1 (en) | 2021-04-12 | 2022-04-12 | Microbubble-assisted ultrasound-guided therapy |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240269287A1 (en) |
EP (1) | EP4322926A1 (en) |
AU (1) | AU2022256437A1 (en) |
CA (1) | CA3216645A1 (en) |
IL (1) | IL307645A (en) |
WO (1) | WO2022221324A1 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1793865A4 (en) * | 2004-08-05 | 2009-05-13 | Baylor Res Inst | Gene or drug delivery system |
US9237898B2 (en) * | 2009-07-21 | 2016-01-19 | University Of Virginia Patent Foundation | Systems and methods for ultrasound imaging and insonation of microbubbles |
US10537725B2 (en) * | 2010-03-05 | 2020-01-21 | Cornell University | Ultrasound-assisted convection enhanced delivery of compounds in vivo with a transducer cannula assembly |
US10357575B2 (en) * | 2010-09-24 | 2019-07-23 | Case Western Reserve University | Stabilized nanobubbles for diagnostic and therapeutic applications |
US20210370037A1 (en) * | 2018-04-27 | 2021-12-02 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Ultrasound-mediated gene and drug delivery |
-
2022
- 2022-04-12 CA CA3216645A patent/CA3216645A1/en active Pending
- 2022-04-12 AU AU2022256437A patent/AU2022256437A1/en active Pending
- 2022-04-12 WO PCT/US2022/024485 patent/WO2022221324A1/en active Application Filing
- 2022-04-12 IL IL307645A patent/IL307645A/en unknown
- 2022-04-12 US US18/554,944 patent/US20240269287A1/en active Pending
- 2022-04-12 EP EP22788800.5A patent/EP4322926A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022256437A1 (en) | 2023-10-26 |
CA3216645A1 (en) | 2022-10-20 |
IL307645A (en) | 2023-12-01 |
US20240269287A1 (en) | 2024-08-15 |
WO2022221324A1 (en) | 2022-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tu et al. | Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated programmed death-ligand 1 attenuation and chemotherapeutics-induced immunogenic cell death | |
Li et al. | Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles | |
Miyazaki et al. | Hyaluronic acid-based pH-sensitive polymer-modified liposomes for cell-specific intracellular drug delivery systems | |
Wei et al. | One-step self-assembly of multifunctional DNA nanohydrogels: an enhanced and harmless strategy for guiding combined antitumor therapy | |
Ortega et al. | Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages | |
JP2022031484A (en) | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors | |
US11471515B2 (en) | Restoration of tumor suppression using MRNA-based delivery system | |
US20120034155A1 (en) | Artificial cells | |
Meissner et al. | Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody | |
US11110168B2 (en) | Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent | |
ES2924138T3 (en) | New pharmaceutical composition comprising particles comprising a complex of a double chain polyribonucleotide and a polyalkylene imine | |
Doshi et al. | Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy | |
Zhu et al. | Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy | |
JP2017512840A (en) | Targeted polymerized nanoparticles for cancer treatment | |
Zhao et al. | Immune-cell-derived exosomes for cancer therapy | |
JP2023520506A (en) | Multilayered RNA nanoparticle vaccine against SARS-COV-2 | |
Li et al. | A general biomineralization strategy to synthesize autologous cancer vaccines with cGAS-STING activating capacity for postsurgical immunotherapy | |
Walters et al. | Nanoparticle-mediated in situ molecular reprogramming of immune checkpoint interactions for cancer immunotherapy | |
KR20220035434A (en) | Multilayer RNA Nanoparticles | |
US11446390B2 (en) | Antigen capturing nanoparticles for use in cancer immunotherapy | |
WO2018022957A1 (en) | T cell binding conjugates and methods of use | |
US20240269287A1 (en) | Microbubble-assisted ultrasound-guided therapy | |
US20240180849A1 (en) | Immunofunctional carrier, methods of uses, and composition matters as an antitumor immunotherapy | |
Lou | Applications of porphyrin nanoparticles in enhancing Cancer immunotherapies | |
US20220162644A1 (en) | Delivery vectors and particles for expressing chimeric receptors and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20231108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |